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Summary 
 
The ability of the fungus Candida albicans to switch interchangeably between yeast and 
hyphal forms of growth contributes significantly to its pathogenesis. This morphogenetic 
shift occurs in response to environmental changes and it is accomplished by a complex 
network of signal transduction pathways. Protein kinases and phosphatases are important 
messengers in these pathways and several of them have been directly implicated in 
controlling C. albicans morphogenesis. Kinases and phosphatases (KP) are enzymes that 
modulate the function of their substrates via reversible phosphorylation and 
dephosphorylation, respectively. While the specificity of KP is tightly controlled, some 
enzymes can target a huge number of proteins and have a master regulatory role over 
various cell processes. The function of KP in C. albicans is poorly understood and methods 
for global analysis of KP interactions have not been adapted to this organism. This study 
developed a protocol for large scale analysis of protein interactions in C. albicans using 
immunoprecipitation and SILAC in conjunction with quantitative mass spectrometry 
analysis. The protocol was successfully applied for identification of Cdc14 interactors using 
the substrate-trapping mutant Cdc14C275S. Cdc14 is a phosphatase required for proper 
hyphal formation, cytoskeletal organisation and cell separation at the end of mitosis. This 
study reveals over 100 potential substrates of Cdc14 and new roles of the phosphatase in 
DNA damage repair, DNA replication, chromosome segregation and transcription regulation. 
In addition, experiments were performed separately with both yeast and hyphae allowing 
for direct comparison of Cdc14 interactome between both forms. Many of the identified 
proteins have unknown function and the significance of these putative interactions remains 
to be found. 
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Chapter 1 
 
Introduction 
 
        
 
1.1. Introduction to Candida albicans  
Candida albicans is a commensal fungus that is normally found on the skin and mucosal 
surfaces of healthy people. However, a wide variety of factors can contribute to abnormal 
overgrowth of this fungus and lead to candidiasis, which is the most prevalent opportunistic 
yeast infection in humans (Martins et al., 2014). In more serious cases, C. albicans can 
disseminate to the bloodstream and internal organs of patients causing life-threatening 
systematic infections (Antinori et al., 2016). Between 50-90 % of cases are caused by C. 
albicans, while the rest are attributed to other species of the Candida genus, such as s C. 
tropicalis, C. glabrata, C. parapsilosis, C. stellatoidea, C. krusei and C. kyfer. Most susceptible 
to infections are immunocompromised individuals, new-born babies and patients with 
implanted medical devices. Additionally, up to 75 % of women suffer from vulvovaginal 
candidiasis at least once in their life (Kabir et al., 2012).  
The transition from commensal to pathogenic state is a multifactorial event. Changes 
in host environment, such as weakened immune response, supressed microbiota due to 
antibiotic treatment, malnutrition or variations in pH can all play a part (Nobile and Johnson, 
2015). In turn, C. albicans has evolved a range of adaptation strategies that allow it to 
survive in a changing environment and invade the host. Of significant importance is the 
ability of C. albicans to form biofilms on soft tissues and medical devices, which are resistant 
to the host immune system or conventional antifungal treatments. Expression of adhesins 
molecules enable the fungus to adhere to a wide variety of surfaces, while secreted 
hydrolytic enzymes degrade host surface molecules (Schaller et al., 2005). Strains with 
impaired production of adhesins or hydrolases are less virulent than wild type strains (Finkel 
et al., 2012). Another striking feature that contributes to C. albicans pathogenicity is its 
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ability to interchangeably switch between unicellular and filamentous growth in response to 
environmental cues. At <30 °C and acidic pH the fungus forms individual yeast cells that 
divide by budding and fully separate from each other at the end of mitosis (fig 1.1). 
Conditions commonly found inside the host, such as 37 °C, neutral pH and presence of blood 
serum and N-acetylglucosamine, induce the formation of hyphae – long filaments with 
parallel walls and multiple nuclei separated in compartments by a septum (Sudbery et al, 
2004). Conditions between these two extremes may favour the production of 
pseudohyphae, which are wider then hyphae and have constrictions at the septation sites. 
The ability of C. albicans to grow as filaments is crucial during biofilm formation and host 
tissue penetration (Whiteway and Oberholzer, 2004). In particular, the yeast-to-hyphae 
transition has been implicated to play a role during infection, because mutant strains that 
cannot form hyphae are less virulent than wild type cells (Lo et al., 1997). However, many of 
the molecular pathways that control morphogenesis also control the expression of various 
virulence factors, and so the effect may be pleiotropic (Trevijano-Contador et al., 2016). 
Interestingly, some hyperfilamentous strains have shown decreased infection rate, while 
some non-filamentous strains have retained their virulence (Alonso-Monge et al., 1999, 
Noble et al., 2010). An additional complication comes from the fact that many studies have 
used URA3 as a selectable marker to create their strains, but adequate expression of this 
gene is required for virulence and for morphological transition (Lay et al., 1998). The 
expression of URA3, however, is dependent on its chromosome position and thus may vary 
in mutants. Altogether, the relationship between morphogenesis and virulence in C. 
albicans is very complex and requires further study to be fully understood. 
Our understanding of the complex nature of C. albicans has greatly advanced in the 
past two decades. This fungus has been employed as a model organism for studying human 
pathogens and polarised cell growth. Many molecular biology techniques have been 
adapted from the Saccharomyces cerevisiae research field, since both fungi are genetically 
related. However, manipulation of the C. albicans genome is more difficult due to its 
obligate diploid nature, genomic plasticity (possible aneuploidy) and the lack of clearly 
defined sexual cycle (Noble and Johnson, 2007). Candida species also have a codon bias for 
the CTG codon, which they translate as serine rather than leucine (Santos and Tuite, 1995). 
Because of this bias, all exogenous genes have to be modified before they can be introduced  
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Fig. 1.1: Morphology of C. albicans. Cells can grow as either yeast, pseudohyphae or “true” hyphae 
depending on their environment. This figure is taken from Sudbery et al., 2004. 
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in C. albicans. The complete genome sequence of the C. albicans strain SC5314 is available 
on the Candida Genome Database (candidagenome.org) since 2004 and it has made genetic 
manipulation of this fungus much easier than before. It has 6218 protein coding genes, only 
a quarter of which have been experimentally verified (fig. 1.2). This means that much more 
remains to be discovered about the biology of C. albicans.  
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Fig. 1.2: Graphical view of protein coding genes in C. albicans (as of 26/06/2016). This figure has 
been adopted from the Candida Genome Database. 
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1.2. The role of protein phosphorylation and dephosphorylation in 
the cell 
Posttranslational modifications, such as protein phosphorylation and dephosphorylation, 
have evolved as mechanisms to control proteins function through reversible alteration of 
their folding, stability and activity. Protein phosphorylation is done by kinases, which 
transfer a phosphoryl group from ATP (or more rarely from GTP) to another protein that is 
their substrate. The addition of a phosphate can change the activity of a protein in two 
ways. First, it could induce a conformational change that prepares the protein for a 
downstream action. Second, it can disrupt a protein’s surfaces in a way that either creates 
or blocks another protein binding site (Cheng et al., 2011). Phosphatases reverse this action 
by catalysing the transfer of a phosphate from a protein to a water molecule, a process 
known as dephosphorylation.  
Kinases and phosphatases (KPs) modulate a huge number of molecular pathways 
implemented in every basic cellular process in the cell. A single enzyme can have up to 
several hundred substrates and interaction with each of them is tightly controlled in space 
and time. KPs have exquisite specificity for their substrates, achieved through recognition of 
selected amino acid sequence surrounding the phosphoacceptor site (Hutti at al., 2004). In 
addition, the structure of the catalytic site, the formation of complexes with regulatory 
subunits, interaction with docking sites on the substrate, localisation of both enzyme and 
substrate, competition of substrates at any given time and various error correction 
mechanisms all affect the specificity of an enzyme (Ubersax and Ferrell Jr, 2007).  
  Since KPs have antagonistic functions, their action must be balanced at any time. 
The main mechanisms for achieving this are compartmentalisation of the enzymes and 
modulation of their activity (Bononi et al., 2011). The spatial organisation of KPs creates a 
gradient of phosphorylated substrates across the cell units. Additionally, KPs often regulate 
each other by positive and negative feedback loops (Kamioka et al., 2010). Disruption of this 
complex interplay has been implicated in variety of human disease and continues to be 
extensively studied. Given their importance, it is not surprising that kinases have become 
one of the most researched classes of drug targets (Zhang et al., 2009).  
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1.3. The role of protein kinases in C. albicans morphogenesis 
 
1.3.1. Cdc28 
Several kinases have been identified to be important for hyphal formation and development 
in C. albicans, although most of their direct targets remain to be found. The cyclin-
dependent kinase Cdc28 (also known as Cdk1) is one of the key regulators of cell cycle 
progression and morphogenesis by controlling several distinct pathways. In association with 
two G1 cyclins Ccn1-Cdc28 and Cln3-Cdc28 initiate cell budding through polarised growth, 
which is maintained during hyphal development by a complex with a third G1 cyclin Hgc1-
Cdc28 (Zheng et al., 2004; Wang, 2016).  One of the known targets of Ccn1-Cdc28 is the 
septin Cdc11, phosphorylated upon hyphal induction first by the kinase Gin4 and then by 
Ccn1-Cdc28 (Sinha et al., 2007). This phosphorylation is then sustained in hyphae by Hgc1-
Cdc28. Abolishing these phosphorylation events impairs hyphal development after initial 
tube evagination. Phosphorylation of another septin, Sep7, is also dependent on Hgc1, 
although the involvement of Cdc28 has not been shown (Gonzalez-Novo et al., 2008). 
However, Sep7 is also phosphorylated by Gin4, which is activated by Clb2-Cdc28 
phosphorylation (Li et al., 2012).  
Hgc1-Cdc28 further support polarised growth by phosphorylation of the GTPase-
activating protein (GAP) Rga2 (Zheng et al., 2007). This event ensures that Rga2 will not go 
to the hyphal tip and inactivate the GTPase Cdc42, which is required for hyphal 
development (Court and Sudbery, 2007). 
 Sec2 and Exo84, which are both involved in the transport of secretory vesicles to the 
tip, are also substrates of Hgc1-Cdc28 (Bishop et al., 2010; Caballero-Lima and Sudbery, 
2014). Exo84 is part of the exocyst, a multiprotein complex at the hyphal tip that tethers 
secretory vesicles before they fuse with the membrane. Sec2 is a guanosine exchange factor 
(GEF) for the Rab GTPase Sec4 involved in the docking of secretory vesicles to the exocyst 
(Guo et al., 1999). The polarisome member Spa2 is yet another protein at the hyphal tip 
phosphorylated by Cdc28 (Wang et al., 2016). Clb2-Cdc28 targets Spa2 in both yeast and 
hyphae, while Hgc1-Cdc28 phosphorylate the protein only in hyphae. Abolishing CDK sites in 
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Spa2 leads to translocation of the protein from the tip to the septum and disrupts hyphal 
morphology.  
Finally, Cdc28 is known to phosphorylate two morphology-related transcription 
factors. Hgc1-Cdc28 regulates Efg1, which blocks the expression of genes involved in septum 
degradation after cytokinesis (Wang et al., 2009). Ccn1/Cln3-Cdc28 together with the kinase 
Cbk1-Mob2 phosphorylate Fkh2 which promotes the expression of genes supporting hyphal 
development (Greig et al., 2015). Given the wide range of substrates that Cdc28 
phosphorylates, it is not surprising that blocking the kinase activity with the ATP analogue 
1NM-PP1 completely disrupted the formation of true hyphae (Sinha et al., 2007). It is 
suspected that many more interactors of Cdc28 remain unknown. 
 
1.3.2. Cbk1 
The nuclear Dbf2-related (NDR) kinases have a highly conserved role in regulation of cell 
cycle and polarised growth. C. albicans has two NDR kinases, Cbk1 and Dbf2, which are 
activated by their regulatory subunits, Mob2 and Mob1 respectively. Cdc28 controls Cbk1 
activity through phosphorylation of Mob2 shortly after hyphal induction, which is required 
for sustaining polarised growth (Gutiérrez-Escribano et al., 2011). Cbk1 and Mob2 are 
members of the regulation of Ace2p activity and cellular morphogenesis (RAM) network 
that maintains cell polarity during yeast budding and hyphal development. Both proteins are 
essential for hyphal growth, as deletion mutants remained permanently locked in the yeast 
form (Song et al., 2008). The importance of Cbk1 for polarised growth has prompted several 
studies to investigate its downstream targets. Bharucha et al. (2011) did a 
haploinsufficiency-based genetic interaction screen for targets of Cbk1 using CBK1/cbk1Δ 
strain. The screen specifically focused on strains displaying morphological defects on Spider 
medium and identified 41 genes that show synthetic interaction with CBK1, half of which 
are under the transcriptional control of Ace2. A third of those genes were also controlled by 
the cAMP-protein kinase A (PKA) pathway, suggesting that the interplay between the RAM 
and cAMP-PKA pathways largely determines cell morphology. Recently, Saputo et al. (2016) 
did a similar screen but solely looking for strains with decreased filamentation on serum 
medium. They found 36 genetic interactions with CBK1, indicating distinct set of substrates 
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during yeast and hyphal growth. The study also identified Rgd3 a second GAP for Cdc42 and 
showed that Cbk1 phosphorylation is required for localisation of Rgd3 to sites of polarised 
growth. Other targets of Cbk1 include the transcription factors Bcr1, which play a role in 
biofilm formation, and the mRNA-binding protein Ssd1 (Gutiérrez-Escribano et al., 2011). On 
hyphal induction, Cbk1-dependent phosphorylation of Ssd1 downregulates the levels of the 
transcription factor Nrg1, which represses the expression of several hyphae-specific genes 
(HSGs) (Lee et al., 2015). 
 
1.3.3. Dbf2 
Dbf2-Mob1 are part of the mitotic exit network (MEN, also including Lte1, Tem1, Cdc5, 
Cdc15, Bfa1, Bub2 and Cdc14) in S. cerevisiae, which regulates late mitotic events and M-G1 
transition. Although the presence of this network in C. albicans has not been established, 
one study looked specifically at the role of Dbf2 in this fungus and found a great degree of 
similarity between both orthologues. González-Novo et al. (2009) showed that while DBF2 is 
an essential gene in C. albicans, conditional mutants, where the gene is downregulated, 
display severe defects in cell separation due to failure to form the primary septum and 
contract the actomyosin ring during mitosis (fig. 1.3). In addition, dividing cells were unable 
to form the mitotic spindle correctly and divide their DNA content equally between the 
mother and daughter cells. The authors also demonstrated that during mitosis Dbf2 
sequentially moves from the nucleus to the mitotic spindle, the spindle pole bodies (SPB) 
and to the bud neck at the end of the cycle. Co-immunoprecipitation experiments proved a 
direct physical interaction with tubulin, which is still the only known CaDbf2-interacting 
protein to date. Finally, the study revealed that the kinase is also important for hyphal 
morphogenesis. Although the cellular localisation of Dbf2 in hyphae was not investigated, 
depletion mutants formed very swollen tubes with no septum between the nuclei and with 
constrictions reminiscing dividing yeast cells. It is unclear whether the morphological defects 
of hyphae are solely due to disruptions in cell cycle progression or the kinase has a separate 
role in polarised growth.  
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Fig. 1.3: Morphology of Dbf2-depleted cells. Mutants have a single Dbf2 allele that is under the 
control of MET3 promoter. When the promoter is induced (2), yeast cells grow as normal wild type 
cells (1). In MET3 repressing conditions, yeast fail to complete cytokinesis and form chains of 
connected cells (3-4). Black arrows in image 3 indicate abnormally wide bud necks. The white arrows 
in image 4 point towards cells with more than one nuclei. Images 1-3 are taken by DIC microscopy, 
and image 4 is a merged picture of DIC and DAPI channels. Images 5-8 show hyphae stained with 
DAPI and Calcofluor White. Comparing to wild type hyphae (5), depleted mutants (6-8) form wider 
tubes with constrictions but no septum (indicated by white arrows). All bars are 5 µm. All images 
were taken from González-Novo et al., 2009. 
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1.3.4. Crk1 
Unlike Dbf2, the Cdc2-related kinase 1, Crk1 is not essential for viability and construction of 
the deletion strain crk1Δ/crk1Δ has revealed a key role in C. albicans filamentation and 
virulence. In the absence of Crk1 cells are swollen and permanently locked in the yeast form 
unable to complete cytokinesis (fig. 1.4) (Chen et al., 2000). On the other hand, ectopic 
expression of Crk1 or its catalytic domain, Crk1N, induces polarised growth on solid YPD (but 
not in liquid YPD) at 30 °C. The authors have shown that crk1Δ/crk1Δ mutants fail to express 
the HSGs ECE1 and HWP1, which are abnormally expressed in yeast when Crk1 or Crk1N are 
ectopically introduced. Introduction of Crk1N in the non-filamentous efg1Δ/efg1Δ, 
cph1Δ/cph1Δ and the double deletion mutants induces polarised growth, indicating that 
Crk1 acts independently from the transcription factors Efg1 and Cph1. The study concludes 
through a series of gene deletion experiments that Crk1 may act in the same pathway with 
Ras1/cAMP to promote hyphal development. Using a yeast-two hybrid system, Ni et al. 
(2004) identified Cdc37 and Sti1 as interacting partners of Crk1, which likely assist with 
protein folding of the kinase. Despite the prominent role of Crk1 in polarised growth its 
substrates remain unknown. In contrast to the other kinases discussed so far, it is unlikely 
that Crk1 phosphorylates proteins involved in cytoskeleton organisation (Dhillon et al., 
2003). The closest homologues of Crk1 are the S. cerevisiae Bur1 (also known as Sgv1) and 
the human Cdk9, both of which are CDKs controlled by a single cyclin Bur2 and CycT 
respectively (Malumbres, 2014). Bur1 and Cdk9 are transcriptional regulators of several 
genes, and it likely that Crk1 has a similar role in C. albicans. Although a Bur2 homologue 
with a cyclin domain exists in the Candida Database, the protein (also called Bur2) is still 
uncharacterised and no association with Crk1 has been shown (Yao et al., 2000). 
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Fig. 1.4: Phenotype of Crk1 mutants. Deletion of both copies of CRK1 produced chain of swollen 
cells under yeast conditions (top). Hyphal formation was also impaired in Lee’s medium, but a single 
allele of CRK1 is sufficient to rescue this phenotype (bottom). All images were taken from Chen et al., 
2000. 
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1.4. Protein phosphatases in C. albicans 
 
1.4.1. General overview 
Protein kinases greatly outnumber protein phosphatases in all studied organisms.  In 
budding yeast, there are 124 protein kinases and 37 protein phosphatases. The exact 
number in C. albicans has not been determined yet, but one comparative study of fungal 
kinomes found about 20% less kinases in this fungus compared to S. cerevisiae, and another 
one reported 28 putative phosphatase genes (Kosti et al., 2010; Hanaoka et al., 2008). 
Analysis of the C. albicans phosphoproteome in hyphae has identified 15,906 unique 
phosphosites on 2,896 proteins (Willger et al., 2015). Overall, it seems that a very small 
group of phosphatases is responsible for the dephosphorylation of thousands of proteins, 
many of which have multiple phosphosites. Studying the phosphatase-substrate network in 
C. albicans is therefore a huge task, which is still at the very beginning. At present, only 17 
genes have been experimentally verified to express a protein phosphatase (summarised in 
table 1.1), 9 of which have been implicated in hyphal development. Very few of the 
substrates of these phosphatases are known. The MAPK phosphatase Cpp1 supresses 
hyphal formation by dephosphorylation of the kinase Cek1 and by repressing HSGs 
expression (Schroppel et al., 2000). Tpd3-Pph21 controls septin ring disassembly by 
dephosphorylation of Sep7 and tpdΔ/tpdΔ mutants grow constitutively as pseudohyphae 
with multiple septin rings (Liu et al., 2016). Ppg1 promotes filament extension through 
downregulation of Nrg1 and induction of several HSGs (Albataineh et al., 2014). Since Cdc14 
is the main target of this study, its role is reviewed in more detail bellow. 
 
1.4.2. Cdc14 
Cdc14 is a dual specificity protein phosphatase, which means that it can dephosphorylate 
both phosphoserine/phosphothreonine and phosphotyrosine residues. The Cdc14 family is 
highly conserved and it is found in all eukaryotes except plants. Cdc14 orthologues are 
among the most extensively studied phosphatases owing to the central role of the founding 
member ScCdc14 in controlling mitotic exit in budding yeast (Mocciaro and Schiebel, 2010).   
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Phosphatase  Description  Reference 
Cmp1  
Calcineurin, a Ca2+-calmodulin-activated, serine/threonine-
specific protein phosphatase, essential for virulence 
 
Bader et al., 
2003 
Cpp1  
VH1 family dual specificity MAPK phosphatase that 
represses yeast-hyphal transition and is required for 
virulence 
 
Csank et al., 
1997 
Cdc14  
Dual specificity phosphatase involved in exit from mitosis 
and morphogenesis 
 
Clemente-Blanco 
et al., 2006 
Glc7  
PP1 serine/threonine phosphatase involved in cell 
morphogenesis, cell cycle progression and DNA damage 
response 
 Hu et al., 2012 
Pph21  
Type PP2A phosphatase that dephosphorylates the septin 
Sep7 and regulates morphogenesis and cytokinesis 
 Liu et al., 2016 
Ptc1  
Type PP2C phosphatase involved in hyphal growth and 
virulence 
 
Hanaoka et al., 
2008 
Ptc2  
PP2C family member involved in regulation of mitochondrial 
physiology and DNA damage checkpoints 
 Feng et al., 2010 
Ptc4  
Type PP2C serine/threonine phosphatase involved in ion 
homeostasis 
 Zhao et al., 2010 
Ptc5 
 
Mitochondrial protein phosphatases of the PP2C family 
involved in antifungal drug sensitivity 
 Zhao et al., 2012 Ptc6 
Ptc7 
Ptc8   
Type PP2C serine/threonine phosphatase required for 
hyphal growth 
 Fan et al., 2009 
Ppz1  
Protein phosphatase Z, serine/threonine specific protein 
phosphatase involved in cation homeostasis, cell wall 
integrity and virulence 
 
Adam et al., 
2012 
Ppg1  
A PP2A-type protein phosphatase controls filament 
extension and virulence 
 
Albataineh et al., 
2014 
Psy2-Pph3  
Phosphatase with a role in filamentous growth induced by 
genotoxic stress and recovery from the DNA damage 
checkpoint 
 Sun et al., 2011 
Sit4  
PP2A phosphatase with a role in cell wall maintenance, 
hyphal growth, and virulence 
 Lee et al., 2004 
Yvh1  
Dual specificity phosphatase that controls growth, cell cycle 
progression and virulence  
 
Hanaoka et al., 
2005 
 
 
Table 1.1: Experimentally characterised protein phosphatases in C. albicans (as of 1/08/2016). 
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Due to the high attention that these phosphatases have received, they are now hold 
responsible for targeting hundreds of substrates in a variety of cellular processes. 
 In S. cerevisiae, the function of Cdc14 is largely controlled by its subcellular 
localisation. From G1 to metaphase, when CDK activity is high, the phosphatase is 
sequestered in the nucleolus by its inhibitor Net1 (also known as Cfi1) as part of the 
regulator of nucleolar silencing and telophase (RENT) complex (Visintin, et al., 1999). A 
recent study suggests that in S phase Clb5-Cdc28 inhibits the phosphatase activity of Cdc14 
by phosphorylating it at S429 (Li et al., 2014). During anaphase the FEAR (fourteen early 
anaphase release) and MEN pathways ensure sequential release of Cdc14 first to the 
nucleoplasm and later to the cytoplasm (Faust et al., 2013; Yellman and Roeder, 2015). At 
the start of anaphase Cdc28 activates the anaphase promoting complex/cyclosome (APC/C) 
that together with Cdc20 degrades securin and activates separase, an enzyme that drives 
separation of sister chromatids (Rudner and Murray, 2000). Separase also promotes Net1 
phosphorylation by Cdc28 and Cdc5, which leads to the initial release of Cdc14 to the 
nucleoplasm (Sullivan and Uhlmann, 2002; Queralt et al., 2006). At this stage, Cdc14 
promotes mitotic spindle elongation and ribosomal DNA segregation (Higuchi and Uhlmann, 
2005). Correct spindle orientation is a prerequisite for Tem1-dpendent activation of the 
kinases Cdc15 and Dbf2-Mob1, both of which further phosphorylate and thus inhibit Net1 
(Visintin and Amon, 2001). Dbf2-Mob1 also directly phosphorylates Cdc14, an event that 
drives export of the phosphatase from the nucleus to the cytoplasm (Mohl et al., 2009). At 
the end of mitosis Cdc14 returns to the nucleolus until the next division.  
 The main role of Cdc14 in budding yeast is to orchestrate late mitotic events by 
transiently inhibiting CDK activity and reversing CDK-dependent events. Cdc14 activates 
Sic1, which inhibits CDKs by direct association with them (Visintin et al., 1998). Cdc14 
further stimulates Sic1 expression by dephosphorylating its transcription factor, Swi5, thus 
enabling it to enter the nucleus. Cdc14 also induces degradation of mitotic cyclins by 
dephosphorylating Cdh1. APC/C-Cdh1 targets cyclins for ubiquitin-dependent proteolysis 
(Visintin et al., 1997). Finally, analysis of known Cdc14 substrates has revealed that the 
phosphatase has a preference CDK consensus sites with one study suggesting a strong bias 
towards phosphoserine over phosphothreonine CDK sites (Gray et al., 2003; Bremmer et al., 
2012; Sanchez-Diaz et al., 2012). In addition to CDK inactivation, Cdc14 has a recognised role 
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in cytoskeleton organisation, septum formation and actomyosin ring contraction consistent 
with its localisation at the bud neck at the end of mitosis (Bloom et al., 2011).  
 The essential role of Cdc14 in mitotic exit is not conserved in all species. The S. 
pombe orthologue Clp1 (also known as Flp1) actively participates in septum formation, 
nuclear division, chromosome segregation and cytokinesis but is not required for cell 
viability (Chen et al., 2013). Clp1 regulates G2-M transition and overexpression blocks the 
cells in G2, which is in contrast to budding yeast Cdc14 that arrests the cells in G1 (Visintin et 
al., 1998; Cueille et al., 2001; Trautmann et al., 2001). In the plant pathogen Fusarium 
graminearum Cdc14 is important for morphogenesis, pathogenesis and cytokinesis (Li et al., 
2015). Similarly, in the fungal entomopathogen Beauveria bassiana the phosphatase 
controls conidiation, virulence and stress response (Wang et al., 2013). In mammals several 
Cdc14 homologues regulate DNA damage repair but are dispensable for mitotic exit 
(Mocciaro and Schiebel, 2010; Lin et al., 2015). Several high-throughput studies of Cdc14 
interactors in fungi have identified proteins involved in DNA repair, but the significance of 
these findings has not been investigated in detail (Bloom et al., 2011; Breitkreutz et al., 
2010; Chen et al., 2013). 
 The C. albicans orthologue displays a cell cycle-controlled localisation pattern that is 
different from that of ScCdc14 (Clemente-Blanco et al., 2006). The phosphatase is 
completely absent from G1 cells and gradually start accumulating in the nucleus and 
nucleolus from S phase onwards. At the start of mitosis, Cdc14 concentrates at the SPB and 
later moves to the bud neck during cytokinesis, after which it is degraded. While the protein 
is not essential for vegetative growth or mitotic progression, deletion mutants fail to 
separate at the end of the cycle due to incomplete septum degradation. Cdc14-dependent 
dephosphorylation of septin regulator Nap1 at the end of mitosis is required for 
translocation of the protein from the septum to the cytoplasm (Huang et al., 2014). 
Additionally, cdc14Δ/cdc14Δ cells did not accumulate the master regulator of cell separation 
Ace2 in daughter nuclei and showed decreased expression of genes controlled by it. Cdc14 
has probably retained its function to counteract CDK activity in C. albicans, since it is 
involved in degradation of the cyclins Clb2 and Clb4 during mitosis, but it is not clear 
whether Cdc14 inhibits CDK activity in any other way. However, in a recent study Yong et al. 
(2016) have proposed a model whereby the kinase Gin4 regulates septin ring assembly at 
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the beginning of mitosis and is dephosphorylated by Cdc14 at the end of the cycle to allow 
disassembly of the ring. As mentioned earlier, Gin4 is also a substrate of Cdc28, which raises 
the possibility that Cdc14 might also target CDK sites in C. albicans.  
In hyphae, Cdc14 localises only to the nucleus of the apical compartment, but not to 
the septum. This pattern is dependent on Hgc1 and Sep7 and if either of them is deleted 
Cdc14 goes to the septum of germ tubes and induces cell separation (Gonzalez-Novo et al., 
2008). Deletion of CDC14 impairs invasive and filamentous growth since in the presence of 
serum, cells form much shorter tubes than wild type hyphae. While in the absence of Cdc14 
yeast cells are able to progress through the cell cycle in time, hyphae exhibit delay in G2-M 
transition, suggesting that mitosis may be regulated differently in these forms. 
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Fig. 1.5: Morphological defects of cdc14Δ/cdc14Δ cells. (A) Yeast cells lacking Cdc14 form clumps 
due to incomplete separation after each cell cycle. (B) Comparing to wild type cells (I-II), deletion 
mutants (III-IV) failed to degrade the septum at the end of mitosis. (C) Hyphae also exhibit severe 
delay in evagination and tube elongation in the presence of serum. All images are taken from 
Clemente-Blanco et al., 2006.  
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1.5. Methods of identifying novel kinase and phosphatase 
interactions 
 
1.5.1. Methods currently used in C. albicans 
So far, studies of C. albicans KPs have mostly focused on investigating individual 
interactions. Putative interacting partners are usually found by either: 1) analogy with KPs in 
other organisms; or 2) co-localisation of fluorescently-tagged enzyme and another protein; 
or 3) implication of an enzyme and a protein in a common pathway (e. g. if deletion mutants 
have similar phenotype). Suspected interactions are then confirmed by co-
immunoprecipitation (co-IP)/affinity purification (AP), KP assays, changes in electrophoretic 
mobility of a substrate in the absence of enzyme activity, co-localisation experiments or 
mutation of putative phosphosites. Although these methods are very useful for 
understanding the role of KPs, a more comprehensive analysis of KP interactions (KPI) is 
required for better interpretation of their function. The complex haploinsufficiency-based 
screen for genetic interactors of Cbk1 is the first (and so far the only) large-scale analysis of 
a kinase substrates in C. albicans (Bharucha et al., 2011; Saputo et al., 2016). These studies 
presented a bigger picture of how a single kinase regulate different pathways in response to 
varying conditions. Although C. albicans-adapted yeast two hybrid technology exist, it has 
not been used for KPI screens (Stynen et al., 2010). 
 
1.5.2. High-throughput techniques used in other species   
In other organisms, proteome-wide screens for KPI have been carried out for over a decade. 
The yeast two-hybrid system is the most applied method for studying physical protein 
interactions but it is becoming less popular with the advancements of more recent 
technologies (Bruckner et al., 2009). High-throughput studies commonly involve affinity-
based purification of a bait (e. g. a kinase, a phosphatase or a regulatory protein) coupled to 
mass spectrometry (MS) analysis for identification of co-eluted prey proteins (Gavin et al., 
2006). In the simplest scenario, the bait and prey proteins are all expressed in the same 
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system and allowed to interact in their natural environment prior to purification (Gavin et 
al., 2002). More commonly however, capturing KPI requires an intervention from the 
researchers that may disrupt the physiological environment of an enzyme. For example, 
baits often have to be overexpressed with the use of exogenous promoters in order to 
provide enough material for an MS analysis (Breitkreutz et al., 2010). Although this might 
create some false positive results, it often allows the capture of many true interactions that 
would not be detected otherwise. Alternatively, a bait of interest may be expressed in large 
amount and purified from a different organism, such as bacteria, before being incubated 
with cell lysates to allow binding to interacting partners (Knebel et al., 2001). A purified bait 
can also be incubated with a phage display library or a protein/peptide array chip. In the 
first method, proteins encoded by cDNA are displayed on the surface of a phage and 
interaction is detected by immunological assays (Zhou et al., 2003). On the other hand, 
incubation of a kinase with a microarray chip array is followed by detection of substrate 
phosphorylation with the use of a phosphorimager (Fasolo et al., 2011). A major caveat of 
this technique is that immobilised proteins do not always fold correctly, which may prevent 
interaction with the enzyme. Several studies have combined in vitro kinase assays with MS 
for identification of kinase targets (Li et al., 2014; Muller et al., 2016). A purified kinase is 
incubated with cell extracts and ATP and phosphorylated proteins are detected by MS. 
Background phosphorylation can be minimised by several strategies, for example, by using 
an analogue-sensitive (AS) enzyme as a bait that are designed to accommodate an ATP 
analogue that other kinases cannot use (Xue and Tao et al., 2013). ATP analogues transfer a 
non-conventional phosphoryl group that labels the substrates and can be identified by MS. 
The use of AS kinases is one of the most reliable methods for studying kinase substrates and 
can also be applied in vivo (Shah et al., 1997). However, not every kinase can be engineered 
to be AS (Koch and Hauf, 2010).  
 Phosphatases can also be modified for improved detection of their targets. 
Substrate-trapping enzymes, constructed by a single amino acid substitution, lose their 
catalytic activity but bind their substrates with higher affinity (Blanchetot et al., 2005). 
Normally, enzyme-substrate complexes are very short-lived but have to remain intact for 
the course of purification experiments. Mutants are more reliable in this regard are 
therefore often used in interaction studies (Bloom et al., 2011).  
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 An alternative method for studying KPs is to look at phosphoproteome dynamics 
rather than physical associations between proteins (Ficarro et al., 2002; Ptacek et al., 2005). 
Proteolytically digested whole cell extracts contain a mixture of phosphorylated and non-
phosphorylated peptides. The former can be isolated by affinity chromatography and 
analysed by MS to create a map of all phosphorylated proteins in the cell, i.e. the 
phosphoproteome. Comparing the phosphoproteome of wild type cells to those of knockout 
mutants reveals downstream pathways controlled by the missing enzyme as well as many of 
its direct phosphosites (Kao et al., 2014). 
 Finally, it is worth noting that several software platforms have been developed to 
predict phosphorylation sites by scanning protein sequences for a known target motif (Xue 
et al., 2005; Hornbeck et al., 2015). This can be a good starting point for identifying new KPI 
and may complement an experimental approach.  
  
 
  
 - 22 - 
 
1.6. Introduction to mass spectrometry  
Mass spectrometry is a century old technique for qualitative and quantitative analysis of 
compounds and molecules. The main principle of MS is separation of charged species from a 
sample based on their mass (m) to charge (z) ratio. The resulting spectrum of masses is used 
to identify the composition of the original sample. MS has many applications in the fields of 
chemistry, physics, biology and others but for the purpose of this study, the discussion here 
is limited to the context of proteomics.  
 
1.6.1. Sample preparation 
A typical MS-based experiment starts with isolation of a protein mixture by cell extraction, 
sometimes followed by enrichment of a desired protein by various methods of purification. 
Complex samples may be separated by gel electrophoreses in one or two dimensions. 
Whole proteins can be analysed by MS, but more commonly, they are digested to shorter 
peptides with enzymes, such as trypsin. Peptides may be further fractionated by 
chromatography or an enrichment method may be used to select for peptides with desired 
characteristics, e.g. phosphorylation.  
 
1.6.2. Principles of MS instruments 
A mass spectrometer generally consists of an ion source, a mass analyser and a detector. 
Protein and peptides are non-volatile and thermally unstable, so ionisation is necessary to 
prevent degradation in the gas phase. Most commonly, analytes in solution are ionised by 
electrospray ionisation (ESI), while dry samples are ionised by matrix-assisted laser 
desorption ionisation (MALDI) (Fenn et al., 1989; Karas and Hillenkamp, 1988). ESI 
instruments are usually coupled to a liquid chromatography (LC) that separates the 
molecules prior to ionisation (Pitt, 2009). There are several other types of ion sources used 
in exceptional cases, but most proteomics studies use ESI-LC-MS instruments.  
 The resulting ions then enter the mass analyser, where they are separated based on 
their m/z ratio. The main types of mass analysers are: 
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 Time-of-flight (TOF) – ions are accelerated through an electric field and their m/z is 
deduced from the time it takes them to reach the detector (Guilhaus, 1995). TOF 
analysers are most often coupled to MALDI ionizers.  
 Quadrupole – ions travel in spiral trajectories between four parallel metal rods in an 
electric field created by static direct current and alternating radio frequency current 
voltage (Finnigan, 1994). Some quadrupoles also include a magnetic field. At any 
given time, only ions of certain m/z reach the detector depending on the applied 
voltage.  
 Ion trap – this analyser works on the same principles as quadrupoles, except that, as 
the name suggests, ions are trapped in confined spaced and sequentially ejected 
(Hager, 2002). Ions can also be fragmented inside the trap, which generates a 
tandem mass spectrum. Variations of this technology include linear ion trap, 
quadrupole ion trap and orbitrap. 
 Fourier transform ion cyclotron resonance (FTICR-MS) – in this analyser electric and 
magnetic fields accelerate the ions of particular m/z around a cyclotron (Marshall et 
al., 1998). Ion frequency and intensity is determined by Fourier transform 
mathematical operation, which is used to calculate the corresponding m/z. 
Some MS instruments may combine two or more mass analysers to achieve higher 
throughput and resolution. Common combinations include quadrupole-TOF, quadrupole-ion 
trap, linear ion trap-orbitrap, triple quadrupole, TOF-TOF and others (Medzihradszky et al., 
2000; Chernushevich et al., 2001). All mass analysers have certain advantages and 
disadvantages. Orbitrap and FTICR-MS instruments offer the highest mass accuracy and 
resolution (Scigelova et al., 2011). 
 After passing through the mass analyser, ions hit a detector that passes the signal to 
a recording system. The most common type of detectors is the electron multiplier (Neetu et 
al., 2012). Some instruments, such as FTICR-MS and orbitrap, have detector plates within 
the mass analyser. 
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1.6.3. Processing of MS data 
The output of an MS experiment is a mass spectrum of ions m/z plotted against their 
intensity. The intensity of ions shows their relative abundance in the sample. This spectrum 
is fed into a software that contains a database of all proteins in the experimental species. In 
the database, proteins have been in silico “digested” with the same enzyme used in the 
experiment creating a library of peptide mass fingerprints (PMF). The real mass spectrum is 
compared to the theoretical one and the software creates a list of peptides that best 
matches the available data. In other words, the computer is sorting the m/z of peptides in a 
way that gives the least probability of identifying proteins that are not in the sample (i.e. 
false positives). The probability of having false positive hits in the final list of proteins is 
presented as false discovery rate (FDR).  
 Deducing the presence of a peptide from a given m/z is not an error-free process. In 
a typical database of thousands of proteins, digestion yields hundreds of thousands of 
peptides, many of which will have the same (or very close) m/z. This means that one 
experimental peptide can be matched to several theoretical peptides. A better way to 
confirm the presence of a peptide is by knowing its amino acid sequence. This information is 
obtained by tandem MS (denoted as MS/MS or MSn) when ions in the mass analyser are 
fragmented following the initial MS scan (Nesvizhskii et al., 2003). The produced ions are 
analysed in the same way like the precursor ions to create an MS2 spectrum, and if they are 
further fragmented, it creates an MS3 spectrum and so on. Sequence information obtained 
by MS/MS significantly improves the quality of the data, but not all mass analysers are 
capable of doing tandem MS. The probability of peptides and proteins of being true hits is 
calculated based on MS/MS and is reported as their respective scores.  
 
1.6.4. Stable isotope labelling of amino acids in cell culture 
One of the challenges of MS-based interaction experiments is distinguishing between prey 
and background proteins. Noise is generated by proteins that stick non-specifically to the 
purification matrix and do not interact with the bait. Housekeeping proteins, that are 
generally found at high abundance in cell extracts, are the most common contaminants, but 
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in some cases they can also be preys. Since there is no rule of thumb to identify bait-specific 
hits, one way to circumvent this problem is to use stable isotope labelling of amino acids in 
cell culture (SILAC) (fig. 1.6). In SILAC, two cell cultures are grown in differentially labelled 
media (Ong and Mann, 2006). One culture grows as normal in the presence of naturally 
occurring light amino acids, while the other grows in medium supplied with one or more 
amino acids containing heavy isotopes, such as 13C or 15N. After a few cycles, the amino 
acids are incorporated into newly synthesised proteins and the proteome becomes fully 
“labelled”. The heavy amino acids do not affect cell growth, nor interfere with any cellular 
processes.  
In MS, heavy and light peptides with identical sequence produce ions with slightly 
different m/z. In the mass spectrum chromatogram, they appear as peak pairs just a few 
daltons (Da) apart. The intensity of the peaks from MS1 is used to compare the relative 
abundance of proteins in the original samples (Trinkle-Mulcahy, 2012). Thus SILAC-MS 
provides additional quantitative information about the analysed samples.  
In a typical AP-MS experiment only one of the cultures expresses a tagged bait of 
interest, while the other one expresses either the tag alone or no tagged proteins. The bait 
is purified via the tag from a combined cell extract containing equal amount of proteins 
from both cultures. Following MS analysis, contaminating proteins show similar intensity of 
light and heavy peptides, while the bait and preys are enriched in the isotopic versions of 
the culture that they came from.  
 A number of other labelling strategies for quantitative MS have also been developed, 
including isobaric tags for relative and absolute quantitation (iTRAQ), tandem mass tags 
(TMT), isotope-coded affinity tag (ICAT), 18O labelling and 15N labelling. The most popular of 
these techniques is iTRAQ, where two or more protein samples are prepared separately and 
digested to peptides, which are then labelled at the N-terminus with different isobaric tags. 
The samples are then mixed together and analysed by MS. All isobaric tags have the same 
mass but can be distinguished from each other through the release of a different reporter 
ion during collision-induced dissociation. ITRAQ is commonly used to compare four or eight 
multiplexed samples, which makes it efficient in terms of reducing mass spectrometry time 
and data analysis. Both, iTRAQ and SILAC, have the advantages of being relatively easy to 
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Fig. 1.6: Identifying protein interactions by co-IP-MS using SILAC. In SILAC, two cell cultures are 
grown in the presence of either heavy or light isotopes. Any amino acid could be labelled, but lysine 
2and arginine are the most common choice. This is because downstream in the experimental 
procedure, proteins are often digested with trypsin, a protease that cleaves the backbone after each 
lysine or arginine residue. Thus, all of the resulting peptides will have one of these two amino acids 
at the C terminus. Consequently, in the heavy labelled proteome, all peptides will carry a heavy 
isotope and can be used for quantitation. 
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use and efficient at labelling. However, in SILAC, samples are mixed early in the 
experimental procedure which minimises handling-induced variation. In contrast, iTRAQ 
samples are processed separately and therefore this method is generally considered less 
accurate. SILAC has also been applied to compare up to five samples simultaneously, 
although the use of multiple isotopes significantly complicates data analysis (Molina et al., 
2009). Using SILAC can be disadvantageous in some eukaryotes that can convert arginine to 
proline, and hence heavy arginine to heavy proline (Marcilla et al., 2011). This can reduce 
the accuracy of data analysis, since the computer algorithms are not programmed to 
account for the additional variant of proline. Various experimental and computational 
methods can be employed to correct this issue (Lossner et al., 2011). This is not problem in 
iTRAQ, because the samples are labelled ex vivo. For the same reason, iTRAQ can be used to 
compare samples prepared in vitro, whereas SILAC is only used for in vivo labelling. 
SILAC experiments have traditionally involved generation of auxotrophic strains that 
must take up the heavy amino acids to survive. Recent studies have demonstrated that S. 
cerevisiae, S. pombe and E. coli all downregulate lysine biosynthesis in the presence of 
exogenous lysine and use the amino acids from the media instead (Frohlich et al., 2013). The 
authors concluded that prototrophs are a viable option in what they termed native SILAC 
(nSILAC). However, subsequent analysis of protein turnover in S. cerevisiae revealed that the 
yeast achieves full metabolic labelling during exponential growth but it restarts the 
production of endogenous lysine during stationary phase (Martin-Perez and Villeń, 2015). 
Nevertheless, nSILAC presents a promising new approach for studying proteome dynamics 
in actively growing cells. 
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1.7. Aims of this study 
 
This study aimed to first of all, develop an unbiased screen for kinase and phosphatase 
interacting partners in C. albicans using co-IP and MS as core techniques and second, to look 
at differences in KPI between yeast and hyphae. Since KPI screens by MS have not been 
previously performed in C. albicans, the project was designed to test established methods in 
other fungi and optimise them for use in Candida. Initially, experiments were guided by 
protocols published by Breitkeutz et al. (2011), who developed a global KPI network screen 
in S. cerevisiae using label-free MS. Two kinases (Dbf2 and Crk1), one phosphatase (Cdc14) 
and one kinase regulatory subunit (Mob1) were selected for preliminary experiments based 
on their established role in C. albicans morphogenesis. These four protein candidates were 
used as baits in a series of co-IP experiments with the aim to optimise AP-MS for each 
individual protein. Following optimisation of co-IP experiments in conjunction with label-
free MS analysis of potential substrates, the project focused on investigating Cdc14 
interactions further with the use of substrate-trapping technology and quantitative MS 
analysis. Strategies were developed and optimised in C. albicans in conjunction with SILAC-
MS for the analysis of interacting partners. This thesis describes the first application of SILAC 
in C. albicans and demonstrates that it is a viable method for studying protein interaction in 
this organism. Furthermore, proteins were labelled with heavy arginine and lysine in a strain 
that is auxotrophic for lysine, but prototrophic for arginine, suggesting that C. albicans may 
also be used for nSILAC. Finally, this study identified over 100 potential Cdc14 substrates in 
yeast and hyphae, suggesting a role of the phosphatase in DNA damage repair, chromosome 
segregation, cytoskeleton organisation and mitotic progression.  
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Chapter 2 
 
Materials and Methods 
 
 
 
 
2.1. Cell culture techniques 
 
2.1.1. Growth media 
All media was sterilised by autoclaving at 121 °C, 15 psi for 20 min after preparation. All 
media was stored at room temperature and once plated solid media was stored at 4 °C. 
YPD 
YPD was prepared using either of the following recipes: 
Ingredients  Amount  
 
  
Difco Bacto-yeast extract  10 g 
Difco Bacto-peptone  20 g 
D-glucose (Fisher Scientific)  20 g 
Uridine  80 mg 
Distilled water  Up to 1 L 
 
Ingredients  Amount  
 
  
Formedium™ YPD broth  50 g 
Uridine  80 mg 
Distilled water  Up to 1 L 
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YNB 
YNB was prepared using either of the following recipes: 
Ingredients  Amount  
 
  
Difco yeast nitrogen base without amino acids  6.7 g 
D-glucose   20 g 
Uridine*  80 mg 
Arginine*  80 mg 
Lysine*  80 mg 
Histidine*  80 mg 
Distilled water  Up to 1 L 
 
 
Ingredients  Amount  
 
  
Formedium™ yeast nitrogen base without amino acids  6.9 g 
D-glucose   20 g 
Uridine*  80 mg 
Arginine*  80 mg 
Lysine*  80 mg 
Histidine*  80 mg 
Distilled water  Up to 1 L 
 
*Amino acids were added selectively depending on cells’ requirements. 
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MET3 promoter-inducing media 
Ingredients  Amount  
 
  
Difco yeast nitrogen base without amino acids  6.7 g 
D-glucose   20 g 
Formedium™ complete supplement mixture drop-out: 
-arginine -lysine -methionine 
  
670 mg 
Uridine  80 mg 
Arginine  80 mg 
Lysine  80 mg 
Distilled water  Up to 1 L 
 
 
MET3 promoter-repressing media 
Ingredients  Amount  
 
  
Difco yeast nitrogen base without amino acids  6.7 g 
D-glucose   20 g 
Formedium™ complete supplement mixture drop-out: 
-arginine -lysine -methionine 
  
670 mg 
Methionine  60.6 mg 
Cysteine  373 mg 
Uridine  80 mg 
Arginine  80 mg 
Lysine  80 mg 
Distilled water  Up to 1 L 
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5-FOA media 
Ingredients  Amount  
 
  
Difco yeast nitrogen base without amino acids  6.7 g 
D-glucose   20 g 
5-fluoroorotic acid*  1 g 
Uridine  80 mg 
Arginine  80 mg 
Lysine  80 mg 
Distilled water  Up to 1 L 
 
*5-fluoroorotic acid powder was resuspended in water and sterilised with a 22μm filter. It 
was added to solution after the media was autoclaved and cooled down to 55 °C in a water 
bath. 
 
Heavy isotopes enriched media 
Ingredients  Amount  
 
  
Difco yeast nitrogen base without amino acids  6.7 g 
D-glucose  20 g 
Uridine  80 mg 
Arginine (13C6, 99%; 15N4, 99%)*  100 mg 
Lysine (13C6, 99%; 15N2,99%)*  100 mg 
Distilled water  Up to 1 L 
 
*Heavy isotopes of arginine and lysine were purchased from Cambridge Isotope 
Laboratories, Inc. 
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2TY 
Ingredients  Amount  
 
  
Difco Bacto-yeast extract  10 g 
Difco Bacto-tryptone  11 g 
NaCl  5 g 
5 M NaOH  adjust pH to 7.4 
Ampicillin*  100 mg 
Distilled water  Up to 1 L 
 
*Ampicillin was filter sterilised and added after the media was autoclaved. 
 
LB 
Ingredients  Amount  
 
  
Difco Bacto-yeast extract  5 g 
Difco Bacto-tryptone  10 g 
NaCl  10 g 
5 M NaOH  adjust pH to 7.4 
Ampicillin*  100 mg 
Distilled water  Up to 1 L 
 
*Ampicillin was filter sterilised and added after the media was autoclaved. 
 
Solid media 
Solid media was prepared by adding 20 g/L Difco Bacto-agar to any of the liquid broth prior 
to autoclaving.  
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Hyphae-inducing media 
Hyphae-inducing media was prepared by adding 20% v/v fetal new-born calf serum to the 
appropriate liquid broth immediately before the media was used. The media was then pre-
warmed to 37 °C before any cells were added. 
 
2.1.2. Growth conditions 
C. albicans strains were revived by inoculating frozen stock of cells on solid media and 
leaving the plates at 30 °C overnight. Plates were then stored at 4 °C for up to 1 week. 
 
C. albicans yeast 
C. albicans yeast was routinely grown in appropriately selected liquid broth in conical flasks 
shaking at 200 rpm at 30 °C. Stationary phase culture was grown overnight. Log phase 
culture was prepared by re-inoculating overnight culture into fresh medium at OD595 = 0.25 
± 0.02 and letting the cells grow until the culture reaches OD595 = 0.8 ± 0.02.  
 
C. albicans hyphae 
C. albicans hyphae were induced by inoculating a stationary phase yeast culture into 
selected pre-warmed hyphae-inducing media. Cells were then grown by shaking at 200rpm 
at 37 °C until hyphae reached the size of interest. 
 
E.coli 
E. coli cells were grown in LB or 2TY broth in conical flasks shaking at 200 rpm at 37 °C for 
the required length of time.  
 
 
 - 35 - 
 
2.1.3. Cell transformations 
All reagents were sterilised prior to use. Transformations were done near a Bunsen flame to 
minimise risk of contamination. 
 
C. albicans 
An overnight yeast culture was inoculated in 50 ml YPD at OD595 = 0.25 and incubated at 30 
°C to OD595 = 0.8. Cells were pelleted by centrifugation at 3000 rpm for 1 min and 
transferred to an eppendorf tube where they were washed with 1 ml of wash buffer (TE [10 
mM Tris-HCl, 1mM EDTA, pH 7.4], 100 mM LiAc, distilled water) and pelleted at 7000 rpm 
for 15 sec. Cells were then resuspended in 200 μl wash buffer by gentle pipetting. Each 
transformation reaction contained the following reagents: 
 
Ingredients  Amount  
   
1 M LiAc  36 μl 
10 x TE  30 μl 
Single stranded DNA from salmon testes (10 g/L)  10 μl 
60 % w/v PEG  300 μl 
Cell suspension   100 μl 
Precipitated DNA to be inserted*  Combined amount of 5 PCR 
reactions 
DMSO**  40 μl 
 
*A transformation reaction containing 100 μl of distilled water instead of DNA was used as a 
negative control. 
**All ingredients except DMSO were mixed together in an eppendorf tube, which was then 
incubated at 30 °C overnight. DMSO was added to the mixture on the following morning and 
the reaction was incubated at 42 °C for 15 min. The cells were pelleted by centrifugation at 
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8000 rpm for 15 sec, resuspended in 200 μl distilled water and plated on minimal media 
supplemented with the appropriate amino acids. Plates were incubated at 30 °C for 2-4 days 
and single colonies were tested for successful integration of the DNA by colony PCR and 
western blot. Successful transformants were grown on a separate plate and stored in the 
collection as described in section 2.1.4. 
 
E. coli 
All E. coli transformations were done using the strain DH5α from Delta Biotechnology.  
 
In order to make the cells competent, 10 μl of an overnight culture was inoculated in 
1 L fresh 2TY broth and left to grow at 37 °C with shaking at 200 rpm until it reached an 
OD550 = 0.5. Cells were pelleted by centrifugation at 4000 rpm for 5 min and resuspended in 
40 ml freshly prepared ice-cold transformation buffer I. Cells were left for 10 min on ice and 
pelleted again in the same manner. Cells were resuspended in 5 ml freshly prepared ice-cold 
transformation buffer II and incubated on ice for 15 min. Cells were then divided into 50 ml 
aliquots, frozen in liquid nitrogen and stored at -80 °C.  
 
Transformation buffer I: 
30 mM KAc 
10 mM RbCl2  
10 mM CaCl2  
50 mM MnCl2  
15 % v/v glycerol  
pH to 5.8 using acetic acid 
Transformation buffer II: 
10 mM MOPS 
75 mM CaCl2 
10 mM RbCl2 
15 % v/v glycerol  
pH to 6.5 using KOH 
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In order to transform E. coli, competent cells were defrosted on ice for 5 min and 25 
μl of cells were mixed with either 1 μl of plasmid DNA or 1 μl of water (negative control). 
Cells were incubated for 1 min at 42 °C and for 3 min on ice. A hundred microliters of 2TY 
was added to each reaction before cells were plated on 2TY solid media containing 
ampicillin and incubated at 37 °C overnight. Individual colonies were screened for positive 
results by inoculating them in 5 ml 2TY containing ampicillin and isolating plasmid DNA by 
doing a miniprep as described further bellow. 
 
2.1.4. Strain storage conditions 
Single colony of transformed cells was inoculated in liquid broth and grown to stationary 
phase overnight. Cells were then re-inoculated in 50 ml fresh medium and grown to OD595 = 
0.8. Cells were harvested by centrifugation, washed twice in 1 ml distilled water and 
resuspended in 2 ml 20 % glycerol. The mixture was split into two eppendorf tubes, which 
were stored in two separate freezers at -80 °C. 
 
2.1.5. C. albicans strains used in this study 
 
Strains constructed in this study 
Number 
in lab 
collection 
  
 
Strain  
  
Parental 
strain 
  
 
Genotype 
 
      
1822  Dbf2-HA  MDL04  DBF2/DBF2-HA::URA3 
1823  Dbf2-MYC  MDL04  DBF2/DBF2-MYC::ARG4 
1824  Cdc14-HA  MDL04  CDC14/CDC14-HA::URA3 
1825  Cdc14-MYC  MDL04  CDC14/CDC14-MYC::URA3 
1826  Cdc14-2xMYC  MDL04  CDC14-MYC::URA3/CDC14-MYC::ARG4 
1827  Cdc14-2xHA  MDL04  CDC14-HA::URA3/CDC14-HA::ARG4 
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Number 
in lab 
collection 
  
 
Strain  
  
Parental 
strain 
  
 
Genotype 
       
1828  Dbf2-2xHA  MDL04  DBF2-HA::URA3/DBF2-HA::ARG4 
1829  Dbf2-2xMYC  MDL04  DBF2-MYC::ARG4/DBF2-MYC::URA3 
1830  Mob1-MYC  MDL04  MOB1/MOB1-MYC::URA3 
1831  Mob1-2xMYC  MDL04  MOB1-MYC::URA3/MOB1-MYC::ARG4 
1832  Crk1-MYC  MDL04  CRK1/CRK1-MYC::ARG4 
1833  Crk1-2xMYC  MDL04  CRK1-MYC::ARG4/CRK1-MYC::URA3 
1834  Cdc14/cdc14Δ  MDL04  CDC14/cdc14::frt 
1835  Dbf2-MYC in Cdc14-
HA 
 MDL04  DBF2/DBF2-MYC::ARG4 
CDC14/CDC14-HA::URA3 
1836  Dbf2-TAP  MDL04  DBF2/DBF2-TAP::ARG4 
1837  Cdc5-MYC  MDL04  CDC5/CDC5-MYC::ARG4 
1838  Tup1-HA  BWP17  TUP1/TUP1-HA::URA3 
1839  Mob1-TAP  MDL04  MOB1/MOB1-TAP::ARG4 
1840  Lys2/lys2Δ  BWP17  LYS2/lys2::frt 
1841  Mob1-2xTAP  MDL04  MOB1-TAP::ARG4/MOB1-TAP::URA3 
1842  MET3-Cdc14  MDL04  CDC14/ARG4::MET3-CDC14 
1843  Cdc14-TAP  MDL04  CDC14/CDC14-TAP::URA3 
1844  Cdc14-2xTAP  MDL04  CDC14-TAP::URA3/CDC14-TAP::ARG4 
1845  cdc14C275S-MYC  MDL04  CDC14/cdc14C275S-MYC::URA3 
1846  cdc14C275S-GFP  MDL04  CDC14/cdc14C275S-GFP::ARG4 
1847  cdc14C275S-TAP  MDL04  CDC14/cdc14C275S-TAP::ARG4 
1848  Mlc1-GFP in 
cdc14C275S-MYC 
 MDL04  CDC14/cdc14C275S-MYC::URA3 
MLC1/MLC1-GFP::ARG4 
1849  MET3-cdc14C275S-
MYC 
 MDL04  CDC14/ARG4::MET3-cdc14C275S-
MYC::URA3 
1850  MET3-Cdc14/ 
cdc14C275S-MYC 
 MDL04  ARG4::MET3-CDC14/cdc14C275S-
MYC::URA3 
       
 39 
 
Number 
in lab 
collection 
  
 
Strain  
  
Parental 
strain 
  
 
Genotype 
       
1851  Cdc14-GFP/ 
cdc14C275S-MYC 
 MDL04  CDC14-GFP::ARG4/cdc14C275S-
MYC::URA3 
1852  Cdc14-GFP  BWP17  CDC14/CDC14-GFP::ARG4 
 
 
Other strains used in this study 
Strain  Genotype  Reference 
     
BWP17  ura3::imm434/ura3:imm434 his1::his1G/his1::his1G 
arg4::hisG/arg4::hisG 
 Wilson et al., 1999 
MDL04  lys2::CmLEU2/lys2::CdHIS1 arg4Δ/arg4Δ leu2Δ/leu2Δ 
his1Δ/his1Δ ura3Δ::imm434/ura3Δ::imm434 
iro1Δ::imm434/iro1Δ::imm434 
 Gift from Munro Lab, 
University of 
Aberdeen 
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2.2. DNA techniques 
 
2.2.1. PCR of plasmid DNA 
DNA sequences containing an epitope tag and a selectable marker of interest were 
amplified by polymerase chain reaction (PCR). The conditions of the reaction were as 
follows: 
 
PCR stage  Temperature  Time  Number of cycles 
       
Initial denaturation  95 °C  5 min  1 
DNA denaturation  95 °C  30 sec   
Primers annealing  50 - 55 °C*  30 sec  30 
DNA extension  72 °C  2-4 min**   
Final DNA extension  72 °C  10 min  1 
       
 
*The annealing temperature of each reaction was primer pair-specific and was determined 
by trial and error. 
**The extension time of each reaction was determined based on the length of the DNA 
template. One minute extension time was allowed for every 1kbp of DNA template. 
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Each PCR contained the following ingredients mixed together in nuclease-free sterile 
tubes: 
 
Ingredients  Amount  
 
  
ddH2O  25 μl 
5x HiFi buffer (Bioline)  10 μl 
10 mM dNTP (Bioline)  5 μl 
5 μM forward and reverse primers  4 μl each 
DNA template at approx. 20ng/ μl  1 μl 
Velocity polymerase (Bioline)  1 μl 
MgCl2*  4 μl 
 
*MgCl2 was added to some reactions if it was found to give better product yield. When 
MgCl2 was added, the amount of ddH2O was reduced to 21 μl. 
 
Vector plasmids were typically used as templates for PCR. Primers were designed to 
contain homologous sequences to the vector that will anneal to it and amplify a cassette, 
and up to 80 bp flanking sequences that are homologous to a region of genomic DNA where 
the cassette will be inserted. Successful amplification of DNA was confirmed by agarose gel 
electrophoreses. When PCR was carried out for the purpose of cell transformation, the 
products of five reactions were mixed together and the DNA was precipitated as described 
in section 2.2.3. 
 
2.2.2. Colony PCR 
After cell transformation, insertion of a DNA cassette was tested by isolating single colony 
cells and re-suspending them in 5 μl ddH2O. Cells were boiled for 5 min at 95 °C and frozen 
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at -80 immediately afterwards. This step aims to break the cells open, so the DNA is released 
in solution. To set up a PCR, each tube contained the following reagents:  
 
Ingredients  Amount  
 
  
Cell suspension   5 μl 
2x Biomix Red  12.5 μl 
5 μM forward and reverse primers  2 μl each 
ddH2O  3.5 μl  
 
The conditions of each reaction were as follows: 
 
PCR stage  Temperature  Time  Number of cycles 
       
Initial denaturation  95 °C  5 min  1 
DNA denaturation  95 °C  30 sec   
Primers annealing  50 – 55 °C*  30 sec  35 
DNA extension  68 °C  1-2 min*   
Final DNA extension  68 °C  10 min  1 
       
*As already mentioned above, primers annealing temperature and DNA extension time 
were reaction-specific and determined as previously described. 
 
Primers used in colony PCR were designed to amplify a DNA product containing a 
few hundred base pairs from the 3’ end of the tagged gene and a few hundred base pairs 
from the 5’ end of the epitope tag. Amplification of the desired PCR product was confirmed 
by agarose gel electrophoresis.  
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2.2.3. DNA precipitation 
In order to precipitate DNA products of PCR, the contents of five reactions were pooled 
together to a total volume of 250 μl and mixed with 25 μl of 3.5 M NaAc at pH 5.2 and 675 
μl of 100% ethanol. The solution was incubated at -20 °C overnight and then spun at 
maximum speed in a microfuge at 4 °C for 30 min. The supernatant was discarded and the 
pellet was resuspended in 500 ml of 70% ethanol. The solution was centrifuged again and 
the supernatant was discarded. The pellet was air-dried in a sterile hood for 15 min and 
then resuspended in 100 μl distilled water. Successful DNA precipitation was confirmed by 
agarose gel electrophoresis. 
 
2.2.4. Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate DNA molecules according to their size and 
charge in order to check for the presence of DNA or estimate its amount in solution, e.g. 
after PCR or DNA precipitation. Commonly, agarose gel was prepared using 1% w/v agarose 
dissolved in 100ml TAE buffer (400mM Tris-HCl, 200 mM acetate and 10 mM EDTA) and 1 μl 
EtBr. Settled gel was fully submerged in TAE buffer and DNA aliquots diluted with DNA 
loading buffer (Bioline) were loaded in wells. HyperLadder I (Bioline) was routinely used as a 
DNA marker in order to visually estimate the size of DNA molecules. Electric current of 80 V 
was applied for 40 min to stimulate migration of DNA along the gel. DNA was visualised by 
exposing the gel to UV transillumination.  
 
2.2.5. Restriction digest 
Restriction digest of DNA with endonucleases was performed prior to ligating two molecules 
in order to generate compatible ends. All enzymes and buffers were purchased from New 
England Biolabs (NEB). Each reaction contained 1 μl of two different nucleases, 2 μl of DNA, 
2 μl of the NEB-recommended buffer and 14 μl of ddH2O. All ingredients were mixed 
together in a tube and incubated at 37 °C for 2 hrs followed by 65 °C for 5 min. Correct size 
of the cut DNA fragments was confirmed by agarose gel electrophoresis. 
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2.2.6. DNA gel extraction 
Following endonuclease digestion, DNA fragments were separated on agarose gel and the 
bands were cut out of the gel with a scalpel while being illuminated by UV light. DNA was 
purified from the gel using Qiagen’s QIAquick Gel Extraction Kit and following the 
manufacturer’s protocol.  
 
2.2.7. DNA ligation 
DNA ligation reactions contained a linearised vector and an insert in a molar ratio of 1:2, 1 μl 
of T4 DNA ligase (NEB) and 1 μl of 10x T4 buffer (NEB) in a total volume of 10 μl. The 
reaction was incubated at 16 °C for 15 hrs and at 65 °C for 10 min.  
When linker oligonucleotides were used, 1 μl of both oligos was mixed with 23 μl of 
ddH2O and incubated at 95 °C for 2 min and then at 45 °C for 10 min to allow for 
hybridisation. One microliter of this solution was added to the ligation reaction before 
incubation at 16 °C.  
One microliter of the ligation reaction was used to transform E. coli cells as described 
above. 
 
2.2.8. Plasmid DNA miniprep 
Plasmid DNA was prepared using QIAprep Spin Miniprep Kit from Qiagen following the 
manufacturer’s instructions. DNA was eluted in 100 μl of ddH2O and stored at -20 °C. 
 
2.2.9. DNA sequencing 
All DNA sequencing was done by the University of Sheffield Core Genomic Facility. Samples 
were prepared by following the facility’s guidelines.  
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2.2.10. Oligonucleotides used in this study 
All oligonucleotides were produced by Sigma Aldrich. 
 
Primer  Sequence in direction 5’->3’ 
S1-Cdc14-XFP  GGATTGCTTCTGGAAACTCACAAACATCAAGAGCACACTCTGGTGGTGTGA
GAAAGTTAAGTGGAAAGAAACATggtgctggcgcaggtgcttc 
S2-Cdc14*-
XFP 
 CCGACTTGGCCAAGCCTAGATCCCGACTAATAGGAATTGATTTGGATGGTAT
AAACGGAAACAAAAAAAAGAGCTGGTACTACtctgatatcatcgatgaattcgag 
Cdc14*-
TAP/HA/MYC_
R 
 CCGACTTGGCCAAGCCTAGATCCCGACTAATAGGAATTGATTTGGATGGTAT
AAACGGAAACAAAAAAAAGAGCTGGTACTACtcgatgaattcgagctcgtt 
S2-Cdc14-XFP  GGATTTCGATATATTGGCTTTTGCATATGGTTCGGAAGAACAAATTGAAATT
GTTGAACCAGCTTATGAAGAAGACTAATTTAGtctgatatcatcgatgaattcgag 
Cdc14-TAP-
MYC_F 
 CTCACAAACATCAAGAGCACACTCTGGTGGTGTGAGAAAGTTAAGTGGAAA
GAAACATggtcgacggatccccgggttagaacagaagcttatatccgaa 
Cdc14-TAP-
HA-MYC_R 
 CGAGTGGCCTATCCAAAAGATTCAACTCAGCCTTATTCCAATAACTGGATTG
AATTGAGTGAAGATAGTGATATTGCTGtcgatgaattcgagctcgtt 
Cdc14-chk_F  GACATCTCCACTTGCTGATTCTTCTG 
Cdc14-chk-
myc_R 
 GGCTTTTGCATATGGTTCGGAAGAAC 
 
Cdc14-
URAF_F 
 GTCTTTCATTCAAAAACACGTTTGTTTCTACCATACCGTTCTAAACTACCTAA
TAATCACAAACACCTTTTCCGctcgaggaagttcctatactttc 
Cdc14-
URAF_R 
 CGAGTGGCCTATCCAAAAGATTCAACTCAGCCTTATTCCAATAACTGGATTG
AATTGAGTGAAGATAGTGATATTGCTGctctagaactagtggatctgaagtt 
NotI-Cdc14-
3’_F 
 GGCGGG GCGGCCGC GTCTTCTTCATAAGCTGGTTCAAC 
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Primer  Sequence in direction 5’->3’ 
SacI-Cdc14-
3’_R 
 GGCGGG GAGCTC CGGAGAATACAAGTACCATTCTCAAG 
Cdc14-S1-
MET3_F 
 AAATGTATATAACGAAGATGACTATCATCAATGGTCCGGTTAGTAAAGCGA
ACAAGCTTTATAAAAATAGTTATGCTGAACGTACCATgaagcttcgtacgctgcag
gtc 
Cdc14-S2-
MET3_R 
 AAAGGTAGAACAATCAATTTGAAGTAGATTTTCCCAACATACTTTTAAGAAA
CTCTATAAGAGGCACATGAACCAGTGAACTATGcatgttttctggggagggtatttac 
MET3-chk_F  GCGCCCCTCTAAAACAATACCC 
Cdc14-
5’chk_R 
 GGTAATGCGTCTTCAACTGTG 
Cdc14-TAP-
MYC_F 
 CTCACAAACATCAAGAGCACACTCTGGTGGTGTGAGAAAGTTAAGTGGAAA
GAAACATggtcgacggatccccgggttagaacagaagcttatatccgaa 
Cdc14-TAP-
HA-MYC_R 
 CGAGTGGCCTATCCAAAAGATTCAACTCAGCCTTATTCCAATAACTGGATTG
AATTGAGTGAAGATAGTGATATTGCTGtcgatgaattcgagctcgtt 
Cdc14-chk_F  GACATCTCCACTTGCTGATTCTTCTG 
Cdc14-chk-
myc_R 
 GGCTTTTGCATATGGTTCGGAAGAAC 
NotI-Cdc14-
3’_F 
 GGCGGG GCGGCCGC GTCTTCTTCATAAGCTGGTTCAAC 
 
SacI-Cdc14-
3’_R 
 GGCGGG GAGCTC CGGAGAATACAAGTACCATTCTCAAG 
Cdc14-S1-
MET3_F 
 AAATGTATATAACGAAGATGACTATCATCAATGGTCCGGTTAGTAAAGCGA
ACAAGCTTTATAAAAATAGTTATGCTGAACGTACCATgaagcttcgtacgctgcag
gtc 
Cdc14-S2-
MET3_R 
 AAAGGTAGAACAATCAATTTGAAGTAGATTTTCCCAACATACTTTTAAGAAA
CTCTATAAGAGGCACATGAACCAGTGAACTATGcatgttttctggggagggtatttac 
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Primer  Sequence in direction 5’->3’ 
S2-Cdc14-XFP  GGATTTCGATATATTGGCTTTTGCATATGGTTCGGAAGAACAAATTGAAATT
GTTGAACCAGCTTATGAAGAAGACTAATTTAGtctgatatcatcgatgaattcgag 
BamHI linker  GAT CCC TCC CAG AAC 
XhoI linker  TCG AGT TCT GGG AGG 
XhoI-Cdc14_F  GGC GGG CTC GAG GGC TTT CCT TTC CTT TGC TAT G 
XbaI-Cdc14-
MYC_R 
 GGC GGG TCT AGA CTA ATT TGT GAG TTT AGT ATA CAT GC 
Cdc14-seq1_R  GAGGCACATGAACCAGTGAAC 
Cdc14-seq2_F  GATGGAAGAGATCTTTTTGGAATTTC 
Cdc14-seq3_F  CCAGAATTGGGCTCCTCATCAAG 
Cdc14-seq4_F  GGTTGTTTGATTGGAGCCCATC 
Cdc14-seq5_F  GCTCACCAGCAAGGTATGACTC 
Cdc14 C275S F  GCAGTACATTCTAAAGCAGGGTTAGG 
Cdc14 C275S 
R 
 CCTAACCCTGCTTTAGAATGTACTGC 
Cdc14C275S_c
hk_R 
 CCGGTTCTTCCTAACCCTGCTTTAG 
URA-F  GGAAGAGATCCAGATATTGAAGG 
URA-R  TGTGCTACTGGTGAGGCATG 
ARG-F1  CTGCTAAAAGTGCCGTTTTAAAACAATT 
ARG-R1  ACCGGTGAAACGACCACCCCATAATTT 
myc-R  GTATACATGCATTTACTTATAATGGCGCGC 
Crk1-TAP-
MYC_F 
 CAGTTTATAAAAGAATTATAAATGAGAAAATGAGGTTTGAAAAGTTATCGG
GAGGACACAAATCTATGggtcgacggatccccgggttagaacagaagcttatatccgaa 
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Primer  Sequence in direction 5’->3’ 
Crk1-TAP-HA-
MYC_R 
 GCTCAGTTGCAAGAATGGTTTAGTGGTAAAATCCAACGTTGCCATCGTTGG
GCCCCGGGTTCGATTCCCGGTTCTTGCtcgatgaattcgagctcgtt 
Crk1-chk_F  GTGCTGTTGCTGTCTAGATCG 
Crk1-
chkout_R 
 CGTGACTTGATGGACCTAAGG 
Dbf2-TAP-
MYC_F 
 GGAAATGGAATTGGAAATGGAAATTCTCGATCAAGTAGATTAAATCCATTA
GCTACATTGTATggtcgacggatccccgggttagaacagaagcttatatccgaa 
Dbf2-TAP-HA-
MYC_R 
 GATAAAATTAAGAATGATTATATTTGGAAACAAGAAAGGGAAGATGAATAA
GAAGAAGAAGAAGAATAGTGGGGAGTGGtcgatgaattcgagctcgtt 
Dbf2-chk_F  CTCCCCAATTGGATAATGAAGAAGATGC 
Dbf2-chk-
myc_R 
 GCCGGATCTCTACGAGTTTACAAGTC 
S1-Mlc1-XFP  GTTGATGAGTTATTAAAAGGGGTCAATGTAACTTCTGATGGAAATGTGGAT
TATGTTGAATTTGTCAAATCAATTTTAGACCAAggtgctggcgcaggtgcttc 
S2-Mlc1-XFP  GGGAACGAGATGGAATCTTTCGTTACGCCTCACATCTGTTTCAGGGTTATCT
ATGCTATTAGCTGTTATCGTTATGCTTTCACTCtctgatatcatcgatgaattcgag 
Mlc1-chk_F  CATCAACAGACCAGACGGTTTC 
Mob1-TAP-
MYC_F 
 CAATTAATTAGCAGGAAAGACTACGGTCCATTAGAGGACTTGGTAGACACG
ATGCTTCAAAGAggtcgacggatccccgggttagaacagaagcttatatccgaa 
Mob1-TAP-
HA_F 
 CAATTAATTAGCAGGAAAGACTACGGTCCATTAGAGGACTTGGTAGACACG
ATGCTTCAAAGAggtcgacggatccccgggttatacccatacgatgttcctgac 
Mob1-TAP-
HA-MYC_R 
 CAATATAAAATCAAACTAACAAAGCTACTTAGATTGCCTACACCAGAAGAAA
TGGGGTCACCACCGTCAGGtcgatgaattcgagctcgtt 
Mob1-chk_F  CCAGTATCATTACCTGCTTGTG 
Mob1-
chkout_R 
 CGAAGAGTTAGAGCAAGAAAG 
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2.2.11. Plasmids used in this study 
 
Plasmids constructed in this study: 
Plasmid  Description  
pINK1  GFP gene was cut out of pRSC3 vector and replaced with CDC14-MYC 
sequence, including 400 bp upstream sequence of CDC14 
pINK2  pINK1 vector containing mutation cdc14C275S 
pINK3  pINK2 vector, where 400 bp downstream sequence of CDC14 was cloned 
between SacI and NotI restriction sites  
 
 
Other plasmids used in this study: 
Plasmid  Application  Reference 
pFA-MYC-URA3  Amplification of MYC-URA3 cassette  Lavoie et al., 2008 
pFA-MYC-ARG4  Amplification of MYC-ARG4 cassette  Lavoie et al., 2008 
pFA-HA-URA3  Amplification of HA-URA3 cassette  Lavoie et al., 2008 
pFA-HA-ARG4  Amplification of HA-ARG4 cassette  Lavoie et al., 2008 
pFA-TAP-URA3  Amplification of TAP-URA3 cassette  Lavoie et al., 2008 
pFA-TAP-ARG4  Amplification of TAP-ARG4 cassette  Lavoie et al., 2008 
pFA-ARG4-MET3  Amplification of ARG4-MET3 cassette  Gola et al., 2003 
pFA-GFP-URA3  Amplification of GFP-URA3 cassette  Gola et al., 2003 
pFA-GFP-ARG4  Amplification of GFP-ARG4 cassette  Gola et al., 2003 
pFA-URA3  Amplification of URA3 cassette  Gola et al., 2003 
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2.3. Protein techniques 
 
2.3.1. Soluble protein extraction 
Protein extraction was achieved by breaking the cells open to release their protein contents 
in solution and removing the cell debris by centrifugation afterwards. This method captures 
only the soluble proteins of the cell and omits the insoluble fractions such as membrane-
embedded proteins. Cell pellets were commonly resuspended in ice-cold lysis buffer (20 
mM HEPES, 150 mM NaCl, pH 7.4, EDTA-free protease inhibitors (Roche), 1mM PMSF) and 
depending on the total volume, cells were broken by one of the following methods: 
 
 Small scale extraction 
When cells were resuspended in less than 1 ml of lysis buffer, they were mixed with the 
same volume of acid-washed glass beads in a tube and violently agitated in a Mini-
Beadbeater-16 (Biospec) for 3x 30 sec. Tubes were chilled on ice for 1 min between 
beatings. Cell debris was pelleted by centrifugation in a top bench centrifuge at maximum 
speed for 10 min at 4 °C. The supernatant was transferred to a clean eppendorf tube before 
being used in downstream applications. 
 
 Large scale extraction 
When large volume of cell lysate was required, pelleted cells were resuspended in 10 ml 
of lysis buffer and broken in a high pressure cell disrupter (Constant Systems Ltd.) at 35 psi, 
4°C. Cell debris was pelleted in a Beckman Coulter Avanti™ J-20 centrifuge using rotor JA-20 
at 20 000 rpm, 4 °C for 15 min. The supernatant was passed through a 44 μm syringe filter 
to get rid of small residual debris. This method gives approximately 10 ml of cell lysate. 
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2.3.2. SDS-PAGE 
Proteins were separated according to their size and charge using sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE). Mini-PROTEAN® TGX™ Precast Gels 4-15% 
(Bio-Rad) were used in all mass spectrometry experiments. For all other applications, gels 
were prepared using the following recipe: 
 
Resolving gel 
Reagents  6%  8%  10%  12% 
         
ProtoGel (30%)  2 ml  2.67 ml  3.33 ml  4 ml 
ProtoGel Resolving Buffer (4x)  2.5 ml  2.5 ml  2.5 ml  2.5 ml 
ddH2O  5.39 ml  4.72 ml  4.06 ml  3.39 ml 
10% w/v APS  100 μl  100 μl  100 μl  100 μl 
TEMED  10 μl  10 μl  10 μl  10 μl 
 
Stacking Gel 
Reagents  Amount 
   
ProtoGel (30%)  0.52 ml 
ProtoGel Stacking Buffer   1 ml 
ddH2O  2.44 ml 
10% w/v APS  20 μl 
TEMED  2 μl 
 
Polymerised gels loaded with protein samples were run in running buffer (25mM 
Tris-Base, 190 mM glycine, 0.1 % w/v SDS) at 180 V for as long as necessary. Protein samples 
were diluted with 5x protein loading dye (62 mM Tris-HCl (pH 6.8), 25% v/v glycerol, 25% 
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w/v SDS, 0.01% w/v bromophenol blue, 0.05% β-mercaptoethanol) and boiled for 5 min at 
95 °C prior to loading on the gel. In order to estimate protein size Prestained Protein Marker 
7-175 kDa (NEB) was loaded on each gel. 
 
2.3.3. Western blot 
Proteins were transferred from the polyacrylamide gel onto nitrocellulose membranes (GE 
Healthcare) using Bio-Rad’s Wet/Tank Blotting System Mini Trans-Blot® Cell. Protein transfer 
was done in transfer buffer (25 mM Tris-HCl (pH 7.6), 190 mM glycine, 20 % v/v methanol) 
at 150 mA for 100 min. Successful transfer was confirmed by staining membranes with 0.2% 
w/v Ponceau S. Membranes were then washed with water to remove the dye and placed in 
SNAP i.d.® 2.0 Protein Detection System (Merk Millipore) where all subsequent steps were 
done. Membranes were blocked with 1 % w/v BSA dissolved in TBST buffer (20 mM Tris pH 
7.5, 150 mM NaCl, 0.1% Tween 20, pH 7.6) for 30 min. Both primary and secondary 
antibodies diluted in 1 % BSA were applied for 15 min, and membranes were washed with 
3x 15 ml TBST buffer after each application. Membranes were then transferred to falcon 
tubes containing 1 ml of each enhanced chemiluminescence (ECL) solutions I and II and 
incubated at 4 °C in the dark for 5 min with gentle rolling. Protein bands were visualised 
using GeneGnomeXRQ gel doc system and GeneTools analysis software, both from Syngene.  
 
ECL I: 
1 ml 1M Tris-HCl pH 8.5 
100 μl 250 mM luminol in DMSO 
44 μl 90 mM p-coumaric acid in DMSO 
8.856 ml sdH2O 
 
 
ECL II: 
1 ml 1M Tris-HCl pH 8.5 
6.1 μl 30 % H2O2  
8.994 ml sdH2O 
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Antibodies used in this study: 
 
Antibody  Dilution  Type  Supplier 
       
Mouse anti-HA  1:3 000  Primary monoclonal  Bioserv 
Mouse anti-MYC   1:1 000  Primary monoclonal  Bioserv 
Mouse anti-GFP  1:1 000  Primary monoclonal  Roche 
Goat anti-mouse  1:10 000  Secondary polyclonal  Roche 
Anti-PSTAIRE  1:10 000  Primary monoclonal  Roche 
 
2.3.4. Stripping of antibodies from a nitrocellulose membrane 
Some membranes were probed with two primary antibodies. In this case after proteins 
were detected with the first antibody, membranes were washed with stripping buffer (20 ml 
10% SDS, 12.5 ml 0.5 M Tris-HCl, 67.5 ml ddH2O, 0.8 ml β-mercaptoethanol) for 2 hrs at 4 °C. 
Membranes were then washed five times with 10 ml TBST for 10 min and probed with the 
second primary antibody as described above. 
 
2.3.5. In vitro protein dephosphorylation 
Dephosphorylation of proteins in vitro was achieved by treating 100 μl protein sample with 
1μl (400 units/μl) λ phosphatase (NEB) in the presence of 1x Buffer for Protein 
Metallophosphatases (NEB) and 1mM MnCl2. The reaction was allowed to proceed at 30 °C 
for 1 hr. A control reaction containing no phosphatase was set up in parallel. The reaction 
was stopped by adding protein loading dye to the samples and boiling them for 5 min at 95 
°C. 
 
 
 
 54 
 
2.3.6. Protein purification 
Proteins fused to an epitope tag were purified from cell lysates with the use of beads 
coupled to an antibody against the tag. All steps were carried while keeping the tubes on ice 
as much as possible. All buffers and solution were pre-cooled to 4 °C prior to use. Cells were 
lysed as previously described and depending on the beads used as an affinity matrix one of 
the following protocols was followed: 
 
 Dynabeads® Protein G (Thermo Fisher Scientific) 
Magnetic Dynabeads® were used according the manufacturer’s instructions with the 
following modifications. A hundred microliters of bead slurry were transferred to a tube and 
beads were pelleted using a magnet. After removing the supernatant, 20 μg of either anti-
MYC or anti-HA antibody diluted in 400 μl of lysis buffer was added to the beads and they 
were incubated at 4 °C for 2 hrs with shaking. The beads were pelleted and washed three 
times with lysis buffer. They were then added to the cell lysate and incubated at 4 °C for 1 hr 
with inversion. Beads were pelleted once again and washed once with lysis buffer. Beads 
were resuspended in 50 μl protein loading buffer and boiled at 95 °C for 5 min to elute the 
antigen. 
 
 EZview™ Red Anti-c-Myc Affinity Gel (Sigma Aldrich) 
EZview™ agarose beads were used according to the manufacturer’s instructions with the 
following modifications. Between 20-200 μl of bead slurry were transferred to a tube and 
beads were pelleted in a bench centrifuge at 1500 rpm for 30 sec. Beads were washed three 
times with lysis buffer and incubated with the cell lysate at 4 °C for 1-2 hrs with rotation. 
Beads were then pelleted again and washed 1-3 times with lysis buffer. Antigen was eluted 
from the beads by adding 1x beads volume of protein loading dye and boiling the 
suspension at 95 °C for 5 min.  
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After proteins were eluted in solution, a small aliquot was analysed by Western blot and, 
if required, a larger aliquot was separated electrophoretically and the gel was stained with 
Coomassie.  
 
2.3.7. Coomassie staining of polyacrylamide gels 
Coomassie staining was used to visualise proteins on polyacrylamide gels. Typically, gels 
were transferred to a sterile and keratin-free Petri dish and were soaked in approximately 
30 ml of Coomassie InstantBlue (Expedeon) for at least 1 hr with gentle shaking. After this, 
gels were washed with ddH2O until water was clear. If gels were not used in the same day, 
they were stored in 1% acetic acid at 4 °C. 
 
2.3.8. Trypsin in-gel digestion of proteins and peptides gel extraction 
Peptide samples prepared by trypsin in-gel digestion were commonly analysed by MS. 
Therefore, great care was taken to minimise keratin contamination during preparation. All 
working surfaces were cleaned with decontamination solvent (0.1% acetic acid in 10% 
isopropanol) prior to work. Proteins were separated on keratin-free precast gels. Gels were 
kept in keratin-free petri dishes and samples and solutions were handled in keratin-free 
falcon or eppendorf tubes. 
Each IP sample was divided into 15-20 bands. Protein bands were excised from a 
Coomassie-stained gel and cut into ca. 1x 1 mm pieces with the aid of sterile scalpel. Gel 
pieces were submerged in 100 μl 50 mM ammonium bicarbonate (ABC) for 5 min before 
adding 100 μl acetonitrile (ACN) for further 10 min. After that the supernatant was 
removed. Gel pieces were repeatedly washed in this manner with ABC and ACN until the 
Coomassie stain was no longer visible (usually 2-4 times). Gel pieces were then dried in a 
vacuum centrifuge at room temperature until they shrink. Dry pieces were soaked in 30 μl 
digestion buffer (12.5 ng/μl Trypsin in 50 mM ABC). Additional 50 mM ABC was added after 
1 hr until it fully covers the gel pieces. Samples were incubated at 37 °C overnight to allow 
for enzymatic digestion of proteins into peptides. On the next day, supernatants were 
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transferred to clean lo-bind collection tubes and gel pieces were soaked in 15 μl 25 mM ABC 
for 10 min at room temperature. Supernatants were transferred to the collection tubes 
again and gel pieces were soaked in 50 μl ACN for 15 min at 37 °C with shaking. 
Supernatants were transferred to the collection tubes and gel pieces were incubated with 
50 μl 5% v/v formic acid (FA) for 15 min at 37 °C with shaking. Supernatants were 
transferred to the collection tubes and gel pieces were submerged in 50 μl ACN for 15 min 
at 37 °C with shaking. The supernatant was transferred to the collection tubes and the gel 
pieces were discarded. At this point all digested peptides are found in solution in the 
collection tubes. Peptides were dried out in a vacuum centrifuge at 30 °C until completely 
dry. Peptides were stored at -20 until further use. 
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2.4. Mass spectrometry 
Dry peptides were resuspended in ca. 10 μl MS buffer C (0.1% Trifluoroactic Acid (TFA), 3% 
ACN prepared with LC-grade H2O) and sonicated in a water bath for 5 min. An aliquot of this 
solution was transferred into MS tubes and loaded on an LC-MS instrument for further 
analysis. The remaining samples were stored at -20 °C. 
Depending on the requirements of the MS analysis, samples were processed in either of 
three MS instruments: 
 
 Amazon ESI-ion trap (Bruker Daltonics) 
Label-free samples were loaded on ESI-ion trap MS coupled to an Ultimate 3000 online 
capillary liquid chromatography system with a 30 cm x 5mm Acclaim PepMap300 C18 
trapping column with 300 Å pore size and 5 µm particle size (Thermo Fisher Scientific, 
Hemel Hempstead, UK). Peptides were separated by linear gradient in Buffer A(0.1% FA, 3% 
ACN) and  Buffer B (0.1% FA, 97% ACN) at 3-36% over 60 min at a flow rate of 300nL/min 
using 15 cm x 75 µm onto Acclaim PepMap C18 column with 100 Å pore size and 5 µm 
particle size (Thermo Fisher Scientific, Hemel Hempstead, UK). MS1 profile scans were 
acquired in positive mode at a range of m/z=300-1500 and a speed of 8100 m/z/s. Collision-
induced dissociation (CID) of 8 ions was performed with active exclusion after 2 spectra and 
release after 2 min. MS2 scans were acquired at a range of m/z=50-3000. During 
fragmentation, the target value of the trap was 250 000 for maximum of 50 ms. 
Raw data was used to generate Mascot Generic Files (MGF) in Data Analysis v 4.1 with 
the following settings: signal to noise threshold of 1, base peak intensity of 0.1, absolute 
intensity threshold of 100, peak width at half maximum m/z 0.1 Charge state deconvolution 
from fragment spectra was allowed. MGF files were submitted to Mascot Deamon v 2.5.1 
(Matrix Science) where searches were performed against the C. albicans database, 
taxonomy all entries, with maximum of 2 missed cleavages allowed, peptide charge +2, +3 
and +4, MS and MS/MS peptide tolerance of 0.1 Da, methionine oxidation as a variable 
modification.  
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 MaXis ESI-QTOF (Bruker Daltonics) 
For the purpose of SILAC experiments, samples were loaded on ESI-QTOF coupled to the 
same LC system with the same settings as described for Amazon ESI-ion trap. Peptides were 
eluted on the PepMap C18 column (as above) by liner gradient in Buffer A and then Buffer B 
4-40% over 90 min at a flow rate of 300 nL/min. MS1 scans were performed in positive 
profile mode with an m/z range of 100-1800. CID fragmentation was performed with 
maximum of three precursor ions per cycle with absolute threshold of 3000, active exclusion 
after 2 spectra and release after 0.25 min. Captive Spray capillary was set to 4500 V and end 
plate offset was set to 500 V. 
Raw data (.baf files) was submitted to Mascot Distiller v. 2.5.1.0 where peak picking and 
peptide quantitation was done by default paramenters for maXis ESI-TOF. Peptides were 
searched against the C. albicans database, with maximum of 2 missed cleavages allowed, 
MS and MS/MS tolerance of 0.1 Da, methionine oxidation as a variable modification, 
peptide charge +2, +3 and +4 and SILAC quantitation (K+8, R+10). True proteins require at 
least 2 peptides, and quantified proteins require at least two peptides with L/H ratios. Data 
was exported to Excel and contaminants were filtered out. The median L/H ratio of all 
proteins was calculated and proteins with L/H < (median L/H)/2 were selected as hits. 
 
 Q Exactive HF ESI-Quadrupole Orbitrap (Thermo Scientific) 
SILAC samples were also analysed by LC-ESI-Quadrupole Orbitrap coupled to the same 
LC system with the same settings as described for Amazon ESI-ion trap. Peptides were 
eluted onto 15cm x 75 µm Easy-spray PepMap C18 column (2 µm particle size and 100 Å 
pore size) in Buffer A and then Buffer B 5-35% over 75 min at a constant flow rate of 300 
nL/min. Peptide ionisation was performed by Q-Exactive HF NSI. MS1 scans were performed 
in positive profile mode with an m/a range of 375-1500. CID fragmentation was performed 
with the 10 most intense ions from the first scan after accumulation of 5e4 ions in m/z 
range of 200-2000. Data was acquired with XCalibur software. 
Raw data was processed by MaxQuant v. 1.5.2.8 using Andromeda search engine and C. 
albicans database. False discovery rate (FDR) of peptides and proteins was set to 1%. MS 
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and MS/MS tolerance was 4.5 ppm, 2 missed cleavages were allowed, methionine oxidation 
was set as a variable modification. 
Data from ProteinGroups.txt files was further processed in Perseus v. 1.2.5.6. 
Contaminants, reversed and identified by site only proteins were filtered out. Hits were 
selected by Benjamini-Hochberg procedure (shown as significance B in Perseus) using the 
normalised H/L ratio and protein intensity, with FDR either 1% or 5%. 
The use of each MS instrument is indicated in the results chapters, when data is 
presented. 
. 
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2.5. Microscopy 
All microscopy was performed using live cells. Differential interference contrast (DIC) images 
were taken on a Leica microscope, model 0202-519-508L coupled to a HC Image Live 
software and a Hamamatsu digital camera. Fluorescence microscopy was carried out on an 
Olympus Delta vision Spectris 4.0 microscope (Applied Precision). Images were captured and 
deconvolved using SoftworxTM 3.2.2. 
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Chapter 3 
 
Optimisation of AP-MS Methods 
 
 
 
3.1. Introduction 
The phosphorylation status of a protein commonly affects its function and subcellular 
localisation. This study sought to investigate the molecular targets of protein kinases or 
phosphatases that are known to be important for hyphal growth in C. albicans. Since the 
experimental workflow includes purification of the enzymes, in order to have better chances 
at capturing sufficient amount of them, only proteins expressed at relatively high levels 
were considered. These criteria were fulfilled by the kinases Dbf2 and Crk1, and by the 
phosphatase Cdc14.  
 
3.1.1. Dbf2 and Mob1 
The NDR family kinase DBF2 is essential for C. albicans growth (Gonzalez-Novo et al., 2009). 
In mutants where its expression is inhibited, cells display pronounced defects in actomyosin 
ring contraction, cytokinesis, mitotic spindle organisation and nuclear segregation. Hyphal 
growth is also impaired in DBF2-depleted cells, which form wider than normal hyphal tubes 
that look swollen and fail to form septa.  
 Dbf2 is highly conserved in higher eukaryotes and it is known to act together with its 
activating subunit Mob1. In S. cerevisiae, binding of Mob1 to Dbf2 is essential for kinase 
activation (Mah et al., 2001). Although Mob1 has not been characterised in C. albicans, it is 
likely that it acts in a similar manner as activator of Dbf2 on the basis of functional 
conservation. Additionally, Mob1 likely physically interacts with the substrates that Dbf2 
phosphorylates and therefore it was selected as bait on its own in this study.  
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3.1.2. Cdc14 
The phosphatase Cdc14 has been extensively studied in animals and fungi, and it has been 
found to interact with hundreds of other proteins. Mitotic exit, chromosome segregation 
and completion of cytokinesis are universally controlled by Cdc14. The phosphatase is also 
involved in DNA replication in budding yeast, DNA repair in humans, and morphogenesis in 
the fungi Fusarium graminearum (Li et al., 2015) and C. albicans (Clemente-Blanco et 
al.,2006).  
 CaCdc14 is not essential for cell viability, but deletion mutants display severe defects 
in cell separation, cell cycle progression and hyphal formation. It is not clear whether Cdc14 
regulates cell morphogenesis through distinct pathways, or the observed phenotype is 
merely a consequence of the cell cycle disruption.  
 
3.1.3. Crk1 
The Cdc2-related protein kinase Crk1 is crucial for hyphal development and virulence of C. 
albicans (Chen et al., 2000). Deletion mutants are unable to form hyphae, while ectopic 
expression of the Crk1 kinase domain (Crk1N) promotes hyphal formation even under yeast-
inducing conditions. Additionally, crk1/crk1 cells exhibit reduced expression of the hyphae-
specific genes ECE1 and HWP1. Crk1 stimulates polarized growth through an unknown 
pathway but independently of hyphal inducers Cph1 and Egf1. The protein sequence of 
Crk1N is most similar to that of S. cerevisiae Bur1 and the human Pkl1/Cdk9. Indeed, ectopic 
expression of either Crk1 or Crk1N in S. cerevisiae can partially complement bur1 mutants 
suggesting some functional homology between the kinases Crk1 and Bur1. Crk1N also 
promotes filamentation of S. cerevisiae cells through the transcriptional regulator Flo8. 
Collectively, these results portray Crk1 as a strong inducer of filamentous growth and thus 
make it an interesting candidate of this study. 
It is clear that Dbf2, Cdc14 and Crk1 all play a role in C. albicans morphogenesis, but 
none of their direct targets were known prior to this study. The homologues of these 
proteins have been well researched in other organisms and it is expected that some 
common interactors will be found.   
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3.2. General overview of experimental workflow 
 
Identification of protein interactions by mass spectrometry is a well-established technique. 
A single experiment takes several weeks to be completed and many steps have to be 
optimised to reflect the strength of the protein interaction, the biological properties and the 
structure of the whole protein complex as well as the individual proteins, the affinity of the 
purified protein to the pull-down matrix, the stability of the complex in vitro and in vivo, the 
concentration and the total amount of protein required, the labelling of the protein, the 
sensitivity of the MS instruments available and the error-inducing steps in data processing 
and analysis. Tandem affinity purification (TAP) is the most common method of protein 
purification, but it is too stringent to preserve weak protein interactions. Complexes were 
thus purified by co-IP using various combinations of tags and antibodies. 
 
 In general, each experiment followed the following steps: 
1. Both copies of a gene of interest were fused at their C termini to an epitope which 
was used as an affinity tag to purify the protein coded by the gene (fig. 3.1). Cells 
were transformed with a PCR-generated cassette containing a tag and a selectable 
marker. Expression of the tagged protein was confirmed by Western blot. The same 
strain was then transformed again in order to tag the second allele with the same 
epitope but a different selectable marker. Integration of the cassette was confirmed 
by PCR by amplifying a DNA starting from the 3’ of the marker and ending within a 
genomic sequence adjacent to the marker. Additionally, protein levels were 
quantified by Western blot, using Cdc28 levels as a normalisation control. A strain 
having both alleles tagged produced a protein band that is approximately twice 
brighter than a single tag band relative to Cdc28 protein brightness. The phenotype 
of the cells was assessed by microscopy to confirm that the tags do not cause any 
visible defects. 
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Fig. 3.1: Tagging a protein with an epitope via PCR-based homologous recombination. An epitope 
of interest (HA) and a selectable marker (URA3) were amplified from pFA vectors using primers with 
homologous sequences to genomic DNA. The forward primer contains the 3’ sequence of the gene 
to be tagged (DBF2) excluding the stop codon. The reverse primer contains a homologous sequence 
about 100bp downstream of the gene. PCR amplification generates a cassette, which when 
transformed into C. albicans cells integrates at the 3’ end of the desired gene. Correct integration is 
confirmed by colony PCR and protein expression bearing the tag is confirmed by Western blot. Dbf2 
produces two bands due to phosphorylation. C – negative control. 
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2. Wild type and epitope-tagged cells were grown in YPD liquid media to an OD595=0.8 
and lysed, and the bait was precipitated from the cell lysate. The lysate was 
incubated with an affinity matrix that interacts with the epitope for 1 hr at 4 °C. 
3. Different affinity matrixes were tested as described below in order to determine 
which one gives the highest yield of bait protein. The bait was eluted from the 
matrix by boiling in protein loading buffer. At this stage the bait and all associated 
proteins were released in solution. 
4. Eluted proteins were separated by SDS-PAGE on a 4-12% gradient gel which was 
stained with Coomassie in order to visualise protein bands. A gradient gel allows for 
optimal separation of all proteins of different sizes. This step is necessary because 
the MS instrument would be overwhelmed if all proteins were loaded on it 
simultaneously. For highest precision, the proteins were separated into fractions 
according to their size. 
5. All protein bands were cut out of the gel and digested with the protease trypsin. 
This step generated 15-20 fractions of proteins. Each fraction was digested overnight 
with trypsin which has a high specificity for cleaving proteins at the carboxyl sites of 
the amino acids lysine and arginine, except when either is followed by proline. The 
generated peptides were extracted from the gel and dried in eppendorf tubes.  
6. Peptide fractions were analysed by MS and the data was processed as described 
later in this chapter. 
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3.3. Affinity purification 
 
3.3.1. Generation of epitope-tagged strains 
The genomic sequences of Dbf2, Mob1, Cdc14 and Crk1 were retrieved from the Candida 
Genome Database (candidagenome.org). A DNA cassette containing either MYC or HA tag 
and either URA3 or ARG4 gene sequence as a selectable marker was amplified by PCR using 
primers containing flanking sequences homologous to a region in the 3’ end of the gene to 
be tagged (fig. 3.1). Cells were transformed with the PCR product and individual colonies 
were screened by colony PCR and by Western blot.  
 Initially Dbf2 and Cdc14 were each consecutively tagged with HA-URA3 and HA-ARG4 
to create Dbf2-2xHA and Cdc14-2xHA. In a similar manner Dbf2-2xMYC and Cdc14-2xMYC 
were created. 
 
3.3.2. Selection of affinity matrix and tag 
All optimisation experiments were carried out with yeast culture, because it is easier to 
handle than hyphae. Dbf2 and Cdc14 were each immunoprecipitated using either anti-HA-
conjugated magnetic Dynabeads Protein G or anti-MYC-conjugated EZview Red Agarose 
Affinity Gel. Both affinity matrixes were tested under the same conditions. One litre of log 
phase culture (OD595=0.8) was used to produce 10 ml of cell lysate, which was incubated 
with affinity beads for 1hr at 4°C. The beads were then washed once and boiled to elute all 
bound proteins. Comparison of protein yield by Western blot showed that the EZview beads 
have higher affinity for their antigen than Dynabeads (fig. 3.2). Additionally, only the EZview 
IP produced a visible band of the bait on a Coommassie stained gel, which is considered a 
good yield for MS analysis. Therefore, all subsequent IPs were done using EZview anti-MYC 
beads.  Mob1-2xMYC and Crk1-2xMYC strains were generated as previously described. 
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Fig. 3.2: Immunoprecipitation of Cdc14 and Dbf2 using either Dynabeads conjugated to anti-HA 
(left) or EZview beads conjugated to anti-MYC (right). Cdc14 is very close to the heavy chain of the 
anti-HA antibody, which produces very thick band on a Western blot (top, left panel). The anti-MYC 
antibody has fragments of different size, which do not migrate near the baits. Some protein 
degradation is seen during Dbf2 precipitation, which produces multiple bands on a Western blot. 
The EZview anti-MYC beads generated higher yield and lower background than Dynabeads. 2% of 
the IPs and 0.1% of the inputs were loaded on the gels for Western blot. 
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Input 
Cdc14 Control Cdc14 Control 
IP and WB: anti-HA IP and WB: anti-MYC 
IP 
Input 
Dbf2 Control Dbf2 Control 
IP and WB: anti-HA IP and WB: anti-MYC 
 68 
 
3.3.3. Optimisation of protein elution from beads 
Proteins can be eluted from the beads either by heating at high temperature or by 
incubation with low pH glycine. The latter method has the potential of eluting less non-
specific proteins bound to the beads. Both elution protocols were tested. Cdc14-2xMYC was 
precipitated as previously described and the protein-bound beads were incubated with 50 
mM glycine pH 2.8 for 10 min at room temperature with shaking. The glycine was then 
removed and the beads were boiled to elute residual proteins. Western blot analysis of both 
elutions showed that most of the bait remained on the beads after the glycine elution (fig 
3.3). Coomassie staining showed that the glycine elution had significantly lower background 
of contaminating proteins (data not shown). However, due to the low yield, glycine elution 
was not a viable option for an MS experiment. All subsequent IPs were therefore performed 
using heat elution. 
 
3.3.4. Optimisation of protein concentration in a cell lysate for IP 
The protein concentration of a cell lysate often correlates with the amount of background 
proteins sticking to the beads. In the initial IP, 1 L of cell culture produced 10 ml of cell 
lysate. This lysate has the highest concentration of proteins that could be achieved by 
breaking the cells in the available cell disrupter. Diluting the cell lysate would supposedly 
reduce the background, but it is only worth doing so if protein yield remains the same. 
 To test the effect of protein concentration of the cell lysate on total yield, Dbf2-
2xMYC cells were lysed as previously described and 3 ml of cell lysate were diluted with 3 ml 
of lysis buffer. Dbf2 was precipitated from either 6 ml of diluted lysate or from 6 ml of 
concentrated lysate. The protein yield was assessed by Western blot and the background 
contamination was assessed by staining a gel with Coomassie (fig.3.4). The experiments 
confirmed that reducing the protein concentration produced visibly less background, but 
unfortunately, it also reduced significantly the yield of Dbf2. It would be difficult to 
objectively measure the optimal balance between bait yield and background. Therefore, the 
protein concentration was kept high in all further experiments, although the exact value was 
not measured. 
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Fig. 3.3: Elution of protein from beads following immunoprecipitation. Cdc14 and Dbf2 were 
immunoprecipitated using EZview anti-MYC beads and the beads were incubated with 50 mM 
glycine pH 2.8 for 10 min at room temperature. The supernatant was then transferred to a fresh 
tube and the beads were resuspended in protein loading dye and boiled for 5 min. As shown here 
the glycine did not elute much of the bait proteins compared to the heat elution. 2% of the eluted IP 
volume and 0.1% of the inputs were loaded on the gels for Western blot. 
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Fig. 3.4: Effect of protein concentration in cell lysate on IP output. Dbf2 was precipitated from 
undiluted and 2x diluted lysate. Western blot (top) shows that diluting the lysate reduces total 
protein yield although it also reduces background contamination as shown on the Coomassie-stained 
gel. 2% of the total IP volume was loaded on the gel for Western blot, and 80% of the IP was loaded 
on the Coomassie-stained gel. 
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3.3.5. Optimisation of total protein amount in a cell lysate for IP 
The total amount of protein in a cell lysate correlates with the amount of the bait protein in 
the lysate. The amount of the bait should be sufficient to saturate the beads to their 
maximum capacity. Unsaturated beads would unnecessarily increase the background 
without proportional increase in bait yield.  
 In order to determine whether more cell lysate would improve protein yield, IP of 
Dbf2-2xMYC was carried out using either 5 ml or 15 ml of cell lysate. Both experiments 
produced the same yield of Dbf2 as well as the same amount of background as determined 
by Western blot and Coomassie staining respectively (fig 3.5). This means that 5 ml of lysate 
is sufficient to fully saturate the beads and more total protein does not result in increased 
background. It is also evident from figure 3.5 that the beads did not fully deplete the pool of 
Dbf2 available in the cell lysate. Significant amount of protein was still seen in the 
flowthrough after immunoprecipitation, although the exact recovery was not formally 
measured. In all further IP experiment 10 ml of cell lysate and 50 µl of beads were used.  
 
3.3.6. Pre-incubation of affinity beads with BSA does not reduce background 
In an attempt to reduce non-specific proteins sticking to the affinity matrix, beads were 
incubated with 3% w/v BSA in lysis buffer for 4 hrs at 4 °C prior to immunoprecipitating 
Cdc14-2xMYC. The beads were then used as previously described. Coomassie staining 
showed no difference in background between blocked and non-blocked beads (fig 3.6). BSA 
blocking was not used in further experiments. 
 
3.3.7. Optimisation of beads-washing steps after IP 
In order to assess the impact of washing the beads with lysis buffer after IP on protein yield, 
Mob1-2xMYC was immunoprecipitated as previously described and the beads were 
separated into two tubes. One aliquot was washed once and the other was washed 3 times 
with 1 ml lysis buffer. Western blot of the eluted proteins showed that washing the beads 3 
times reduced the yield of Mob1 approximately two times comparing to washing them once   
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Fig. 3.5: Effect of total protein amount in cell lysate on IP output. Dbf2 was precipitated from either 
5 ml or 15 ml cell lysate. Western blot (top) shows the same protein yield from both experiments 
and considerable amount of Dbf2 remain unbound in the flowthrough. This indicates that the affinity 
beads are saturated with the bait even with 5 ml of lysate. No difference was seen in the amount of 
contaminants on a Coomassie-stained gel (bottom). 2% of the eluted IP and 0.1% of the flowthrough 
and input volumes were loaded on the gel for Western blot. 80% of the IP was loaded on the 
Coomassie-stained gel. 
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Fig. 3.6: Incubation of affinity beads with BSA prior to IP. Blocking the beads with BSA before the IP 
does not reduce the amount of contaminants sticking to the them as shown on this gel. 80% of the 
IP was loaded on the Coomassie-stained gel. 
 
 
 
 
 
 
 
 
  
BSA - + 
Coomassie-
stained gel 
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(fig. 3.7). This means that the antibody-antigen bond is not strong enough to overcome 
multiple washes. Although the background was also significantly lower in experiment with 3 
washes, in all further experiments beads were washed only once. 
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Fig. 3.7: Immunoprecipitation of Mob1 after one and three bead-washing steps. Mob1 yield and 
contamination were both reduced in IP with 3 washes compared to IP with only 1 wash. 2% of the IP 
volume was loaded on the gel for Western blot, 80% of it was loaded on the Coomassie-stained gel. 
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3.4. Mass spectrometry analysis 
Once the affinity purification of all four proteins was optimised, mass spectrometry of the 
eluted fractions was performed to identify the proteins. The simplest way to do that is label-
free MS since it does not require the additional step of protein labelling. However, as 
discussed later in this chapter, quantitative data analysis of label-free MS is challenging 
especially for the identification of protein interaction and a large amount of data is required 
in order to obtain statistically significant results. 
 
3.4.1. Fractionation of eluted proteins followed by MS 
Affinity purification of a single bait protein results in the elution of several hundred to 
several thousand other proteins in the mixture. Protein abundance varies highly and reflects 
the chances of a protein to be detected by MS. If the MS instrument is overwhelmed by the 
most abundant proteins, it is likely to miss some of the least abundant. Therefore, 
separating the eluted protein mixture into fractions is optimal for detecting the greatest 
number of proteins. 
 Following affinity purification, proteins were separated according to their size (also 
influenced by charge) by SDS-PAGE and the gel was stained with Coomassie. No proteins 
were allowed to run out of the gel. All protein bands were cut out of the gel into 15-20 
fractions, so that each fraction contains proteins of similar size. Each fraction was 
individually digested with trypsin and the resulting peptides were analysed by ESI-MS using 
an amaZon ion trap instrument coupled to an online capillary liquid chromatography 
system.  
 Six IPs were analysed by MS in total: Dbf2, Mob1, Cdc14 and Crk1 were each used as 
bait separately in four of them and the remaining two were mock IPs of the wild type strain 
where no bait was present. The mock IP was duplicated in order to capture all 
contaminating protein. All experiments were done in yeast.  
 The results of each MS are summarised in table 3.1. Although great care was taken 
to keep the conditions of all experiments the same, there is a striking variability in the  
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IP bait Dbf2 Mob1 Crk1 Cdc14 Control 1 Control 2 
Total number of proteins 
identified by MS 
1403 785 832 747 1155 710 
FDR 1.39% 1.26% 1.28% 1.37% 1.57% 1.49% 
Number of proteins after 
applying ProHits filters 
648 388 345 313 514 325 
 
Table 3.1: General results from label-free MS. Untagged wild type cells were used as controls. FDR – 
False discovery rate. 
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 number of proteins identified from each IP. These proteins include bait-specific interactors 
as well as contaminants. In order to separate both groups all six lists of identified proteins 
were compared in parallel. 
 
3.4.2. Analysis of MS results using ProHits software 
Defining protein-protein interactions from label-free MS data is a challenging bid. Each set 
of data presents a list of proteins identified by MS but on its own this list does not entail any 
information about protein interactions within it. Comparison of all six data sets is likely to 
reveal such information in two ways. First, the mock IPs contain only non-specific proteins 
sticking to the beads and thus those proteins can be regarded as contaminants in all other 
experiments. Second, bait specific interactors would be missing from IPs using different bait. 
However, as previously discussed, Dbf2 and Mob1 are likely to interact with many common 
proteins and Cdc14 may also dephosphorylate some of Dbf2’s substrates since they act in 
the same pathway in other species of yeast.  
 The software ProHits provides means of comparing label-free MS data sets with the 
aim of evaluating bait specific hits (Liu et al., 2010). In particular, ProHits was used to 
compare the total number of peptides representing a given protein across all 6 experiments 
(table 3.2). In order to reduce false positive result, an arbitrary filter for protein score <50 
and unique peptides <2 was applied. All baits were successfully recovered, but some of 
them do not stand out in the noise of contaminants. For example, Dbf2 was represented by 
only 11 peptides when used as a bait, and there were 284 proteins with more peptides from 
the same IP. Its activating partner, Mob1 was not found at all in this experiment. When 
Mob1 was the bait, it was represented by 33 peptides, ranking at position 93. Interestingly, 
Dbf2 ranked 14th in the Mob1 IP with 102 peptides. This means that more of the Dbf2 
protein was pulled when Mob1 was the bait, rather than the kinase itself. Nevertheless, the 
overwhelming number of background proteins makes it difficult to identify true preys in any 
of the experiments. The most abundant contaminants include ribosomal proteins (e.g. 
RPL10, RPP0, RPL6, RPL3, RPL8B, RPS16A, RPL20B etc.), glycolytic enzymes (e.g. TDH3, 
PDC11, ENO1, CDC19, FBA1, PGI1 etc.), translation elongation factors (e.g. CEF3, TEF2,   
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Gene ID 
 
Gene Name 
 
Crk1 
 
Cdc14 
 
Dbf2 
 
Mob1 
 
Control 1 
 
Control 2 
 
P02768-1 P02768-1 216 
     
P00761 P00761 178 
 
192 433 241 269 
orf19.6814 TDH3 171 135 301 156 177 130 
orf19.4152 CEF3 143 137 228 121 197 119 
orf19.1065 SSA2 131 129 119 145 157 123 
orf19.2877 PDC11 129 93 226 126 149 66 
orf19.979 FAS1 127 135 209 91 284 101 
orf19.382 TEF2 119 186 301 135 237 109 
orf19.395 ENO1 112 116 270 155 159 104 
orf19.5788 EFT2 99 76 153 96 131 105 
orf19.6515 HSP90 93 101 133 121 136 101 
orf19.7392 DED1 92 105 63 108 76 77 
orf19.5949 FAS2 89 97 147 93 191 80 
orf19.4980 HSP70 89 73 84 79 95 65 
orf19.2803 HEM13 86 135 144 180 82 51 
orf19.6367 SSB1 86 101 152 75 114 77 
orf19.6312 RPS3 82 63 96 78 60 50 
orf19.4477 CSH1 77 86 127 136 71 89 
orf19.2360 URA2 76 54 105 80 300 117 
orf19.3575 CDC19 72 98 158 105 96 88 
orf19.2478.1 72 73 60 85 53 40 
orf19.3523 CRK1 69 
     
orf19.6873 RPS8A 68 83 99 106 30 45 
orf19.717 HSP60 67 49 73 53 69 43 
orf19.2935 RPL10 66 70 54 51 46 45 
orf19.7015 RPP0 63 72 56 56 41 38 
orf19.3003.1 RPL6 60 47 84 65 46 53 
orf19.1601 RPL3 57 52 59 56 40 43 
orf19.6002 RPL8B 56 69 92 68 57 71 
orf19.5653 ATP2 56 49 103 69 112 57 
orf19.5341 RPS4A 55 58 92 60 68 59 
orf19.2551 MET6 55 40 61 58 60 41 
orf19.236 RPL9B 55 37 56 38 34 30 
orf19.4618 FBA1 54 60 114 66 56 54 
orf19.6854 ATP1 54 52 59 80 99 54 
orf19.2994.1 RPS16A 53 55 68 48 28 40 
orf19.4632 RPL20B 52 65 70 43 43 35 
orf19.6265.1 RPS14B 50 45 27 23 20 33 
orf19.4660 RPS6A 49 37 22 56 26 32 
orf19.171 DBP2 48 50 39 39 49 28 
orf19.6906 ASC1 48 28 57 43 55 27 
orf19.7018 RPS18 46 53 59 41 32 31 
orf19.3888 PGI1 46 24 55 49 47 24 
orf19.930 PET9 45 42 86 47 58 39 
orf19.2651 CAM1-1 45 20 53 41 31 33 
orf19.2309.2 RPL2 44 45 66 43 34 37 
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Gene ID 
 
Gene Name 
 
Crk1 
 
Cdc14 
 
Dbf2 
 
Mob1 
 
Control 1 
 
Control 2 
 
orf19.1896 SSC1 44 36 45 45 56 34 
orf19.5982 RPL18 44 33 61 46 31 43 
orf19.1700 RPS7A 43 35 57 45 30 33 
orf19.4371 TAL1 43 13 64 37 25 22 
orf19.5904 RPL19A 42 54 63 25 42 44 
orf19.3334 RPS21 42 46 57 49 25 28 
orf19.2232 RPL11 42 41 31 23 20 42 
orf19.4622 42 30 32 25 30 28 
orf19.4336 RPS5 42 29 77 42 47 20 
orf19.840 RPL21A 42 25 15 15 12 20 
orf19.5197 APE2 42 21 38 46 30 33 
orf19.493 RPL15A 41 35 41 36 36 47 
orf19.4931.1 RPL14 40 51 49 38 44 36 
orf19.2262 40 28 29 25 8 16 
orf19.6385 ACO1 40 20 44 48 45 33 
orf19.771 LPG20 39 42 42 60 22 13 
orf19.903 GPM1 39 25 76 37 25 21 
orf19.2013 KAR2 39 22 50 29 44 25 
orf19.3465 RPL10A 38 45 56 29 27 39 
orf19.2340 CDC48 38 42 54 63 19 28 
orf19.838.1 RPS9B 37 31 47 36 26 38 
orf19.5996.1 RPS19A 36 36 40 27 15 30 
orf19.7382 CAM1 36 30 39 38 19 30 
orf19.6375 RPS20 36 29 30 18 13 27 
orf19.2435 MSI3 36 25 74 45 76 27 
orf19.5466 RPS24 35 49 39 33 19 27 
orf19.1378 SUP35 35 32 38 41 58 30 
orf19.6975 YST1 34 42 56 53 45 54 
orf19.3002 RPS1 34 40 54 46 42 34 
orf19.1839 RPA190 34 23 31 6 28 35 
orf19.3138 NOP1 34 20 27 29 18 17 
orf19.3911 SAH1 34 11 45 28 26 27 
orf19.7466 ACC1 33 60 49 75 76 44 
orf19.1635 RPL12 33 43 40 13 26 9 
orf19.827.1 RPL39 33 29 19 17 13 22 
orf19.5024 GND1 33 22 80 40 45 25 
orf19.4149.1 32 33 21 30 13 32 
orf19.4193.1 RPS13 31 40 24 25 18 26 
orf19.1854 HHF22 31 32 14 23 12 22 
orf19.3690.2 31 26 26 30 11 17 
orf19.5225.2 RPL27A 30 53 47 17 25 41 
orf19.1064 ACS2 30 34 43 43 73 33 
orf19.4885 MIR1 30 23 40 40 36 21 
orf19.4602 MDH1-1 30 17 45 20 29 28 
orf19.7238 NPL3 29 47 31 35 26 45 
orf19.2364 MIS11 28 30 58 52 25 25 
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Gene ID 
 
Gene Name 
 
Crk1 
 
Cdc14 
 
Dbf2 
 
Mob1 
 
Control 1 
 
Control 2 
 
orf19.2994 RPL13 28 26 36 40 28 36 
orf19.2111.2 RPL38 28 26 
 
12 5 10 
orf19.51 
 
28 19 63 38 59 28 
orf19.3788.1 RPL30 28 14 33 11 21 12 
orf19.3812 SSZ1 28 10 24 15 30 9 
orf19.6540 PFK2 27 48 67 60 38 19 
orf19.542 HXK2 27 23 52 40 50 12 
orf19.7217 RPL4B 26 96 103 76 51 79 
orf19.3149 LSP1 26 26 39 29 21 19 
orf19.6265 RPS22A 26 20 28 15 19 20 
orf19.4393 CIT1 26 7 45 28 41 29 
orf19.6541 RPL5 25 34 58 20 35 27 
orf19.6561 LAT1 25 18 18 20 32 21 
orf19.5112 TKL1 25 7 20 23 56 12 
orf19.3311 IFD3 24 33 22 38 12 22 
orf19.2864.1 RPL28 24 33 19 29 14 18 
orf19.3037 24 25 30 41 64 32 
orf19.3415.1 RPL32 24 25 15 17 7 19 
orf19.7569 SIK1 24 24 42 27 31 12 
orf19.5964.2 RPL35 24 19 13 17 7 16 
orf19.2489 24 16 54 32 51 32 
orf19.7332 ELF1 24 13 42 32 40 16 
orf19.3572.3 23 33 23 24 26 30 
orf19.6286.2 RPS27 23 19 
 
9 
 
14 
orf19.3504 RPL23A 23 17 9 8 13 12 
orf19.778 PIL1 23 15 45 18 10 18 
orf19.2560 CDC60 23 12 56 24 38 26 
orf19.2709 ZUO1 23 9 21 16 25 10 
orf19.3325.3 RPS21B 23 8 
 
6 8 4 
orf19.6085 RPL16A 22 35 34 28 21 36 
orf19.7417 TSA1 22 34 48 23 33 30 
orf19.5943.1 22 15 21 12 20 7 
orf19.2179.2 RPS10 22 14 8 9 14 18 
orf19.1288 FOX2 22 
  
5 
  
orf19.687.1 RPL25 21 26 38 13 16 23 
orf19.4490 RPL17B 21 16 19 12 12 24 
orf19.6702 DED81 21 15 23 15 22 12 
orf19.6127 LPD1 20 22 33 29 36 14 
orf19.6663 RPS25B 20 22 7 17 13 9 
orf19.3789 RPL24A 20 21 16 22 14 17 
orf19.5927 RPS15 20 20 31 17 19 13 
orf19.6472 CYP1 20 15 25 16 14 18 
orf19.1578 20 15 4 5 15 8 
orf19.4635 NIP1 20 13 37 45 24 16 
orf19.4506 LYS22 20 
 
33 24 30 9 
orf19.5746 ALA1 19 13 39 38 26 22 
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Gene ID 
 
Gene Name 
 
Crk1 
 
Cdc14 
 
Dbf2 
 
Mob1 
 
Control 1 
 
Control 2 
 
orf19.5858 EGD2 19 11 24 31 22 22 
orf19.6403.1 RPP2A 19 8 12 12 11 7 
orf19.1652 POX1-3 19 
 
3 
   
orf19.4311 YNK1 18 21 22 14 21 22 
orf19.5383 PMA1 18 18 43 47 131 28 
orf19.2329.1 RPS17B 18 18 18 8 12 7 
orf19.6090 18 16 10 15 17 17 
orf19.18 IMH3 18 15 23 9 26 12 
orf19.3541 ERF1 18 11 38 13 43 14 
orf19.6701 18 11 45 11 39 9 
orf19.6584 PRT1 18 10 15 31 33 7 
orf19.3942.1 RPL43A 18 10 7 12 11 7 
orf19.7239 MDG1 18 7 22 8 23 9 
orf19.6749 KRS1 17 13 24 19 41 16 
orf19.3997 ADH1 16 63 156 79 65 58 
orf19.1199 NOP5 16 27 31 17 37 14 
orf19.1154 EGD1 16 12 13 6 12 11 
orf19.4560 BFR1 16 6 16 10 12 6 
orf19.3014 BMH1 15 25 36 23 32 12 
orf19.5007 ACT1 15 23 29 24 8 14 
orf19.7534 MIS12 15 13 17 22 17 9 
orf19.6745 TPI1 15 11 32 18 15 11 
orf19.6160 15 8 11 13 10 
 
orf19.3010.1 ECM33 15 6 31 
 
30 
 
orf19.6925 HTB1 14 18 25 17 10 16 
orf19.6665 14 14 11 18 8 9 
orf19.1750 SLR1 14 8 6 10 8 9 
orf19.2138 ILS1 13 17 60 28 53 24 
orf19.6253 RPS23A 13 17 6 7 5 5 
orf19.5294 PDB1 13 16 22 16 12 8 
orf19.1470 RPS26A 13 16 13 9 6 
 
orf19.1295 VAS1 13 14 49 23 40 14 
orf19.946 MET14 13 13 21 12 6 7 
orf19.2407 DPS1-1 13 12 16 16 28 12 
orf19.4623.3 NHP6A 13 12 5 
 
6 10 
orf19.198 ASN1 13 8 31 15 30 9 
orf19.5806 ALD5 13 3 20 7 9 7 
orf19.3967 PFK1 12 40 69 75 35 15 
orf19.2183 KRE30 12 13 16 20 27 6 
orf19.1833 12 12 18 20 12 7 
orf19.1042 POR1 12 12 20 15 13 5 
orf19.5493 GSP1 12 11 26 6 11 7 
orf19.1738 UGP1 12 6 17 10 12 4 
orf19.4718 TRP5 12 6 10 4 20 4 
orf19.4223 GCD11 12 5 11 12 12 5 
orf19.269 SES1 12 4 28 16 21 9 
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Gene ID 
 
Gene Name 
 
Crk1 
 
Cdc14 
 
Dbf2 
 
Mob1 
 
Control 1 
 
Control 2 
 
orf19.4427 SKP1 12 
 
14 11 10 8 
orf19.7188 RPP1B 12 
 
14 
 
7 
 
orf19.4284 BUR2 12 
     
orf19.6987 DNM1 11 28 
 
38 2 18 
orf19.5928 RPP2B 11 14 13 9 9 8 
orf19.6165 KGD1 11 11 19 23 8 18 
orf19.5137.1 HHO1 11 11 
 
6 
 
9 
orf19.5081 FUN12 11 2 31 20 22 5 
orf19.5281 11 
 
50 29 30 17 
orf19.3426 ANB1 11 
 
10 
 
12 6 
orf19.1051 HTA2 11 
 
5 
 
6 
 
orf19.3324 TIF 10 30 60 35 36 25 
orf19.6763 SLK19 10 22 
 
5 6 5 
orf19.1853 HHT2 10 17 4 4 3 7 
orf19.5177 10 13 19 15 20 8 
orf19.6785 RPS12 10 9 19 10 9 12 
orf19.3599 TIF4631 10 7 24 10 19 9 
orf19.6213 SUI2 10 6 18 10 13 4 
orf19.2960 FRS2 10 3 15 14 8 7 
orf19.5641 CAR2 10 
 
13 14 4 
 
orf19.2573 FRS1 10 
 
18 9 13 5 
orf19.1149 MRF1 9 54 46 48 25 23 
orf19.5682 9 15 25 9 23 14 
orf19.492 ADE17 9 14 36 12 29 10 
orf19.6257 GLT1 9 11 40 16 49 10 
orf19.6882.1 9 11 6 8 6 12 
orf19.6387 HSP104 9 7 17 7 
  
orf19.7161 SUI3 9 5 8 7 3 9 
orf19.3358 LSC1 9 4 11 3 6 
 
orf19.4777 DAK2 9 
 
34 12 15 
 
orf19.3428 9 
     
orf19.5779 RNR1 8 19 26 28 11 13 
orf19.4716 GDH3 8 9 49 32 41 18 
orf19.6345 RPG1A 8 9 19 14 5 20 
orf19.2929 GSC1 8 9 42 5 30 3 
orf19.7048.1 RPS28B 8 9 
 
3 
 
7 
orf19.1409.1 8 7 11 4 8 8 
orf19.3591 APE3 8 5 8 7 14 8 
orf19.2843 RHO1 8 5 10 
 
5 5 
orf19.437 GRS1 8 4 11 12 12 4 
orf19.759 SEC21 8 4 18 10 
 
3 
orf19.3423 TIF3 8 4 14 7 10 5 
orf19.7312 ERG13 8 2 14 10 11 7 
orf19.3349 8 
 
30 15 13 10 
orf19.5801 RNR21 8 
 
19 11 7 4 
orf19.5263 SER33 8 
 
34 10 19 6 
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Gene ID 
 
Gene Name 
 
Crk1 
 
Cdc14 
 
Dbf2 
 
Mob1 
 
Control 1 
 
Control 2 
 
orf19.5964 ARF2 8 
 
21 10 15 4 
orf19.1030 8 
 
5 9 14 
 
orf19.2098 ARO8 8 
 
17 7 20 4 
orf19.2992 RPP1A 8 
 
12 5 15 
 
orf19.4704 ARO1 7 11 52 19 37 10 
orf19.2871 SDH12 7 10 18 16 31 13 
orf19.3391 ADK1 7 10 32 11 19 19 
orf19.3590 IPP1 7 9 23 7 16 5 
orf19.3838 EFB1 7 8 22 19 14 6 
orf19.2884 CDC68 7 8 
   
4 
orf19.5437 RHR2 7 4 17 13 11 
 
orf19.5130 PDI1 7 4 20 10 21 6 
orf19.7308 TUB1 7 4 10 10 7 
 
orf19.4813 GUA1 7 4 13 8 22 7 
orf19.2937 PMM1 7 4 28 7 15 6 
orf19.5854 SBP1 7 
 
24 15 11 7 
orf19.1613 ILV2 7 
 
18 7 17 3 
orf19.6034 TUB2 7 
 
13 7 14 2 
orf19.6109 TUP1 7 
 
21 6 13 6 
orf19.6507 7 
 
13 5 6 
 
orf19.822 HSP21 7 
     
orf19.3097 PDA1 6 10 16 17 8 5 
orf19.3579 ATP4 6 9 19 10 17 18 
orf19.5750 SHM2 6 8 14 14 25 7 
orf19.3268 TMA19 6 7 15 5 11 
 
orf19.7062 RPA135 6 7 12 4 20 4 
orf19.754 YBN5 6 6 23 9 12 9 
orf19.1672 6 5 15 7 9 11 
orf19.5550 MRT4 6 5 7 5 3 4 
orf19.2168.3 6 5 4 
 
3 4 
orf19.6634 VMA2 6 2 17 10 16 
 
orf19.6081 PHR2 6 2 14 6 
 
5 
orf19.4879.2 NTF2 6 2 
    
orf19.387 GCR3 6 
  
10 
  
orf19.4309 GRP2 6 
 
24 9 4 
 
orf19.4956 RPN1 6 
 
15 6 13 9 
orf19.3015 ARX1 6 
 
11 6 19 
 
orf19.3915 6 
 
10 
 
2 
 
orf19.3034 RLI1 6 
 
9 
 
13 3 
orf19.2416.1 MLC1 6 
 
4 
 
2 3 
orf19.4317 GRE3 6 
 
2 
 
5 
 
orf19.3087 UBI3 5 9 7 6 3 
 
orf19.5885 5 6 
 
5 5 
 
orf19.339 NDE1 5 6 10 
 
4 
 
orf19.685 YHM1 5 5 6 12 7 
 
orf19.7509.1 ATP17 5 4 
 
4 
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Gene ID 
 
Gene Name 
 
Crk1 
 
Cdc14 
 
Dbf2 
 
Mob1 
 
Control 1 
 
Control 2 
 
orf19.6717 5 4 5 
 
4 8 
orf19.7611 TRX1 5 4 
   
6 
orf19.3700 TOM70 5 3 8 2 16 
 
orf19.6197 DHH1 5 3 11 
 
8 4 
orf19.7057 GUS1 5 
 
19 9 18 8 
orf19.4261 TIF5 5 
 
13 7 6 
 
orf19.92 
 
5 
 
16 6 10 
 
orf19.6126 KGD2 5 
 
10 5 10 
 
orf19.7136 SPT6 5 
 
9 4 
  
orf19.3430 5 
 
6 4 
  
orf19.4536 CYS4 5 
 
7 3 7 
 
orf19.3129 5 
  
3 3 
 
orf19.7421 CYP5 5 
 
9 
 
7 
 
orf19.6645 HMO1 5 
 
8 
 
6 
 
orf19.5917.3 5 
 
6 
 
4 
 
orf19.5351 TIF11 5 
 
6 
  
3 
orf19.6229 CAT1 5 
 
4 
   
orf19.6010.1 RPB11 5 
 
3 
 
3 4 
orf19.4021 5 
 
2 
   
orf19.2241 PST1 5 
     
orf19.2288 CCT5 5 
     
orf19.4833 MLS1 5 
     
orf19.789 PYC2 4 9 48 31 70 19 
orf19.3496 CHC1 4 8 36 18 26 5 
orf19.3955 MES1 4 5 21 10 15 4 
orf19.4099 ECM17 4 5 41 9 23 6 
orf19.1770 CYC1 4 4 4 
 
4 
 
orf19.4959 4 4 
   
5 
orf19.3171 ACH1 4 3 11 3 7 4 
orf19.7011 4 
 
25 9 17 
 
orf19.3799 4 
 
10 8 10 
 
orf19.6724 FUM12 4 
 
11 7 11 
 
orf19.5285 PST3 4 
 
15 5 8 10 
orf19.3507 MCR1 4 
 
7 4 7 6 
orf19.2066.1 ATP18 4 
  
4 
  
orf19.6327 HET1 4 
 
12 
 
9 2 
orf19.2014 BCY1 4 
 
11 
 
9 
 
orf19.3974 PUT2 4 
 
11 
 
6 
 
orf19.2694 TYS1 4 
 
7 
 
5 
 
orf19.3294 MBF1 4 
 
5 
  
7 
orf19.7384 NOG1 4 
 
3 
 
6 
 
orf19.3150 GRE2 4 
 
2 
   
orf19.4577.3 TIM10 4 
     
orf19.5597.1 4 
    
2 
orf19.3651 PGK1 3 62 128 65 49 48 
orf19.953.1 COF1 3 7 13 
 
6 
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Gene ID 
 
Gene Name 
 
Crk1 
 
Cdc14 
 
Dbf2 
 
Mob1 
 
Control 1 
 
Control 2 
 
orf19.526 NHP2 3 4 4 5 
 
5 
orf19.6994 BAT22 3 
 
22 13 5 
 
orf19.7438 UBA1 3 
 
26 12 16 
 
orf19.6317 ADE6 3 
 
47 5 25 14 
orf19.4754 ZWF1 3 
 
11 4 
 
2 
orf19.3959 SSD1 3 
 
6 3 
  
orf19.5627 3 
 
5 2 5 
 
orf19.2531 CSP37 3 
 
4 2 2 
 
orf19.5006 GCV3 3 
 
11 
  
3 
orf19.2598 VMA4 3 
 
10 
 
6 
 
orf19.7187 MAM33 3 
 
7 
   
orf19.4650 ILV6 3 
 
6 
 
4 
 
orf19.1402 CCT2 3 
 
4 
   
orf19.4870 DBP3 3 
   
6 3 
orf19.873.1 COX6 3 
   
5 
 
orf19.5198 NOP4 3 
     
orf19.7459 3 
     
orf19.5850 NOC2 2 3 2 
 
15 5 
orf19.3467 SEC27 2 
 
11 12 2 3 
orf19.3053 2 
 
13 
 
5 
 
orf19.7592 FAA4 2 
 
6 
 
5 
 
orf19.5968 RDI1 2 
     
orf19.7288 2 
     
280717 ALB 
 
54 5 52 
 
15 
orf19.1048 IFD6 
 
42 58 48 26 26 
orf19.4476 
 
35 50 34 24 
 
orf19.1880 HEM15 
 
34 42 45 30 30 
orf19.4192 CDC14 
 
32 
    
orf19.6190 SRB1 
 
31 50 30 12 18 
3848 KRT1 
 
21 121 76 45 61 
orf19.4826 IDH1 
 
18 32 21 15 23 
orf19.657 SAM2 
 
12 21 10 2 6 
orf19.88 ILV5 
 
11 38 17 21 10 
orf19.6047 TUF1 
 
11 16 11 4 8 
orf19.1591 ERG10 
 
10 24 10 7 11 
orf19.3223 ATP3 
 
9 4 6 5 
 
orf19.4827 ADE12 
 
8 8 7 
 
6 
orf19.6415.1 
 
8 
 
6 
 
8 
orf19.3356 ESP1 
 
8 
    
orf19.5260 RPN2 
 
7 17 11 3 2 
orf19.385 GCV2 
 
7 9 10 4 3 
orf19.1986 ARO2 
 
7 12 8 6 5 
orf19.646 GLN1 
 
7 30 3 10 12 
16687 Krt6a 
 
7 
    
orf19.1860 LSC2 
 
6 20 7 7 7 
orf19.5791 IDH2 
 
6 25 5 13 12 
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Gene ID 
 
Gene Name 
 
Crk1 
 
Cdc14 
 
Dbf2 
 
Mob1 
 
Control 1 
 
Control 2 
 
orf19.327 HTA3 
 
6 
  
5 
 
3858 KRT10 
 
5 73 36 12 8 
orf19.6250 
 
5 3 9 11 5 
orf19.3442 
 
5 
 
4 
 
3 
3868 KRT16 
 
5 
    
orf19.2310.1 RPL29 
 
5 
    
orf19.5328 GCN1 
 
4 4 22 3 3 
3857 KRT9 
 
4 
 
9 
 
17 
orf19.2352 
 
4 
 
5 
  
orf19.5015 MYO2 
 
4 22 3 4 
 
orf19.1254 SEC23 
 
4 10 3 4 
 
orf19.2119 NDT80 
 
4 
 
3 
  
orf19.2507 ARP9 
 
4 9 
 
13 
 
orf19.2644 QCR2 
 
4 9 
 
5 6 
3872 KRT17 
 
4 
    
orf19.4437 
 
4 
    
orf19.5685 THS1 
 
3 16 6 21 4 
orf19.4060 ARO4 
 
3 16 4 4 
 
orf19.5591 ADO1 
 
3 10 4 6 4 
orf19.3126 CCT6 
 
3 14 
 
2 
 
orf19.5450 ETR1 
 
3 9 
 
10 
 
orf19.5793 PR26 
 
3 9 
 
8 
 
orf19.5025 MET3 
 
3 9 
 
2 
 
orf19.2511.1 MRPL33 
 
3 
    
orf19.2873 TOP2 
 
3 
    
orf19.3276 PWP2 
 
3 
    
orf19.4831 MTS1 
 
2 12 9 5 5 
orf19.3527 CYT1 
 
2 6 8 7 
 
orf19.2422 ARC1 
 
2 8 5 4 4 
orf19.2967 TIF34 
 
2 10 
 
5 
 
orf19.691 GPD2 
 
2 8 
   
orf19.2917 
 
2 7 
 
5 
 
orf19.2533.1 
 
2 4 
   
orf19.2699 ABP1 
 
2 2 
 
5 4 
orf19.2017 
 
2 
  
6 
 
orf19.6447 ARF1 
 
2 
    
orf19.1223 DBF2 
  
11 102 
  
orf19.5528 MOB1 
   
33 
  
3849 KRT2 
  
87 23 12 17 
orf19.4732 SEC24 
  
2 14 
  
orf19.1342 SHM1 
  
10 11 8 4 
orf19.528 SEC26 
  
6 11 4 
 
orf19.3870 ADE13 
  
13 10 22 5 
orf19.1680 TFP1 
  
11 9 20 7 
orf19.1618 GFA1 
  
8 8 9 
 
orf19.7626 EIF4E 
  
19 7 9 5 
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Gene ID 
 
Gene Name 
 
Crk1 
 
Cdc14 
 
Dbf2 
 
Mob1 
 
Control 1 
 
Control 2 
 
orf19.6539 
  
12 7 5 
 
orf19.316 SEC13 
  
4 7 6 
 
orf19.518 
   
2 7 7 
 
orf19.7178 PRE5 
   
7 3 
 
orf19.1047 ERB1 
  
9 6 11 
 
orf19.506 YDJ1 
  
9 6 3 
 
orf19.2250 SPE3 
  
8 6 4 
 
orf19.5639 HIS4 
  
8 6 
  
orf19.3335 
  
6 6 4 2 
orf19.1661 DBP5 
  
2 6 6 
 
orf19.7424 NSA2 
   
6 
  
orf19.6217 PGA63 
  
14 5 6 5 
orf19.6882 OSM1 
  
8 5 
  
orf19.2275 
  
5 5 3 
 
orf19.1756 GPD1 
   
5 4 
 
orf19.3278 GSY1 
   
5 4 
 
orf19.585 
    
5 
  
orf19.6402 CYS3 
  
19 4 3 
 
orf19.2525 LYS12 
  
12 4 5 
 
orf19.922 ERG11 
  
9 4 5 
 
orf19.5645 MET15 
  
9 4 
  
orf19.406 ERG1 
  
8 4 
  
orf19.1559 HOM2 
  
7 4 7 
 
orf19.2785 ATP7 
  
7 4 2 8 
orf19.1789.1 LYS1 
  
6 4 
  
orf19.338 
   
5 4 4 
 
orf19.4931 
  
3 4 10 
 
orf19.1569 UTP22 
  
3 4 3 
 
orf19.5991 
  
2 4 
  
orf19.3681 
   
4 7 3 
orf19.4375.1 RPS30 
   
4 
  
orf19.4413 CMD1 
   
4 
  
orf19.5607 
   
4 
  
orf19.6696 TIM9 
   
4 
  
orf19.6220.3 MMD1 
  
15 3 7 
 
orf19.7327 PHO88 
  
10 3 2 
 
orf19.3941 URA7 
  
8 3 12 
 
orf19.5893 RIP1 
  
7 3 3 
 
orf19.2720 
  
6 3 6 
 
orf19.6757 GCY1 
  
6 3 
  
orf19.5061 ADE5,7 
  
5 3 7 
 
orf19.7483 CRM1 
  
4 3 
  
orf19.1233 ADE4 
   
3 3 
 
orf19.1966 BUD23 
   
3 
  
orf19.2500 
   
3 
  
orf19.522 PIM1 
   
3 
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Gene ID 
 
Gene Name 
 
Crk1 
 
Cdc14 
 
Dbf2 
 
Mob1 
 
Control 1 
 
Control 2 
 
orf19.96 TOP1 
   
3 
  
orf19.734 GLK1 
  
8 2 
  
orf19.5083 DRG1 
  
7 2 4 
 
orf19.3348 
  
5 2 
  
orf19.6524 TOM40 
  
5 2 
  
orf19.441 RPT1 
  
3 2 10 
 
orf19.5420 
  
3 2 
  
orf19.5505 HIS7 
  
3 2 
  
orf19.7064 GLN4 
   
2 4 
 
orf19.3367 
   
2 
  
orf19.7328 
   
2 
  
orf19.125 EBP1 
  
41 
 
46 
 
orf19.5776 TOM1 
  
30 
 
15 
 
orf19.744 GDB1 
  
26 
 
22 
 
orf19.1517 ARO3 
  
21 
 
5 4 
orf19.2947 SNZ1 
  
17 
 
12 3 
orf19.3462 SAR1 
  
17 
 
9 
 
orf19.1552 CPR3 
  
17 
 
3 
 
orf19.3341 
  
15 
 
23 
 
orf19.637 SDH2 
  
15 
 
10 
 
orf19.6099 CCT8 
  
14 
 
9 
 
orf19.1631 ERG6 
  
14 
 
2 
 
orf19.4040 ILV3 
  
13 
 
13 
 
orf19.2023 HGT7 
  
13 
   
orf19.2951 HOM6 
  
13 
  
9 
orf19.5180 PRX1 
  
12 
 
6 
 
orf19.2852 
  
12 
 
5 4 
orf19.3554 AAT1 
  
12 
 
4 
 
orf19.512 
   
11 
 
6 
 
orf19.544.1 PRE6 
  
11 
 
5 2 
orf19.2762 AHP1 
  
11 
 
2 
 
orf19.4517 
  
11 
  
3 
orf19.1336 PUP3 
  
10 
 
6 
 
orf19.3013 CDC12 
  
10 
 
6 
 
orf19.850 
   
10 
 
6 3 
orf19.251 GLX3 
  
10 
 
4 
 
orf19.5073 DPM1 
  
10 
 
4 
 
orf19.1815 
  
10 
 
3 
 
orf19.1375 LEU42 
  
10 
   
orf19.1448 APT1 
  
10 
   
orf19.505 SRV2 
  
10 
   
orf19.4969 KEM1 
  
9 
 
7 
 
orf19.3064 MRPL27 
  
9 
 
6 
 
orf19.4016 
  
9 
 
6 
 
orf19.4051 HTS1 
  
9 
 
6 
 
orf19.847 YIM1 
  
9 
 
2 
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Gene ID 
 
Gene Name 
 
Crk1 
 
Cdc14 
 
Dbf2 
 
Mob1 
 
Control 1 
 
Control 2 
 
orf19.1868 RNR22 
  
9 
   
orf19.2396 IFR2 
  
9 
   
orf19.3221 CPA2 
  
9 
   
orf19.401 TCP1 
  
9 
   
orf19.5956 PIN3 
  
9 
   
orf19.7297 
  
9 
   
orf19.7481 MDH1 
  
9 
   
orf19.610 EFG1 
  
8 
 
8 
 
orf19.3206 CCT7 
  
8 
 
6 3 
orf19.4076 MET10 
  
8 
 
5 
 
orf19.5773 
  
8 
 
4 
 
orf19.5378 SCL1 
  
8 
 
3 
 
orf19.3168 RPN8 
  
8 
   
orf19.4491 ERG20 
  
8 
   
orf19.7269 
  
8 
  
5 
orf19.7600 FDH3 
  
8 
   
orf19.7676 XYL2 
  
8 
   
orf19.1086 
  
7 
 
6 3 
orf19.4759 COX5 
  
7 
 
6 
 
orf19.2930 
  
7 
 
5 
 
orf19.6041 RPO41 
  
7 
 
5 8 
orf19.4233 THR4 
  
7 
 
4 
 
orf19.5085 
  
7 
 
3 
 
orf19.941 SEC14 
  
7 
 
3 
 
orf19.2640 FUR1 
  
7 
 
2 4 
orf19.548 CDC10 
  
7 
 
2 
 
orf19.2483 RIM1 
  
7 
   
orf19.3696 TOM22 
  
7 
  
5 
orf19.645.1 VMA13 
  
7 
   
orf19.797 BAT21 
  
7 
   
orf19.3192 STI1 
  
6 
 
13 2 
orf19.7655 RPO21 
  
6 
 
11 5 
orf19.680 TIM50 
  
6 
 
8 
 
orf19.7448 LYS9 
  
6 
 
7 
 
orf19.300 AIP2 
  
6 
 
6 
 
orf19.2555 URA5 
  
6 
 
5 
 
orf19.5021 PDX1 
  
6 
 
5 
 
orf19.5484 SER1 
  
6 
 
5 
 
orf19.997 SNL1 
  
6 
 
4 
 
orf19.1967 
  
6 
 
3 
 
orf19.1840 
  
6 
   
orf19.213 
   
6 
   
orf19.2244 
  
6 
   
orf19.239 
   
6 
   
orf19.3103 
  
6 
   
orf19.424 TRP99 
  
6 
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Gene ID 
 
Gene Name 
 
Crk1 
 
Cdc14 
 
Dbf2 
 
Mob1 
 
Control 1 
 
Control 2 
 
orf19.4290 TRR1 
  
6 
   
orf19.4697 MDN1 
  
6 
   
orf19.5211 IDP1 
  
6 
   
orf19.6285 GLC7 
  
6 
   
orf19.828 
   
6 
   
orf19.4246 
  
5 
 
6 
 
orf19.3054 RPN3 
  
5 
 
5 
 
orf19.3052 YPT1 
  
5 
 
4 
 
orf19.4609 
  
5 
 
4 
 
orf19.1164 GAR1 
  
5 
 
3 
 
orf19.2841 PGM2 
  
5 
 
3 
 
orf19.3350 MRP20 
  
5 
 
3 
 
orf19.4248 
  
5 
 
3 
 
orf19.550 PDX3 
  
5 
 
3 
 
orf19.1390 PMI1 
  
5 
 
2 
 
orf19.238 CCP1 
  
5 
 
2 
 
orf19.4909.1 RPL42 
  
5 
 
2 
 
orf19.5912 MAK21 
  
5 
 
2 
 
orf19.1115 GUK1 
  
5 
   
orf19.1229 
  
5 
   
orf19.1354 UCF1 
  
5 
   
orf19.1946 
  
5 
   
orf19.2571 SEC4 
  
5 
   
orf19.390 CDC42 
  
5 
   
orf19.4382 
  
5 
   
orf19.4492 
  
5 
   
orf19.482 RPT4 
  
5 
   
orf19.5235 
  
5 
   
orf19.5480 ILV1 
  
5 
   
orf19.5525 
  
5 
   
orf19.5620 
  
5 
   
orf19.6014 RRS1 
  
5 
   
orf19.7124 RVS161 
  
5 
   
orf19.895 HOG1 
  
5 
   
orf19.978 BDF1 
  
5 
   
orf19.6632 ACO2 
  
4 
 
13 
 
orf19.5419 ATP5 
  
4 
 
4 
 
orf19.6559 
  
4 
 
4 
 
orf19.7215 
  
4 
 
4 
 
orf19.763 
   
4 
 
4 
 
orf19.1299 RPN6 
  
4 
 
3 
 
orf19.1687 
  
4 
 
3 
 
orf19.2233 PRE2 
  
4 
 
3 
 
orf19.4490.2 QCR8 
  
4 
 
3 
 
orf19.7635 DRS1 
  
4 
 
3 
 
orf19.1575 PRS1 
  
4 
 
2 
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Gene ID 
 
Gene Name 
 
Crk1 
 
Cdc14 
 
Dbf2 
 
Mob1 
 
Control 1 
 
Control 2 
 
orf19.2795 LHP1 
  
4 
 
2 
 
orf19.3300 ZPR1 
  
4 
 
2 
 
orf19.1153 GAD1 
  
4 
   
orf19.1340 
  
4 
   
orf19.1553 ENT3 
  
4 
   
orf19.1649 RNA1 
  
4 
   
orf19.1665 MNT1 
  
4 
   
orf19.1691 
  
4 
   
orf19.2093 RFA1 
  
4 
   
orf19.2549 SHP1 
  
4 
   
orf19.2895 VMA8 
  
4 
   
orf19.3038 TPS2 
  
4 
   
orf19.3106 MET16 
  
4 
   
orf19.3340 SOD2 
  
4 
   
orf19.3478 NIP7 
  
4 
   
orf19.3707 YHB1 
  
4 
   
orf19.4591 CAT2 
  
4 
  
3 
orf19.4796 
  
4 
   
orf19.4848 SKI3 
  
4 
   
orf19.5228 RIB3 
  
4 
   
orf19.5369 
  
4 
   
orf19.5517 
  
4 
   
orf19.5622 GLC3 
  
4 
   
orf19.5832 HPT1 
  
4 
   
orf19.6151 ARC15 
  
4 
   
orf19.6176 SEC61 
  
4 
   
orf19.6729 TIP120 
  
4 
   
orf19.6809 
  
4 
   
orf19.7019 YML6 
  
4 
   
orf19.7021 GPH1 
  
4 
   
orf19.7322 
  
4 
   
orf19.798 TAF14 
  
4 
   
orf19.886 PAN1 
  
4 
   
orf19.989 
   
4 
   
orf19.1453 SPT5 
  
3 
 
5 
 
orf19.5647 SUB2 
  
3 
 
5 
 
orf19.7215.3 
  
3 
 
5 
 
orf19.1055 CDC3 
  
3 
 
4 
 
orf19.1214 
  
3 
 
4 
 
orf19.6810 
  
3 
 
4 
 
orf19.4236 RET2 
  
3 
 
3 
 
orf19.5440 RPT2 
  
3 
 
3 
 
orf19.6136 
  
3 
 
3 
 
orf19.6837 FMA1 
  
3 
 
3 
 
orf19.5100 MLT1 
  
3 
 
2 
 
orf19.6417 TSR1 
  
3 
 
2 
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Gene ID 
 
Gene Name 
 
Crk1 
 
Cdc14 
 
Dbf2 
 
Mob1 
 
Control 1 
 
Control 2 
 
orf19.1085 
  
3 
   
orf19.1394 
  
3 
   
orf19.1630 
  
3 
   
orf19.1646 
  
3 
   
orf19.1891 Apr-01 
  
3 
   
orf19.2283 DQD1 
  
3 
   
orf19.3003 
  
3 
   
orf19.3123 RPT5 
  
3 
   
orf19.3251 ARC19 
  
3 
   
orf19.3297 
  
3 
   
orf19.3322 DUT1 
  
3 
   
orf19.3846 LYS4 
  
3 
   
orf19.3962 HAS1 
  
3 
   
orf19.4204 
  
3 
   
orf19.4451 RIA1 
  
3 
   
orf19.4640 PWP1 
  
3 
   
orf19.4751 
  
3 
   
orf19.5078 
  
3 
   
orf19.5126 
  
3 
   
orf19.5178 ERG5 
  
3 
   
orf19.5230 MRPS9 
  
3 
   
orf19.5293 
  
3 
   
orf19.5698 
  
3 
   
orf19.581 
   
3 
   
orf19.5834 
  
3 
   
orf19.5870 CTP1 
  
3 
   
orf19.6293 EMP24 
  
3 
   
orf19.6322 ARD 
  
3 
   
orf19.6503 
  
3 
   
orf19.6798 SSN6 
  
3 
   
orf19.6804 
  
3 
   
orf19.688 
   
3 
   
orf19.6948 CCC1 
  
3 
   
orf19.7264 
  
3 
   
orf19.7335 PRE8 
  
3 
   
orf19.7409 ERV25 
  
3 
   
orf19.7613 HCR1 
  
3 
   
orf19.7654 CPR6 
  
3 
   
orf19.809 
   
3 
   
orf19.863 
   
3 
   
orf19.1235 HOM3 
  
2 
 
4 
 
orf19.3133 GUT2 
  
2 
 
3 
 
orf19.2755 
  
2 
 
2 
 
orf19.7236 TIF35 
  
2 
 
2 3 
orf19.976 BRE1 
  
2 
 
2 
 
orf19.1108 HAM1 
  
2 
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Gene ID 
 
Gene Name 
 
Crk1 
 
Cdc14 
 
Dbf2 
 
Mob1 
 
Control 1 
 
Control 2 
 
orf19.1166 CTA3 
  
2 
   
orf19.1628 LAP41 
  
2 
   
orf19.1662 
  
2 
   
orf19.2214 
  
2 
   
orf19.3938 
  
2 
   
orf19.4024 RIB5 
  
2 
   
orf19.4032 RPN5 
  
2 
   
orf19.4230 
  
2 
   
orf19.4669 AAT22 
  
2 
   
orf19.4686 
  
2 
   
orf19.4898 
  
2 
   
orf19.5104 LTP1 
  
2 
   
orf19.5226 WRS1 
  
2 
   
orf19.5597 POL5 
  
2 
   
orf19.5629 QCR7 
  
2 
   
orf19.5747 
  
2 
   
orf19.5958 CDR2 
  
2 
   
orf19.6236 NOP6 
  
2 
   
orf19.6264.3 
  
2 
   
orf19.667.1 RPL37B 
  
2 
   
orf19.6752 
  
2 
   
orf19.6844 ICL1 
  
2 
   
orf19.7035 RFC2 
  
2 
   
orf19.7086 
  
2 
   
orf19.7153 
  
2 
   
orf19.7261 GDI1 
  
2 
   
orf19.810 
   
2 
   
orf19.882 HSP78 
  
2 
   
orf19.7076 GBP2 
    
8 3 
orf19.231 APL2 
    
5 
 
orf19.1949 VPS1 
    
4 4 
orf19.2150 
    
4 
 
orf19.4683 MLP1 
    
4 
 
orf19.5516 
    
4 
 
orf19.5544 SAC6 
    
4 
 
orf19.6812 PMT2 
    
4 
 
orf19.7201 SLA2 
    
4 
 
orf19.7501 
    
4 
 
orf19.7678 ATP16 
    
4 
 
orf19.1494 RAD23 
    
3 
 
orf19.3547 
    
3 
 
orf19.3755 
    
3 
 
orf19.4089 SGT1 
    
3 
 
orf19.4594 CLC1 
    
3 
 
orf19.6063 UBP6 
    
3 
 
orf19.2028 MXR1 
    
2 
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Gene ID 
 
Gene Name 
 
Crk1 
 
Cdc14 
 
Dbf2 
 
Mob1 
 
Control 1 
 
Control 2 
 
orf19.2095 
    
2 
 
orf19.2286 
    
2 
 
orf19.2601 HEM1 
    
2 
 
orf19.2672 NCP1 
    
2 
 
orf19.2688 NAN1 
    
2 
 
orf19.3205 MPRL36 
    
2 
 
orf19.3333 
    
2 
 
orf19.3480 
    
2 
 
orf19.4093 PES1 
    
2 
 
orf19.4102 RPN10 
    
2 
 
orf19.4147 GLR1 
    
2 
 
orf19.498 
     
2 
 
orf19.5989 
    
2 
 
orf19.6582 PRE10 
    
2 
 
orf19.6612 
    
2 
 
orf19.6967 USO6 
    
2 
 
orf19.7081 SPL1 
    
2 
 
orf19.7234 
    
2 
 
orf19.7552 
    
2 
 
orf19.6924 HTA1 
     
7 
 
 
Table 3.2: Proteins identified by MS. Six IP-MS experiments were carried out where the bait protein 
was either Crk1, Cdc14, Dbf2, Mob1 or none. In the control experiments untagged cells were used in 
the same manner as the other four tagged strains. The results of the MS experiments were 
processed using the software ProHits, where this table was exported from. The Gene ID is a unique 
number assigned to each gene in the Candida Genome Database. If the genes have been 
characterised, they also have names corresponding to the protein names. Blank spaces in the second 
column indicate that the genes are uncharacterised. The numbers in the remaining six columns 
indicate the number of total peptides of the corresponding protein, that have been identified in each 
experiment. Results are filtered, so that only proteins with at least 2 unique peptides are present, 
and only peptides with a score >50 are counted. Cell colours indicate peptide abundance in a 
decreasing order from red to blue.  
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CAM1-1, CAM1, SUP35 etc.) and chaperones (e.g. SSA2, HSP90, HSP70, KAR2, SSZ1, HSP104 
etc.). 
 
3.4.3. SAINT analysis of MS results  
The Significance Analysis of INTeractome (SAINT) is another computational method to 
assess interaction probabilities in a set of MS data (Choi, et al., 2011). SAINT is an integrated 
tool of ProHits and provides a more sophisticated analysis for quantifying the probability of 
an interaction between two proteins by using spectral counts normalised to the length of 
the proteins and to the total number of spectra in the purification.  
 Unfortunately, after the MS data was processed by SAINT, the software was not able 
to find any interactions, because it would require more data sets to generate statistically 
significant scores.   
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3.5. Discussion 
 
Affinity purification coupled to mass spectrometry is the main tool of this study for 
identifying interacting partners of Dbf2, Mob1, Cdc14 and Crk1. All four proteins were 
immunoprecipitated using agarose beads coupled to antibodies against a MYC tag fused to 
the proteins. This combination of a tag and affinity matrix was found to capture the most 
amount of bait, while also producing less background than the other tested variations.  A 
series of optimisation experiments were used to derive the optimal conditions for maximal 
yield of bait proteins, which is a major limiting factor in the pipeline. Although a large 
amount of purified bait proteins was achieved, Coomassie-stained gels showed an 
overwhelming background of contaminants which likely obstruct the identification of low 
abundant specific interactors. Experimental methods that reduce the non-specific binding of 
proteins the affinity matrix, inevitably compromise bait recovery and are likely to disturb 
protein interactions. Increasing signal-to-noise ratio was a major goal in following 
experiments. 
 Label-free MS can be a powerful tool for identifying unknown proteins in a mixture 
but it is likely not the easiest way to map interactions. Previously Breitkreutz, et al. (2011) 
have used label-free MS followed by SAINT to construct a global kinase and phosphatase 
interaction network in S. cerevisiae. Their success was in part due to the fact that bait 
proteins were very strongly overexpressed in order to force a maximum number of in vivo 
interactions. Another hallmark of their study is the use of 276 different baits, which allowed 
them to devise a sophisticated statistical method for analysis of the MS results. This study 
attempted to use their approach on a smaller scale in C. albicans. However, due to 
insufficient data size no statistical significance was reached by SAINT.  
Although ProHits provides a rather loose method for identifying interactions, very 
few proteins stand out as likely hits. Proteins present in all six experiments can be excluded 
as interactors with high confidence, but proteins present in a single IP are very few. An 
example of such protein is Bur2, which was represented by 12 peptides in the Crk1 IP, but it 
was not found in any of the other IPs. Bur2 is also a known cyclin of Bur1 (the Crk1 
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homologue in S. cerevisiae) and it was even identified as a prey in the Breitkreutz study. 
Thus Bur2 is most likely to be a real hit, which raises the possibility that Crk1 is a cyclin-
dependent kinase, although further experiments would be needed to confirm it. 
  The vast majority of proteins are found in 2-5 IPs. Some of those proteins have very 
different representation in each experiment. For example, Sec27 has 12 peptides in Mob1 
IP, 11 peptides in Dbf2 IP, 3 peptides in one of the mock IPs, and 2 peptides in the other 
mock IP and Crk1 IP. As previously discussed, Dbf2 and Mob1 are likely to pull the same 
interactors. Sec27 is visibly overrepresented in these 2 IPs comparing to the rest, but the 
presence of a few peptides in the other three IPs creates the possibility that it may be a 
contaminant. In fact, Sec27 was identified as interactor of Dbf2 in S. cerevisiae by MS (Ho et 
al., 2002), but the ProHits analysis is not sufficient to confidently call it a hit in C. albicans. 
This example illustrates the difficulty in using a label-free MS data for assigning protein 
interactions.  
 It is noteworthy that Mob1 has pulled significantly more of the Dbf2 protein than the 
direct IP of the kinase. On the other hand, Mob1 was not recovered at all in the Dbf2 IP. 
Thus, it is likely that significant proportion of Mob1 in the cell is bound to Dbf2, whereas 
very little of the Dbf2 pool is bound to Mob1. Considering that Dbf2 is only active when 
bound to Mob1, the direct IP of Dbf2 most likely recovered predominantly an inactive 
kinase. The Dbf2-Mob1 complex recovered in the Mob1 IP suggests that this dataset is likely 
to contain more clients of the kinase. In conclusion, Mob1 is better suited as a bait in IP 
experiments aiming to identify Dbf2 targets. 
 Expanding the current data by doing more IPs would likely create more meaningful 
results. However, rather than that, a strategic decision was made to take a different 
approach for identifying interactions, namely using SILAC in conjunction with MS analysis. 
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Chapter 4 
 
Characterization of the Substrate-Trapping 
Mutant Cdc14C275S  
 
 
 
4.1. Introduction 
 
Protein phosphorylation and dephosphorylation are transient reactions in which kinases or 
phosphatases remain bound to their substrates for a very short time until a phosphate 
group is added to or removed from the proteins. Such interactions are often too short-lived 
to withstand co-IP experiments and thus are very difficult to detect by AP-MS.  
  Previous research has shown that the interaction between protein tyrosine 
phosphatases (PTP) and their targets can be artificially enhanced if the catalytic residues of 
the enzymes are changed (Tonks and Neel, 1996). Phosphatase-dead (PD) mutants are 
engineered by substitution either of two essential catalytic amino acids within the active 
pocket of the enzyme – Cys -> Ser/Ala or Asp -> Ala (reviewed in Blanchetot et al., 2005). 
Substrate-trapping mutants have significantly lower or completely absent catalytic activity 
and thus may interrupt downstream events governed by their substrates. Nevertheless, 
since PD phosphatases have higher affinity for their substrates, they have been a valuable 
tool for identifying physiological interactions. 
 Structural and kinetic analyses of hCdc14B have demonstrated striking similarities 
between the active pocket of this phosphatase and other PTPs (Gray et al., 2003). The study 
identified the active Cys and Asp residues in the signature motif of hCdc14B, which were 
later found to be conserved in Cdc14 homologues in all species. PD mutants of Cdc14 have 
been engineered in H. sapiens (Lanzetti et al., 2007), S. cerevisiae (Bloom et al., 2011), S. 
pombe (Wolfe and Gould, 2004) and recently in Fusarium graminearum (Li et al., 2015). 
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Importantly, the use of these mutants in AP-MS experiments has revealed many substrates 
of the phosphatase which were not detected by the same experiments, but using the wild 
type enzyme. This illustrates the power of using PD Cdc14 when looking for substrates of 
this phosphatase. 
 The substrate-trapping approach was recognised as a possible solution of the 
problems encountered in the initial MS experiments, namely the difficulty of obtaining 
sufficient amount of bound substrates to be detected by MS. Therefore, this approach was 
employed in this study too.  
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4.2. Generation of phosphatase-dead strains 
 
4.2.1. Identification of the catalytic residues in the active pocket of Cdc14 
The protein sequences of CaCdc14 and ScCdc14 were aligned using the Basic Local 
Alignment Search Tool (BLAST). The catalytic residues of ScCdc14 are D253 and C283. The 
corresponding amino acids in CaCdc14 are D244 and C275 respectively (fig. 4.1). C275 was 
arbitrarily chosen to be substituted with a serine to create a PD Cdc14. 
 
4.2.2. Generation of cdc14C275S 
In order to engineer PD Cdc14 in C. albicans, one of the endogenous alleles of CDC14 was 
mutated to cdc14C275S using the cloning strategy illustrated in figure 4.2. A cassette 
containing cdc14C275S-MYC::URA3 was cut out of the vector and transformed into MDL04 
strain. The insert replaces one of the wild type alleles of CDC14 creating a strain expressing 
one wild type allele of CDC14 and one PD allele of cdc14C275S fused to a MYC epitope. A 
wild type allele of CDC14 was purposely left in the genome, because cell expressing only a 
PD allele have a specific phenotype as discussed later in this chapter. 
 A separate strain expressing the PD allele cdc14C275S fused to GFP was also created 
in order to visualise the localisation of the protein. MYC::URA3 was replaced by GFP::ARG4 
in the genome by homologous recombination.  
 Strains expressing cdc14C275S will from now on be written as Cdc14PD. 
 
4.2.3. Generation of a regulatable Cdc14PD 
The inactive Cdc14PD is expected to affinity purify more targets than the wild type enzyme. 
In order to further optimise the AP-MS and enrich protein binding partners, CDC14PD was 
put under a regulatable MET3 promoter, which allows the gene to be overexpressed several  
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Fig. 4.1: Alignment and CaCdc14 (Query) and ScCdc14 (Sbjct) amino acid sequence using BLAST. The 
catalytic residues in ScCdc14 D253 and C283 correspond to D244 and C275 in CaCdc14. 
  
6
6 
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Fig. 4.2: Cloning steps for the generation of cdc14PD.  
START: The backbone vector used in the 
cloning procedure is pRSC3. 
 
STEP 1: The GFP gene was cut out of the 
vector using the endonucleases BamHI 
and XbaI generating a linearized plasmid. 
 
STEP 2: CDC14-MYC was amplified from 
gDNA starting from 400 bp upstream of 
CDC14 (insert 1).  
 
STEP 3: The insert contained the 
restriction sites for XhoI (5’ end) and 
XbaI (3’ end) and was digested with 
these two enzymes to create sticky ends. 
 
NOTE: The insert could not be designed 
with a BamHI end, because it has this 
restriction site internally. 
 
STEP 4: The insert and the linear vector 
were ligated together with the use of a 
short linker sequence containing BamHI 
and XhoI restriction sites (pINK1). 
 
STEP 5: The pINK1 plasmid was amplified 
by PCR using a primer pair that mutates 
a TGT (Cys275) codon to a TCT (Ser) 
codon (pINK2). 
 
STEP 6: A 400 bp sequence downstream 
of CDC14 was amplified by PCR from a 
gDNA (insert 2). This sequence 
contained restriction sites for NotI (5’ 
end) and SacI (3’ end). 
 
STEP 7: The pINK2 vector and insert 2 
were both digested with NotI and SacI 
and ligated together to create the final 
vector pINK3. 
 
STEP 8: pINK3 was digested with XhoI 
and SacI. This created 3 fragments, the 
biggest of which contains CDC14-
MYC::URA3 flanked by 400 bp upstream 
and downstream sequence of CDC14. 
This fragment was transformed into C. 
albicans cells to create the mutant strain 
cdc14PD. 
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folds above physiological levels. For this purpose, cells expressing Cdc14PD-Myc were 
transformed with ARG4::MET3 cassette containing flanking sequences of the 5’ region of 
CDC14. The cassette may integrate in the 5’ region of either CDC14 or cdc14PD. To separate 
these two outcomes apart, PCR-positive colonies were grown individually in MET3-inducing 
media and MET3-repressing media. Using Western blot, two colonies were identified to 
have upregulated levels of Cdc14PD in a MET3-on culture and completely absent Cdc14PD in a 
MET3-off environment (fig. 4.3). This shows that in these colonies, the MET3 promoter is 
controlling the expression of Cdc14PD.  
The expression of CDC14 cannot be measured by Western blot because the gene is 
not fused to an epitope. Thus, integration of the cassette in front of CDC14 was confirmed 
by DNA sequencing. However, the Western blot pattern of Cdc14PD of one of the colonies 
suggested this to be the case as explained in figure 4.3. In a MET3-on culture Cdc14PD was 
expressed at its natural levels but without the characteristic hyperphosphorylation seen in 
the MET-off environment (as discussed in section 4.3.1). Clp1 is known to 
transautodephosphorylate in S. pombe (Wolfe et al., 2006). This is the first evidence 
suggesting that CaCdc14 may be doing the same. Overexpression of the catalytically active 
Cdc14 produced fully dephosphorylated Cdc14PD, while downregulating Cdc14 results in 
hyperphosphorylated Cdc14PD. Further evidence that in this strain the MET3 promoter 
controls CDC14 expression came from the observation that cell with induced MET3 display 
the same phenotype as cdc14Δ/Δ (see section 4.4.1), while cells with repressed MET3 have 
the phenotype of wild type cells. 
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Fig. 4.3: Colony screen for integration of MET3 promoter in front of either CDC14 or cdc14PD-MYC. 
Six colonies transformed with MET3 were grown in liquid broth that renders the promoter either on 
or off. Colonies 2 and 4 showed highly increased expression of cdc14PD when the promoter is 
switched on and complete absence of the protein when the promoter is off. This indicates that the 
MET3 promoter was integrated in front of the mutant allele in these two colonies. The wild type 
CDC14 allele is not fused to any tagged so its expression cannot be tested by Western blot. However, 
the expression pattern of colony 6 suggests that MET3 is controlling CDC14. When the promoter is 
on, cdc14PD losses its characteristic hyperphosphorylation pattern. Cdc14 is known to 
autodephosphorylate in S. pombe, so overexpression of the wild type protein likely 
dephosphorylates the mutant protein. When the promoter is off, i.e. no wild type Cdc14 is 
expressed, the majority of cdc14PD is phosphorylated. Colonies 1, 3 and 5 were unsuccessful 
transformants. Control is lysate from untagged cells. 
  
on on on on on on off off off off off off 
Control Colony 1 Colony 2 Colony 3 Colony 4 Colony 5 Colony 6 
MET3: 
Cdc14PD 
WB:  
anti-MYC 
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4.3. Characterisation of Cdc14PD by Western blot 
 
4.3.1. Phosphorylation status of Cdc14PD 
Cdc14 expressed form asynchronous cells produces a single band on a Western blot, 
although the protein is phosphorylated in a part of the cell cycle. In contrast to this, Cdc14PD 
extracted from cdc14PD/CDC14 cells, produced a clearly smeared band, characteristic of 
phosphorylated proteins. To confirm that the protein is indeed phosphorylated, cell lysates 
were incubated in the presence or absence of lambda phosphatase at 37 °C. The 
phosphatase-treated sample produced a single band on a Western blot (fig. 4.4). Hence, the 
smear of Cdc14PD is due to phosphorylation of the protein. 
 
4.3.2. Expression of Cdc14PD in yeast and hyphae 
Protein levels of Cdc14 vary widely throughout the cell cycle from being completely absent 
in G1 to being highly expressed in anaphase in both yeast and hyphae (Clemente-Blanco et 
al., 2006). To follow the expression of Cdc14PD, an overnight culture of cdc14PD/CDC14 cells 
was left in water at room temperature for 4 hours to induce all cells into entering stationary 
phase. Cells were then released into fresh medium and allowed to grow as either yeast or 
hyphae for 90 min. Although this method of synchronisation is not as efficient as elutriation, 
it is much easier to carry out in the lab and the vast majority of cells are in the same phase 
of the cycle. Samples were taken every 15 minutes and cells were immediately lysed to 
extract soluble proteins. As shown by Western blot on fig. 4.5, the Cdc14PD was not 
detectable in the initial stages and its levels increased steadily during the course of the 
experiment in both yeast and hyphae. This shows that Cdc14PD follows the same expression 
pattern as the active Cdc14. 
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         λ phosphatase  
 
 
 
 
Fig. 4.4: Phosphatase treatment of Cdc14PD. Cdc14PD produces a band shift on a Western blot which 
collapses to a sharp band when a cell lysate is treated with λ phosphatase. This shows that the 
protein is phosphorylated and most likely at multiple sites, since no clear distinction can be made 
between the phosphorylated and non-phosphorylated forms on a Western blot. Note: the white 
mark in the untreated sample is a defect of the membrane. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.5: Comparison of expression levels of Cdc14 and Cdc14PD. A time course experiment showed 
very similar expression pattern of the wild type and the mutant proteins. Cells were grown overnight 
and then starved in water for 4 hours to induce transition into G0. They were then released into 
fresh medium and left to grow in either yeast- or hyphae-promoting conditions. Cells are semi-
synchronised. Cells were taken every 15 min and lysed. The phosphatase is not present in stationary 
phase cells and it starts appearing after about 45 min in yeast and 60 min in hyphae. More 
importantly, Cdc14PD does not show any signs of untimely expression. The budding index after 
starvation in water was not measured. 
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4.3.3. Co-IP of Cdc14 and Cdc14PD 
As already mentioned in section 4.2.3, overexpression of the wild type Cdc14 completely 
diminished the phosphorylation of Cdc14PD. The possibility of interaction between both 
forms of the phosphatase was further investigated by co-IP. The substrate-trapping Cdc14PD-
Myc was co-expressed with Cdc14-GFP and cell lysates were incubated with anti-Myc 
affinity beads. Western blot of the immunoprecipitated proteins detected both forms of 
Cdc14 (fig. 4.6), adding further evidence for direct physical interaction.  
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Fig. 4.6: Co-immunoprecipitation of Cdc14PD and Cdc14. IP of Cdc14PD pulls down the wild type 
phosphatase Cdc14, suggesting physical interaction between both proteins. 
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4.4. Phenotypic analysis of Cdc14PD using microscopy 
 
4.4.1. Morphology of PD mutants 
CDC14/cdc14PD cells grew completely normal in both yeast and hyphae-inducing conditions. 
Cell displayed no visible differences to CDC14/CDC14 when examined by brightfield 
microscopy. Hyphal formation was also not affected by the presence of the mutant allele 
(fig. 4.7). This suggests that C. albicans is haplosufficient for CDC14 and that cdc14PD is not a 
dominant negative allele.  
When the wild type allele was repressed by MET3 promoter, MET3-CDC14/cdc14PD 
cells exhibited the same phenotype as cdc14Δ/Δ, namely defects in cell separation resulting 
in chains of yeast cells and inability to form proper hyphae (fig 4.7). This is an evidence that 
Cdc14PD has indeed lost its phosphatase activity. 
 When Cdc14PD was overexpressed with the use of MET3, cells grown in the absence 
of methionine remained with normal morphology, but grew slightly slower than wild type 
cells. Overexpression of cdc14PD likely depletes the large pool of Cdc14 substrates. 
Considering the role of Cdc14 in mitotic progression through anaphase, this phenotype is 
not surprising. However, it is evident that as long as one wild type allele of the phosphatase 
is expressed, cells are able to grow without morphological defects. 
 
4.4.2. Localisation of Cdc14PD 
The localisation of Cdc14PD-GFP was examined by fluorescent microscopy. The mutant 
showed difference to wild type protein localisation in neither yeast, nor hyphae. In yeast, 
Cdc14PD was seen in the nucleus during interphase and at the spindle pole bodies during cell 
separation (fig. 4.7). In hyphae, Cdc14PD was only detected in the nucleus. This is also the 
localisation pattern of wild type Cdc14-GFP in the presence of Cdc14PD. All of these results 
show that the catalytic inactivation of Cdc14PD does not affect its localisation in the cell. 
  
Yeast 
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Fig. 4.7: Phenotype of Cdc14PD. (A) In cdc14PD-GFP/CDC14 cells, CDC14 is dominant to cdc14PD, since 
in the presence of both alleles cells did not display any visible defects. Just like the wild type 
phosphatase, Cdc14PD-GFP localised to two spots likely corresponding to the spindle pole bodies in 
dividing yeast and to one spot, most likely the nucleolus, in non-dividing yeast and hyphae. (B) In 
cdc14PD/MET3-CDC14 the wild type allele was turned off with the use of MET3 promoter, and only 
Cdc14PD was expressed. As a result, hyphal formation was severely impaired even 2 hours after 
induction. The budding index was not measured. 
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4.4.3. Localisation of Mlc1 in the presence of Cdc14PD 
Cdc14Δ/Δ cells have severe defects in septum formation (Clemente-Blanco et al., 2006). To 
examine whether this process is affected by cdc14PD, the septum marker protein Mlc1 was 
fused to GFP in CDC14/cdc14PD background. As in wild type cells, Mlc1 localised to the 
septum of both yeast and hyphae and demonstrated dynamic contraction of the septum 
ring at the end of mitosis (fig. 4.8).  
 
4.4.4. IP of Cdc14PD  
IP of overexpressed Cdc14PD was performed as previously described, except that the affinity 
beads were washed 3 times instead of 1 time after incubation with cell lysate. It was 
hypothesised that the stronger bait-pray interaction will withstand the washes, while the 
level of contaminants will be lower than previously seen. Indeed, Coomassie stained gel 
showed much brighter Cdc14PD bands on a much clearer background (data not shown).  
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Fig. 4.8: Localisation of Mlc1-GFP in cdc14PD/CDC14 background. A) Time lapse microscopy shows 
that Mlc1 localises to the cytokinetic ring in hyphae and its contraction is not affected by the 
presence of Cdc14PD. B) In yeast, Mlc1 has a normal localisation at the bud neck. Bright field and 
fluorescence images are overlaid.   
A 
B 
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4.5. Discussion  
 
The initial experiments of this study, where label-free MS was used, showed ambiguous 
results and did not allow for clear identification of interacting partners of the baits. Such 
potential partners were often underrepresented in comparison to the contaminants, which 
reflects the fact that interactions are easily lost in the experimental procedure due to their 
weak and transient nature. At this stage it became evident that in order to produce 
meaningful results, the ratio of prey-to-background proteins has to be significantly higher. 
 This study made use of a substrate-trapping method to stabilise the interaction of 
the phosphatase Cdc14 with its partners. The method employing a single amino acid 
substitution has already aided in identification of Cdc14 clients in other organisms. The 
catalytic Cys and Asp residues of Cdc14 are highly conserved across species and their 
position was easily identified in C. albicans by sequence alignment. The phosphatase dead 
Cdc14C275S was created by series of cloning steps. The catalytic activity of the mutant was 
not directly measured by in vitro assay, but the phenotype of MET3-CDC14/cdc14PD when 
MET3 is repressed reminisces that of cdc14Δ/Δ, which strongly suggested that Cdc14PD is 
not functional. It was confirmed that this phenotype is not due to haploinsufficiency since 
cells with a single copy of functional Cdc14 display wild type characteristics. These findings 
were taken into consideration when further MS experiments were performed, namely all 
strains used in these experiments were expressing one active and one inactive allele of 
Cdc14. The active phosphatase is required to maintain the cells in a healthy physiological 
state. The disadvantage of keeping the wild type Cdc14 is that it competes for the same 
substrates as Cdc14PD. However, the mutant phosphatase is overexpressed and largely 
outnumbers the wild type protein. Thus, competition for substrates is not a concern, as 
most of them will be bound to Cdc14PD. 
 A conserved feature of all Cdc14 phosphatases is that they become constitutively 
hyperphosphorylated when mutated to inactive enzymes and CaCdc14 is no exception. In 
vitro phosphatase treatment abolished the gel shift seen in non-treated samples of Cdc14PD. 
Wolfe et al. have shown that in fission yeast Clp1 regulates its own activity by 
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dephosphorylating itself at six Cdk1 sites. This is likely the case with Cdc14 since interaction 
between Cdc14 and Cdc14PD was shown by co-immunoprecipitation. Additionally, 
overexpression of Cdc14 reduced the phosphorylation state of Cdc14PD to a single gel band. 
Although this is not a direct evidence for autodephosphorylation, it makes a strong case 
towards this hypothesis. Additional experiments would be required to prove beyond doubt 
that Cdc14 is acting on itself, such as in vitro dephosphorylation reaction. However, it was 
not the aim of this study to investigate Cdc14 regulation, so no additional experiments were 
performed.  
 The localisation of Cdc14PD was further studied by fluorescent microscopy. It is 
important that Cdc14PD localised in the same manner as Cdc14, as mislocalisation of the 
protein could cause non-physiological interactions. In addition, Cdc14PD disrupted neither 
the morphology nor the growth of the cells, as long as the wild type protein is also 
expressed. The completion of cytokinesis was specifically examined, because Cdc14 is 
known to be involved in this process. In the presence of Cdc14PD, Mlc1 showed proper 
localisation at the bud neck of dividing cells and time lapse movies demonstrated successful 
and undisrupted contraction of the septum ring in hyphae.  
 Overexpression of Cdc14PD is another tactic that was employed with the aim to 
capture maximum number of protein partners. Cdc14 is not an abundant protein, which 
makes AP-MS very difficult without overexpressing it. Furthermore, it is not universally 
expressed throughout the cell cycle as shown by Clemente-Blanco et al. (and the same 
pattern was observed here for Cdc14PD). Instead, its levels vary widely from completely 
missing in G1 to peaking in anaphase. Although the phosphatase is present for the most of 
the cell cycle, it is thought to be active only for a brief period during mitosis. This makes a 
screen for interactors very difficult, because capturing sufficient amount of the bait and 
prays would be very challenging. On the other hand, overexpression of the phosphatase 
creates the risk of identifying false positive hits, i.e. interaction that would not normally 
occur at physiological levels of Cdc14. Nevertheless, taking everything into account, a 
decision was made that an overexpressed protein is likely to produce a better quality data. 
It is important to mention that purifying Cdc14 from synchronised cells in mitosis (when the 
protein is most abundant) was not a viable option due to technical constraints. Cell 
elutriation is a rather laborious technique that can be used to synchronise a small amount of 
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cells in the same phase of the cycle. An MS experiment requires far more cells than could 
possibly be obtained by elutriation. Other methods for obtaining mitotic cells include 
generating mutants that arrest the cells in mitosis. However, perturbing molecular pathways 
creates an artificial environment for Cdc14 and may also lead to identifying false 
interactions. Thus, for the purpose of this study, using non-synchronised cells was the best 
option. 
All of the findings presented here cumulatively indicate that Cdc14PD is a viable 
candidate for an MS screen of Cdc14 interactions. The rest of this study focussed solely on 
identifying Cdc14 targets.  
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Chapter 5 
 
SILAC Labelling in Candida albicans  
 
 
 
5.1. Introduction 
Stable isotope labelling by amino acids in cell culture (SILAC) is a metabolic labelling 
technique that produces mass difference between two proteomes read out by MS. It was 
originally developed in 2002 for use in mammalian cell lines, but since then it has been 
successfully applied to various organisms, including bacteria, yeast, plants, worms and flies 
(Ong et al., 2002; Kerner et al., 2005; Jiang and English, 2002; Gruhler et al., 2005). SILAC 
depends on in vivo incorporation of stable isotope-labelled amino acids present in the 
growth medium of cell cultures. Thus, any organism that feeds on amino acids can be used 
in SILAC experiments (Ong and Mann, 2006). This study describes the first application of 
SILAC labelling in C. albicans. 
 The first important consideration in SILAC is the choice of labelled amino acids. This 
is largely dependent on the protease used to digest the samples prior to MS analysis. 
Ideally, every peptide coming from a heavy-labelled proteome should carry at least one 
heavy amino acid. Heavy and light peptide analogues form SILAC pairs in the mass spectrum 
that show their relative abundance in each sample. Trypsin cleaves at the C-terminus of 
arginine (Arg) and lysine (Lys), so it is commonly used in combination with heavy Arg and 
Lys. In cases where only one of those amino acids is used, e.g. only Lys, peptides cleaved 
after Arg are not used in quantitation but are still used for protein identification. 
Alternatively, other protease may be used (e.g. LysC cleaves only after Lys) or other heavy 
amino acids may be added. Amino acid labelling is achieved with the use of the heavy 
isotopes 13C and 15N, while naturally occurring forms contain 12C and 14N. Deuterium (2H) is 
rarely used because it may affect the retention time of the peptides in the chromatography 
phase (Zhang and Regnier, 2001).  
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 Many organisms have metabolic pathways for conversion of Arg into other amino 
acids, most notably proline (Pro). This includes some yeast species, such as S. cerevisiae and 
S. pombe (Gruhler et al., 2005; Bicho et al., 2010). Arginine is utilised as a nitrogen source, 
when other sources are not available. The arginine degradation pathway has not been 
studied in C. albicans, but orthologues of all S. cerevisiae genes involved in it have been 
found (fig. 5.1). In experiments using heavy Arg, conversion to Pro creates additional 
satellite peaks in the mass spectrum that reduce the intensity of heavy ions and change the 
ratio of SILAC pairs. Therefore, the presence of heavy Pro must be carefully examined in all 
experiments, because it can significantly compromise the quality of the data. 
 SILAC experiments are inherently reliant on full incorporation of the heavy amino 
acids into the proteome, so it is important to allow the cells sufficient time to grow in heavy 
medium. Most cultures require at least five doublings for that, but the exact number may 
vary between species. Labelling efficiency must be determined by MS analysis of cell 
extracts derived solely from a heavy-labelled population before proceeding further with 
experiments. Incorporation efficiency of >95% is considered good, because anything less 
than that will decrease the maximum observable ratio of the SILAC pairs. For example, at 
95% incorporation the ratio of heavy to light peptides will be 1:20, whereas at 90% it can 
only go up to 1:10. 
 SILAC typically involves using essential amino acids for proteomic labelling, which 
cells cannot synthesise on their own. The use of prototrophic organisms has only recently 
been investigated, but seems to be a valid approach in some yeast and bacteria (Frohlich et 
al., 2013). In the presence of readily available Lys sources, growing cells downregulate 
endogenous Lys production and achieve full incorporation of the heavy variants. This 
method, termed native SILAC (nSILAC), conveniently bypasses the requirement of 
generating auxotrophic strains. However, it is important to note that cells can switch back to 
producing Lys if they sense the need to do so, for example if they reach a stationary phase 
of growth (Martin-Perez and Villeń, 2015). 
 This chapter explores the opportunity of using the SILAC method in C. albicans by 
carefully examining labelling strategies and cell behaviour. The use of this fungus for nSILAC 
is also discussed.  
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5.2. Media formulation and growth conditions used in SILAC 
 
5.2.1. Lysine 
All SILAC experiments were done using cells expressing Cdc14PD under the MET3 promoter 
in MDL04 background strain. Cdc14PD was used as bait and untagged MDL04 cells as control. 
Both strains were grown in MET3 inducing media. MET3-Cdc14PD cells were always grown in 
“heavy” medium, while wild type cells were grown in “light” medium. Both strains are lysine 
auxotrophs, so they were supplemented with either 100 mg/L unlabelled Lys or 80 mg/L 
Lys8 (13C6, 15N2). The molar concentration of lysine in both media is the same because Lys8 
has higher molecular weight (MW) than Lys (227.05 g/mol and 182.6 g/mol respectively).  
 
5.2.2. Arginine 
The MET3-Cdc14PD strain does not require supplementation with any amino acids other 
than Lys. However, in order to label Arg-containing tryptic peptides, MET3-Cdc14PD was 
grown in the presence of 80 mg/L Arg10 (13C6, 15N4). MDL04 requires supplementation with 
arginine, so 100 mg/L of unlabelled Arg was added to the media of wild type cells. Again, 
both media were formulated with equal molar concentration of arginine, which explains the 
difference in mass concentration (Arg MW=174.2 g/mol; Arg10 MW=220.59 g/mol). When 
cells were cultured in media with equal mass concentration, they grew at different rate 
(data not shown). 
 
5.2.3. Other constituents of the media 
Both heavy and light MET3-inducing media contained glucose, yeast nitrogen base, 
complete supplement media lacking methionine, lysine and arginine, and 100 mg/L uridine. 
Although MET3-Cdc14PD cells did not require uridine, it was added to both media to keep 
the conditions as equal as possible. When hyphae were induced, both media were mixed 
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with 10% v/v serum. MET3-repressing media contained methionine and cysteine in addition 
to all ingredients of MET3-inducing media. 
 
5.2.4. Growth conditions in SILAC media 
To prepare a yeast culture, MET3-Cdc14PD cells were allowed to grow in heavy MET3-
repressing medium overnight and were then subcultured into fresh heavy MET3-inducing 
medium at OD595 0.25 for 4 hrs. The control culture was grown in the same conditions but in 
“light” medium. Both strains grew at the same rate. After four hours the light and heavy 
cultures reached and OD595 0.70 and 0.69 respectively. Cell morphology was inspected by 
bright field microscopy and the heavy isotopes did not cause any visible phenotype (data 
not shown). The conclusion is that the presence of heavy isotopes in the growth medium of 
C. albicans does not affect cell development. 
 When hyphae were induced, an overnight yeast culture of both strains was prepared 
as described above. Each strain was then inoculated into six flasks containing SILAC media 
plus serum at OD595 0.4.  Cells were allowed to grow at 37 °C for 60, 75, 90, 105, 120 and 
135 min. All cell pellets were mixed together and processed further as one sample. This 
means that all hyphal experiments examine the interactions of Cdc14PD that occur in hyphae 
between 60-135 min after induction. This is the time when the phosphatase is most 
abundant, so it is likely to be most active as well (Clemente-Blanco et al., 2006).  
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5.3. Labelling efficiency in yeast 
The incorporation efficiency of Lys8 and Arg10 into the proteome of MET3-Cdc14PD was 
measured by MS. Heavy-labelled cell extract were prepared as described in chapter 3 and 
proteins were separated by SDS-PAGE. The gel was stained with Coomassie to make protein 
bands visible and a small piece of the gel was excised. Proteins contained within this piece 
were digested with trypsin and the resulting peptides were extracted from the gel and 
analysed by MS.  
 The data analysis yielded in total 1777 peptides (after filtering out contaminants) 
assigned to 184 proteins. In a SILAC data each peptide is represented by a heavy and a light 
form and a software program measures the intensity of each form. This is used to calculate 
the heavy to light ratio (H/L). Incorporation of the heavy amino acids in each peptide was 
calculated by the following equation: 
 
Incorporation =
H/L
H/L + 1
× 100 
 
Peptides that are found only in the heavy form are fully labelled, so the 
incorporation is 100%. Peptides that are only light have incorporation of 0%. An example of 
selected peptides is given in table 5.1. The labelling efficiency in the whole sample was 
calculated by taking the average incorporation of all 1776 peptides, which is 93.87%.  
The incorporation of Lys8 and Arg10 was also calculated separately by averaging 
peptides containing only one of these amino acids. Altogether 1129 peptides contained only 
Lys8 with incorporation of 95.43%, while 499 Arg10 peptides had 89.54% incorporation. The 
incorporation of both amino acids is good enough to proceed with SILAC experiments.  
Large scale analysis was performed by quadrupole orbitrap and data was processed 
by MaxQuant. However, this procedure was repeated routinely on a smaller scale before 
each SILAC experiment as a quality control. Representative mass spectra from QTOF-MS are 
shown in figure 5.2.  
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Peptide 
sequence 
Lys8 Arg10 Missed 
cleavages 
Ratio 
H/L 
Intensity Intensity L Intensity H Incorpo
ration % 
SINPNYTPVPVP
ETK 
1 0 0 NaN 2.08E+08 0 207870000 100 
PTIPVDKEDLFK 2 0 1 NaN 6368400 0 6368400 100 
DAYVYQRPVYIG
LPSNLVDMK 
1 1 0 NaN 6928900 0 6928900 100 
ALKEDDDFKSNL
NDPVYTLGK 
3 0 2 NaN 8113800 0 8113800 100 
RYEDPEVQR 0 2 1 NaN 8820500 0 8820500 100 
NPENTIVNFR 0 1 0 9.2414 6747600 1177400 5570200 90 
VTPSFVAFTSEE
R 
0 1 0 7.4277 80531000 9744800 70787000 88 
AFNMFILDPIFR 0 1 0 NaN 1982800 0 1982800 100 
KIDLSLHPNDPE
SQTEVIETVEK 
2 0 1 NaN 17580000 17580000 0 0 
RLETINEEDLQK 1 1 1 NaN 73065000 73065000 0 0 
VVAIVESTSGDK
VPPNTPSDEQSR 
1 1 1 NaN 5949800 5949800 0 0 
EVVFGMSK 1 0 0 52.238 15727000 309240 15417000 98 
SLDSIMAVGEK 1 0 0 47.863 53559000 1117400 52442000 98 
YVEDVLK 1 0 0 35.625 21063000 552740 20510000 97 
 
Table 5.1: Incorporation efficiency of Arg10 and Lys8. The MaxQuant software reports the intensity 
of light and heavy version of each peptide. The sum of both is the total peptide intensity (column 6). 
The H/L ratio in column 5 was used to calculate the incorporation efficiency of the heavy amino acids 
(last column). Heavy amino acids are underlined. NaN – not a number 
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Fig. 5.2: Determining labelling efficiency using an ion chromatogram. An ion chromatogram 
displays the m/z of identified ions (x axis) plotted against their intensity (y axis). Part A shows a SILAC 
pair of the peptide YVEFNLVLDR which is equally enriched in light (blue) and heavy (red) isotopes, 
because both ions have the same intensity. Parts B and E show example of ions that are 
predominantly labelled, but have a small amount of unlabelled species. Parts C and D show ions that 
are fully labelled (the blue squares indicate the area where the light ions would be seen if they were 
present). Part A comes from a mixed sample (i.e. heavy and light culture in 1:1 ratio) and parts B-E 
come from a heavy-labelled sample. In this case the sample would be considered successfully 
labelled. All samples were analysed by QTOF-MS.   
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5.4. Labelling efficiency in hyphae 
 
Hyphal formation is commonly induced by addition of serum to the growth medium. The 
amino acid composition of the serum is not known. If the serum contains light Lys and Arg, it 
could potentially reduce the labelling efficiency of cells. In order to test if this is the case, 
labelled cell extracts from hyphae were prepared as described in section 5.3 and analysed 
by QTOF-MS. The QTOF data is processed using Mascot Distiller, which does not produce a 
comprehensive table of peptide intensities like MaxQuant does. Therefore incorporation 
cannot be calculated on a large scale. Instead, isotope incorporation was visually assessed 
using the ion chromatogram.  
As shown in figure 5.3 Lys8 achieved high percent of incorporation (>98%). The vast 
majority of peptides examined contained no light peaks at all. However, the percent of 
Arg10 incorporation was lower (fig. 5.4). Residual unlabelled peptides were a common 
place, but their intensity was typically below 5% (100% is the intensity of the most abundant 
ion hitting the detector in a given time point). In contrast, heavy ions produced significantly 
greater intensities. Thus, it is clear that Arg10 incorporation was very high, but not as high 
as Lys8 incorporation. 
 The data presented here show that C. albicans can successfully incorporate the 
heavy amino acids Arg10 and Lys8 when cells are grown as either yeast or hyphae. 
Therefore, SILAC-MS is a viable method for investigating protein interactions in this 
organism. 
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Fig. 5.3: Incorporation of Lys8 in hyphae. All three peptides here show full incorporation of heavy 
amino acids as no light analogues are present in the blue squares. Figure annotation is the same as 
fig 5.2.  
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Fig 5.4: Incorporation of Arg10 in hyphae. Labelling with Arg10 was less efficient than that with 
Lys8. Nevertheless, labelled peptides showed significantly higher intensity than the light ones. Here 
the intensities of the light peaks are 2.89% (A), 4.80% (B) and 5.18% (C), while the intensities of the 
heavy peaks are 61.79 (A), 100% (B) and 82.49% (C) respectively. Peptides incorporation rates are 
95.5% (A), 95.4% (B) and 94.1% (C), which is 95% on average. Figure annotation is the same as fig. 
5.2.  
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5.5. Examination of Arg10 to Pro6 conversion 
Cellular metabolism of the labelled amino acid Arg10 may lead to production of labelled 
proline, i.e. Pro6 (13C5, 12N). To test if this is the case, the heavy-labelled protein sample 
described in section 5.3 was processed in MaxQuant with Pro6 as a variable modification. 
The results were as follows: 
 Proline:  
Total number   1147 
Light Pro   930 (81.1%) 
Heavy Pro6   217 (18.9%) 
 
 Peptides: 
Total number    1777 
With Pro and/or Pro6  819 (46.1%) 
With Pro6 only  186 (10.5%) 
Without Pro6   1591 (89.5%) 
 
 Proteins: 
Total number   184 
With Pro6   62 (33.7%) 
 The data shows that Arg10->Pro6 conversion has indeed occurred, which has caused 
almost a fifth of all proline residues to be labelled with heavy isotopes. Almost half of all 
tryptic peptides in the sample contained a proline amino acid with 10.5% containing Pro6. 
At the protein level, a third of all identified proteins have a Pro6-containing peptide. 
 So why does all of this matter? When using a heavy form of arginine, heavy isotope 
labels can be inserted into proline through arginine catabolism. If the stable isotope 
incorporated into proline is not considered, ratios of proline-containing light and heavy 
peptides can be incorrectly calculated, leading to a reduction in intensity of the isotopic 
labeled heavy peptide. As explained in figure 5.5, the intensity of heavy peptides is divided 
between several peak clusters, but the software is programmed to match one light ion to   
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Fig. 5.5: Effect of Pro6 on H/L ratio. Pro6-containing peptides have additional satelite peaks on the 
mass spectrum. Each Pro6 residue in a peptide creates one additional cluster of peaks. However, 
when SILAC pairs are quantified, only the first cluster of heavy peaks is accounted for. In the 
examples shown here, the software will report that the light analogue is more abundant than the 
heavy one. However, the intensity of the heavy peptides is actually the sum of the intensities of all 
heavy isoforms, i.e. all red squares together. In that case, it is easy to see that the heavy and light 
forms have much similar intensities than what is originally presented. Figure annotation is the same 
as fig 5.2 
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one heavy ion, so it takes only the first cluster into account. This skews the H/L ratio of 
peptides in favour of the light ones. In this study proteins of interest are enriched in heavy 
peptides, so the additional Pro6 may create some false negatives, but not false positives.   
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5.6. Discussion 
SILAC labelling is a powerful and accurate method to distinguishing between bait-interacting 
proteins and contaminants in a complex mixture in conjunction with quantitative MS 
analysis. In order to use SILAC for identifying Cdc14 interactors, a protocol for labelling of 
the C. albicans proteome was developed.  
 In the present study all MS samples were prepared by trypsin digestion and tryptic 
peptides universally contain an arginine or lysine residue at the carboxyl terminus (except 
the C terminal peptide of every protein). This project used the C. albicans strain MDL04, 
which requires supplementation with arginine, lysine and uridine. However, two of the 
selectable markers, arginine and uridine, were used to generate the mutant strain MET3-
Cdc14PD. This leaves only lysine as an essential amino acid. In order to label every peptide, 
cells have to grow in the presence of both heavy arginine and heavy lysine. Therefore, we 
tested the ability of C. albicans to incorporate both amino acids in a strain that can 
synthesise arginine. MET3-Cdc14PD cells were grown in “heavy” medium overnight and re-
inoculated into fresh “heavy” medium for either 4hrs (yeast) or 60-135 min (hyphae). This 
time should be sufficient, because most organisms require about 5-10 cell divisions to fully 
incorporate labelled amino acids. As expected, MS analysis showed that Lys8 incorporation 
was very high (>95% in yeast) and it can be used in further SILAC experiments.  
Arg10 incorporation was also high (almost 90% in yeast), which shows that cells use 
amino acids that are readily available to them even if they can make them endogenously. 
However, about 10% of all arginine was light. There are three possible reasons, why arginine 
peptides were not fully labelled. In the first scenario, cells had used up all of the Arg10 in 
the medium (possibly overnight) and had to switch back to endogenous production to meet 
their needs. A second possibility is that cells never fully turned off arginine biosynthesis, and 
so they used 90% from the medium and made 10% internally throughout the course of the 
experiment. However, the most likely explanation is that cells had enough arginine in the 
medium overnight and they achieved full incorporation, but when they reached stationary 
phase they restarted synthesis of light arginine. When cells were reinoculated into fresh 
medium, they started using the heavy arginine again, but could not replace all light isotopes 
within the given time. This speculation is based on a study by Martin-Perez and Villeń 
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(2015), who showed that an S. cerevisiae prototroph reach full incorporation of Lys8 after 10 
hrs, but after that, cells restarted endogenous lysine synthesis, regardless of the Lys8 
availability in the medium (fig. 5.6). The authors suggested that nSILAC should be limited to 
exponentially growing cells for that reason. Therefore, to improve Arg10 incorporation it is 
proposed that cells are grown for 10 hours instead of overnight (about 16 hrs) and then 
reinoculated as described above, resulting in potentially higher isotope incorporation. The 
obvious caveat of this approach is that some work will have to be done at very inconvenient 
times during the night. 
 Ninety percent Arg10 incorporation is still satisfactory, so it was concluded that 
SILAC experiments can be performed using both Arg10 and Lys8. The incidence of Lys8 
peptides was much higher than that of Arg10 peptides, so the average rate of isotope 
abundance was 93.87%. Thus the presented protocol here was applied in further SILAC 
experiments with the aim to identify Cdc14PD interactors. 
 This study also examined the amount of arginine to proline conversion in C. albicans, 
which may be a source of error in quantitative SILAC experiments. Indeed, it was found that 
cells metabolised Arg10 to Pro6, so nearly a fifth of all proline in the proteome was labelled. 
There are several ways to prevent Arg10->Pro6 conversion. The easiest one is to add proline 
to the growth media, because as described above, cells tend to use what is available first. 
Alternatively, the amount of Arg10 may be reduced instead, because too much arginine 
stimulates proline production. However, this is not an option here, because low Arg10 
availability may prompt the cells to revert to biosynthesis. Some studies report using strains 
with deleted genes involved in arginine catabolism, while others have taken a bioinformatics 
approach to account for the additional heavy Pro (Borek et al., 2015; Park et al., 2009). In 
summary, Arg10->Pro6 conversion may be prevented prior to MS or corrected after that. In 
this study we have determined the percent of stable isotope incorporated in proline, which 
may be corrected for computationally in downstream quantitative proteomic analysis.  
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Fig. 5.6: Relative Lys8 abundance in S. cerevisiae. An auxotroph (AUX) and a prototroph (PRO) strain 
of S. cerevisiae was grown in the presence of Lys8 and the rate of isotope abundance (RIA) was 
followed for 48 hrs. Both strains achieved full incorporation at the same rate after 10 hrs of growth. 
However, longer incubation time resulted in a decay of RIA, mostly in the prototrophic strain. This 
figure is taken from Martin-Perez and Villeń (2015). 
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Chapter 6 
 
A Screen for Cdc14PD Interacting Partners Using 
Quantitative SILAC-MS 
 
 
 
6.1. Introduction 
Following the extensive optimising and preparatory work done so far, this chapter returns to 
the main objective of this study – identifying protein interactions by MS. After taking on 
board the limitations of the initial preliminary screen described in chapter 3, several 
improvements to the experimental strategy were made. First, the interactions between 
Cdc14 and its substrates were stabilised by engineering the phosphatase-dead mutant 
Cdc14PD. Second, Cdc14PD was overexpressed in order to improve the signal-to-noise ratio in 
MS data. And third, a SILAC protocol in C. albicans was developed with the aim to make a 
better discrimination between interactors and contaminants.  
 Initially SILAC experiments were performed using a QTOF-MS, because it was the 
most sensitive instrument in the facility, where this project was carried out. However, at a 
later stage, an even better quadrupole orbitrap-MS (QO-MS) was purchased, and 
subsequent experiments were done with the new equipment. The data from both 
instruments was analysed using different software, so experimental results cannot be 
combined together. The QO-MS is superior in terms of sensitivity and resolution, so the data 
produced by it if of a higher quality. 
It is important to note that the results presented here are not final. As shown in 
chapter 5, C. albicans has used the labelled arginine to synthesise labelled proline. The data 
shown here has not accounted for the heavy proline. An additional correction to the 
intensity of proline-containing peptides will be applied, but due to time constrains, it was 
not completed prior to submitting this thesis. Nevertheless, it is expected that the final 
results will have only minor differences from the results described in this chapter.  
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6.2. Cdc14PD interactors in yeast 
The general workflow described in this chapter is shown in figure 1.6. Cdc14PD was 
overexpressed with the use of MET3 promoter and purified separately from yeast and from 
hyphae. The growth conditions and SILAC media are described in section 5.3. In all 
experiments, MET3-Cdc14PD was grown in heavy medium, and MDL04 was grown in light 
medium. This means that proteins of interest are enriched in heavy isotopes. Cell pellets 
from both cultures were weighted and mixed in 1/1 ratio prior to IP and MS analysis. 
Therefore non-specific background proteins will be present in approximately a 1:1 ratio. Cell 
extracts and IP of Cdc14PD were prepared as described in chapter 3. MS sample preparation 
is described in section 5.3. 
 
6.2.1. SILAC experiments in yeast using QTOF-MS 
Cdc14PD was immunoprecipitated from yeast three times and each experiment (termed Y1, 
Y2 and Y3) was run separately on QTOF-MS. The data from each run was analysed 
individually and then data from all three experiments was combined and analysed together 
using Mascot Distiller. This software performs peptide identification and quantitation, and 
then matches the identified peptides to a database of theoretical peptides in order to assign 
them to proteins. The false discovery rate (FDR) in all experiments was below 2%. Results 
are summarised in table 6.1 and presented in detail in figure 6.1 and table 6.3. The number 
of identified proteins varied between 448-1101. Over 70% of proteins were quantified and 
all data sets. Protein quantitation is reported as the L/H ratio. The L/H ratio of a protein is 
derived from the L/H ratios of all peptides assigned to it. If equal amounts of cells were 
mixed at the start of the experiment, contaminating proteins should have an L/H ratio close 
to 1. Cdc14PD-bound proteins should be enriched in heavy peptides, so their L/H ratio should 
be <1. How much less than one is difficult to determine in empirical manner, so a cut off 
value of over two times enrichment in heavy peptides was taken as an arbitrary criterion. In 
other words, proteins that have two times more heavy peptides than light peptides are 
considered likely Cdc14PD interactors, i.e. hits. Due to handling errors, cells could never be 
mixed in exactly 1/1 ratio, but a ratio between 0.5-2 was considered acceptable. In order to   
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Y1 
 
Y2 
 
Y3 
 
Y1+Y2+Y3 
 
H1 
 
H2 
 
H1+H2 
 
Identified proteins 717 448 804 1101 515 568 616 
Quantified proteins 513 370 641 856 409 428 407 
Median L/H ratio 1.22 1.1 1.15 1.19 0.64 0.77 0.69 
L/H ratio of hits <0.61 <0.55 <0.58 <0.59 <0.32 <0.39 <0.35 
Hits 26 17 21 39 19 17 21 
 
Table 6.1: Summary of SILAC data from all experiments performed by QTOF-MS. 
 
 
 
 
 
 
 
Y1 
 
Y3 
 
Y1+Y3 
 
H2 
 
H3 
 
H2+H3 
 
Identified proteins 2541 2228 2947 1831 1543 2085 
Quantified proteins 2275 1844 2539 1512 1195 1795 
Hits 77 44 82 51 47 55 
Very low confidence hits 31 27 28 63 8 59 
 
Table 6.2: Summary of SILAC data from all experiments performed by QO-MS. 
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SILAC Y1 QTOF-MS 
SILAC Y2 QTOF-MS 
 
B 
 
A 
 139 
 
 
 
 
Fig. 6.1: SILAC results from QTOF-MS experiments in yeast. Each dot represents a protein identified 
by MS. The L/H ratio of proteins is plotted against their score. Proteins with over two times 
enrichment in heavy peptides are shown in red. Proteins that are considered to be contaminants are 
marked in blue. Note that only some of the red dots are labelled due to insufficient space on the 
graph. The full list of enriched proteins is shown in table 6.2.  
SILAC Y3 QTOF-MS 
SILAC Y1+Y2+Y3 QTOF-MS 
 
C 
 
D 
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L/H ratio 
 
 
Protein IDs 
 
Gene 
 
Y1 (<0.61) 
 
Y2 (<0.55) 
 
Y3 (0.58) 
 
Y1+Y2+Y3 (<0.59) 
 
orf19.1340  
 
0.19 
  orf19.1494 RAD23 
   
0.38 
orf19.1515 CHT4 0.51 
   orf19.2002  0.58 
  
0.58 
orf19.2263  
 
0.10 
  orf19.2322.3  0.28 
   orf19.2422 ARC1 
 
0.10 
  orf19.2650.1  
  
0.54 
 orf19.267 NET1 0.43 
  
0.43 
orf19.2684  0.16 0.27 0.20 0.18 
orf19.2949  
  
0.00 0.00 
orf19.3000 ORC1 0.35 
  
0.35 
orf19.3041  
   
0.15 
orf19.316 SEC13 
  
0.22 0.22 
orf19.3290  0.00 0.00 0.00 0.00 
orf19.3357  
  
0.36 
 orf19.3551 DAD2 0.16 
  
0.14 
orf19.3873 ARC40 
 
0.17 
 
0.17 
orf19.3942.1 RPL43A 0.09 
   orf19.3962 HAS1 
 
0.23 
  orf19.4122  
 
0.52 
 
0.52 
orf19.4192 CDC14 0.06 0.03 0.03 0.04 
orf19.4208 RAD52 0.32 
 
0.06 0.08 
orf19.4221 ORC4 0.49 
  
0.48 
orf19.4473 SPC19 0.19 
 
0.23 0.21 
orf19.4495 NDH51 0.41 
  
0.49 
orf19.4560 BFR1 
 
0.38 
  orf19.4675 ASK1 0.13 0.20 0.16 0.15 
orf19.4836 URA1 0.14 
  
0.55 
orf19.4837 DAM1 
 
0.25 0.23 0.25 
orf19.4882  
  
0.24 0.24 
orf19.4988  0.09 
  
0.22 
orf19.5008.1 DAD1 0.19 
  
0.19 
orf19.5103  
 
0.02 
 
0.02 
orf19.5235  0.12 
  
0.17 
orf19.5358  0.28 
   orf19.5395  0.02 
  
0.02 
orf19.5806 ALD5 0.43 
   orf19.5958 CDR2 
   
0.46 
orf19.6000  
  
0.47 
 orf19.6234  0.08 
  
0.35 
orf19.6417 TSR1 
   
0.40 
orf19.652  0.10 0.04 0.05 0.07 
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L/H ratio 
 
 
Protein IDs 
 
Gene 
 
Y1 (<0.61) 
 
Y2 (<0.55) 
 
Y3 (0.58) 
 
Y1+Y2+Y3 (<0.59) 
 
orf19.6601.1 YKE2 
   
0.01 
orf19.691 GPD2 
 
0.54 
  orf19.6942 ORC3 0.54 
  
0.17 
orf19.7021 GPH1 
 
0.47 
  orf19.709 PUP2 
  
0.27 0.46 
orf19.7136 SPT6 
  
0.07 0.26 
orf19.7152  
  
0.50 0.50 
orf19.7215.3  
  
0.15 0.15 
orf19.7477 YRB1 
  
0.53 0.53 
orf19.7652 CKA1 
  
0.46 
 orf19.7664  
 
0.39 
  orf19.7672  
   
0.23 
orf19.768 SYG1 
  
0.00 0.00 
orf19.88 ILV5 0.08 
    
Table 6.3: Proteins identified as hits in each data set (yeast QTOF-MS). Values show the L/H ratio 
of each protein. Empty cells indicate that the protein either did not reach the minimum 
threshold (shown in brackets) or it was not identified in that experiment. Empty spaces in 
the Gene column mean that the gene has not been named in the Candida Genome 
Database.  
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account for errors in mixing, the median L/H ratio of all proteins was calculated (table 6.1). 
The cut off value for hits is the median L/H ratio divided by 2. Table 6.3 shows all protein 
hits and their respective L/H ratio. Proteins are shown with their ORF number instead of 
their names, because such is the format of the output files. The scatter plots in figure 6.1 
show the L/H of all quantified proteins plotted against protein score.  
In total, 56 proteins were identified as potential hits (excluding the bait). Cdc14 was 
recovered with high score and low L/H ratio, which is a positive sign that the experiment is 
working. However, apart from the L/H ratio of these proteins, other criteria can also be used 
to indicate the likelihood of proteins being true hits. It is evident from looking at the graphs, 
that low-scoring proteins have higher variation in their L/H ratio than high-scoring proteins. 
Thus, the former are less likely to be true hits than the latter, even though they are all 
enriched in heavy isotopes. Low-scoring proteins are generally represented by very few 
peptides, so they are more likely to have deviations in the L/H ratio just by chance. 
 Further indication of a protein being a true hit comes from comparing the results in 
table 6.3. Proteins that were repeatedly identified as hits in more than one experiment have 
the highest probability of being such (e.g. orf19.2684, orf19.652, Rad52, etc.). However, this 
does not mean that proteins identified only once are not true hits (e.g. Orc4, Pup2, Spt6, 
etc.). There are many reasons why a protein would not be identified by MS: it can be lost at 
any stage during the purification process, the sample preparation or during the data-
dependent MS analysis. While reproducibility is certainly a good confirmation of results, the 
lack of it should not be regarded as a reason to discard hits. High reproducibility was not 
expected in only three experiments. 
 The information contained in the last column of table 6.3 can be used as a criterion 
for assigning a confidence tag to non-reproducible hits. Combining the data from all three 
experiments together allows the processing software to make more accurate calculations. 
For example, Cht4 was a hit in Y1, but not in any of the other experiments. When the data 
was combined, this protein no longer appeared as a hit, because the overall L/H ratio is 
higher than the threshold. Hence, this protein was most likely a false positive in Y1. On the 
other hand hits like Dad2, which is also only a hit in Y1, remain with low L/H ratio even after 
the combined analysis. Such proteins are high confidence hits. 
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In each experiment, over 95% of identified proteins could be clearly distinguished as 
contaminants based on their quantitative ratios. Moreover, the quantitative SILAC analysis 
enabled the identification of some strongly enriched proteins in the Cdc14PD based on their 
H/L ratios. Between these two extremes, proteins have a narrow difference in their isotope 
contents and a clear line separating hits and contaminants does not exist. In QTOF-MS 
experiments, proteins with two times higher abundance of heavy versus light peptides were 
selected as hits. However, this is not to say that every one of those hits was bound to 
Cdc14PD during the pull down procedure. The list of hits is highly enriched in Cdc14PD 
interactors, but it will inevitably contain some non-specific proteins. The latter are false 
positives that may be enriched in heavy peptides for two reasons. First, their abundance 
may have been higher in the labelled strain either by chance, or as a consequence of genetic 
differences between both strains. Second, even if a protein is present at equal amounts in 
both strains, unequal peptide intensity may be detected by chance. This is more likely to 
happen if a protein has low peptide intensity. Peptide quantitation is less accurate when the 
signal of the peptide is low. This means that proteins with low intensity would be less 
confident hits than proteins with high intensity. Unfortunately, Mascot Distiller (software 
processing QTOF data) does not report protein intensities, so protein score would be the 
next best parameter to look at. The protein score is based on the probability of a random 
match between the theoretical and experimental data bases. While score and intensity are 
correlated, they are not directly proportional to one another. In this regard, low scoring 
proteins have lower probability of being true hits. 
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6.2.2. SILAC experiments in yeast using QO-MS 
Tryptic peptides from Y1 and Y3 were also analysed by a QO-MS instrument. Again, data 
from each experiment was processed separately, as well as in combination together, this 
time using the software MaxQuant. This software reports the H/L ratio of proteins (not the 
L/H ratio like seen above), so now hits have values >1. MaxQuant also have inbuilt 
algorithms for normalising the H/L ratio, so median value was not calculated here. The 
software also reports protein intensity, which was used to calculate the probability of 
proteins being hits. This was done in Perseus, a software that is designed to perform 
bioinformatic analysis of output from MaxQuant. In Perseus, hits were selected based on 
the H/L ratio relative to intensity using the Benjamini-Hochberg procedure with false 
discovery rate (FDR) below 5% and below 1% (as described by Cox and Mann, 2008).  
 The QO instrument used in this study is one of the latest and most advanced mass 
spectrometers produced in recent times and it is also coupled to improved data analysis 
software, namely MaxQuant. Data derived by QO-MS is therefore higher quality than QTOF 
data. Results from QO-MS are summarised in table 6.2. QO-MS experiments in yeast 
resulted in the identification of over 2000 proteins. In comparison, QTOF data contained 
significantly less proteins per experiment (see table 6.1) than QO data. These numbers 
illustrate the huge difference in performance between the QTOF and QO instruments. Hits 
from the QO instrument are shown in figure 6.2 and table 6.4. 
 As expected, bait recovery was good and most proteins have H/L ratio close to 1. The 
QO data yielded two times more hits than the QTOF data, 115 in total (table 6.4). As 
discussed above, proteins found in all columns of table 6.4 have the highest probability of 
being true hits, while non-reproducible hits are questionable.  
 There is certainly a significant overlap between QTOF and QO data, but in the case of 
discrepancies, the QO data is regarded valid. For example, if a protein was identified as a hit 
by QTOF but not by QO in the same experiment, it is not a hit. Hits identified by both 
instruments have the highest probability of being true. 
The selection of hits here was based on protein isotopes ratio as well as protein 
intensity. As shown in tables 6.4 and 6.7, the H/L ratio of some hits was as low as 1.2 (after   
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SILAC Y1 QO-MS 
SILAC Y3 QO-MS 
 
A 
 
B 
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Fig. 6.2: SILAC results from QO-MS experiments in yeast. Blue proteins are contaminants. Red 
proteins are hits with FDR<1%. Black proteins are hits with FDR<5%. Parts A and B show data from 
two single experiments, while part C show the combined data from A and B analysed together. 
  
SILAC Y1+Y3 QO-MS  
C 
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Y1 
 
 
Y3 
 
 
Y1+Y3 
 
 
Protein IDs 
 
Gene 
 
Ratio H/L 
(normalized) 
 
FDR 
 
Ratio H/L 
(normalized) 
 
FDR 
 
Ratio H/L 
(normalized) 
 
FDR 
 
orf19.1091 
     
1.6254 <5% 
orf19.113 CIP1 
  
1.4971 <1% 
  orf19.1153 GAD1 
  
1.4303 <5% 
  orf19.1223 DBF2 1.5703 <5% 
  
1.5703 <1% 
orf19.1267 
 
1.5345 <5% 
    orf19.1288 FOX2 1.6928 <1% 
    orf19.1428 DUO1 5.8654 <1% 
  
5.7418 <1% 
orf19.1442 PLB4 2.0096 <1% 
  
1.8839 <1% 
orf19.1446 CLB2 
  
4.197 <1% 4.8501 <1% 
orf19.147 YAK1 1.734 <1% 
  
1.734 <1% 
orf19.1515 CHT4 1.5648 <1% 
  
1.4188 <1% 
orf19.1591 ERG10 1.6956 <1% 
    orf19.1598 ERG24 1.5823 <5% 
    orf19.1608 
   
1.4301 <5% 1.3586 <1% 
orf19.1631 ERG6 1.7492 <1% 
  
1.4508 <1% 
orf19.164 
   
8.5791 <1% 2.2292 <1% 
orf19.1652 POX1-3 1.5327 <1% 
    orf19.1996 CHA1 3.5988 <1% 
  
3.5988 <1% 
orf19.2084 CDH1 16.977 <1% 
  
16.977 <1% 
orf19.2125 
   
1.6317 <1% 1.6317 <1% 
orf19.2369 
 
11.63 <1% 9.1691 <1% 10.521 <1% 
orf19.2381 
 
4.0396 <1% 2.0437 <1% 3.8213 <1% 
orf19.2389 
 
1.6238 <5% 
    orf19.2397 
 
1.8769 <1% 
  
1.8769 <1% 
orf19.2400 
   
1.7204 <5% 
  orf19.2416.1 MLC1 1.9855 <1% 
    orf19.2488 FAL1 
  
1.6188 <5% 
  orf19.2644 QCR2 
  
1.43 <5% 
  orf19.267 NET1 3.1376 <1% 2.1859 <1% 2.9978 <1% 
orf19.2672 NCP1 1.5197 <1% 
  
1.4135 <1% 
orf19.2684 
 
7.0405 <1% 5.7543 <1% 6.1973 <1% 
orf19.2826 
 
3.3565 <1% 
  
3.3565 <1% 
orf19.2827 
 
2.4765 <1% 
  
2.4765 <1% 
orf19.3000 ORC1 10.971 <1% 3.7814 <1% 10.667 <1% 
orf19.3014 BMH1 1.3864 <5% 
    orf19.3139 
 
1.6234 <5% 
    orf19.3231 CDC27 1.8517 <1% 
  
1.8517 <1% 
orf19.3240 ERG27 1.6935 <1% 
  
1.6645 <1% 
orf19.3289 
     
12.987 <1% 
orf19.3311 IFD3 
  
1.5724 <1% 
  orf19.3356 ESP1 2.014 <1% 
  
2.1129 <1% 
orf19.3477 
 
2.1341 <1% 
    orf19.355 
   
4.8789 <1% 3.3597 <1% 
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Y1 
 
 
Y3 
 
 
Y1+Y3 
 
 
Protein IDs 
 
Gene 
 
Ratio H/L 
(normalized) 
 
FDR 
 
Ratio H/L 
(normalized) 
 
FDR 
 
Ratio H/L 
(normalized) 
 
FDR 
 
orf19.3551 DAD2 10.087 <1% 4.1752 <1% 7.043 <1% 
orf19.3561 CDC7 4.0357 <1% 5.3986 <1% 5.2344 <1% 
orf19.3684 
 
1.6343 <1% 
    orf19.3689 
     
1.9167 <1% 
orf19.3707 YHB1 
  
2.1273 <1% 1.8295 <1% 
orf19.3733 IDP2 
  
1.5442 <1% 1.5049 <1% 
orf19.3737 
 
1.7414 <5% 
    orf19.3788 SPC34 5.1598 <1% 4.4694 <1% 4.7585 <1% 
orf19.384 
 
2.3802 <1% 
  
2.3802 <1% 
orf19.4013 
 
1.7812 <1% 
  
1.7812 <1% 
orf19.4025 PRE1 
  
1.4293 <5% 1.4822 <5% 
orf19.4157 SPS20 1.3707 <5% 
    orf19.4192 CDC14 39.523 <1% 49.501 <1% 43.7 <1% 
orf19.4208 RAD52 21.25 <1% 39.354 <1% 35.248 <1% 
orf19.4221 ORC4 7.0215 <1% 6.7989 <1% 6.817 <1% 
orf19.427 
 
28.157 <1% 
  
28.157 <1% 
orf19.4295 
 
1.7727 <5% 2.5392 <1% 2.3258 <1% 
orf19.4341 
 
1.7645 <5% 
  
1.7645 <1% 
orf19.4371 TAL1 1.3622 <5% 
    orf19.4435 
 
1.7689 <1% 
  
1.7689 <1% 
orf19.4473 SPC19 4.2083 <1% 3.6084 <1% 4.0749 <1% 
orf19.4476 
 
2.2008 <1% 7.3655 <1% 
  orf19.4675 ASK1 7.1272 <1% 
  
7.1891 <1% 
orf19.4716 GDH3 
  
1.5981 <1% 1.2539 <5% 
orf19.4837 DAM1 3.9217 <1% 3.1348 <1% 3.1348 <1% 
orf19.4960 
     
1.6432 <5% 
orf19.4988 
 
10.134 <1% 9.5358 <1% 10.325 <1% 
orf19.5005 OSM2 1.7133 <1% 
    orf19.5166 DBF4 
    
2.7929 <1% 
orf19.5181 NIK1 2.0339 <1% 
    orf19.520 
 
2.5985 <1% 
  
2.5985 <1% 
orf19.5246 
 
1.7909 <1% 
  
1.7468 <1% 
orf19.5276 
 
1.8916 <1% 
  
1.8916 <1% 
orf19.5293 
 
1.5601 <5% 
    orf19.5358 
 
7.0547 <1% 1.7848 <1% 6.9636 <1% 
orf19.5389 FKH2 2.0378 <1% 
  
2.0378 <1% 
orf19.539 LAP3 
  
1.5264 <1% 1.4166 <5% 
orf19.5437 RHR2 
  
1.4625 <5% 
  orf19.5491 
 
24.362 <1% 
  
23.466 <1% 
orf19.5518 
 
8.3083 <1% 5.1215 <1% 6.7519 <1% 
orf19.557 
 
4.5763 <1% 
  
4.5763 <1% 
orf19.5727 
 
1.9117 <1% 
  
1.9117 <1% 
orf19.5797 PLC2 2.0764 <1% 
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Y1 
 
 
Y3 
 
 
Y1+Y3 
 
 
Protein IDs 
 
Gene 
 
Ratio H/L 
(normalized) 
 
FDR 
 
Ratio H/L 
(normalized) 
 
FDR 
 
Ratio H/L 
(normalized) 
 
FDR 
 
orf19.5806 ALD5 1.5208 <1% 
    orf19.5825 NCB2 1.9226 <1% 
    orf19.5959 NOP14 
  
1.7357 <5% 
  orf19.6021 IHD2 
    
1.6664 <5% 
orf19.6155 
     
1.7412 <1% 
orf19.6254 ANT1 2.035 <1% 
  
2.035 <1% 
orf19.6257 GLT1 
  
1.4094 <5% 
  orf19.6291 
 
3.2507 <1% 
  
3.3709 <1% 
orf19.6294 MYO1 
    
1.2733 <1% 
orf19.6385 ACO1 
    
1.2314 <5% 
orf19.6443 
 
1.7819 <5% 
  
1.7819 <1% 
orf19.652 
 
46.599 <1% 36.301 <1% 42.754 <1% 
orf19.6583 
 
2.0663 <1% 
  
2.0803 <1% 
orf19.6596 
   
1.69 <1% 1.69 <1% 
orf19.6610 
 
1.7923 <1% 
  
1.7923 <1% 
orf19.6758 
   
1.8268 <1% 1.5017 <5% 
orf19.6868 
   
1.849 <1% 1.849 <1% 
orf19.691 GPD2 1.7831 <1% 
    orf19.6942 ORC3 2.2915 <1% 
  
2.2915 <1% 
orf19.7111.1 SOD3 
  
1.8992 <1% 1.8992 <1% 
orf19.7140 
 
2.8008 <1% 
    orf19.7288 
     
1.3306 <1% 
orf19.7297 
     
1.2742 <1% 
orf19.7469 ARG1 
  
2.0986 <1% 2.0986 <1% 
orf19.7520 POT1 2.4198 <1% 
    orf19.7600 FDH3 
  
1.4373 <5% 1.4373 <1% 
orf19.7663 
 
4.3581 <1% 
  
4.3581 <1% 
orf19.771 LPG20 
    
1.2961 <1% 
orf19.827.1 RPL39 
    
1.2363 <5% 
 
Table 6.4: Proteins identified as hits in each dataset from yeast QO-MS. The table show the 
normalised H/L ratio, but note that the protein intensity was also factored in when selecting hits. 
Some proteins have H/L>2, which was the criterion for hits in the QTOF data. The Benjamini-
Hochberg method used in Perseus is a more accurate way of selecting outliers in a dataset. If a 
protein has an H/L ratio that is significantly different from the ratios of other proteins with similar 
intensity, it is picked as a hit. The FDR next to the ratio indicates the chance of a protein being a false 
positive. If a protein was not an outlier or not present in the dataset, the space is left blank. 
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normalisation where 1 is the median intensity of the whole population), which is much 
lower than the ratio required for QTOF hits to be selected. Nevertheless, hits with low H/L 
ratio were found at high intensities, so the probability of this ratio occurring by chance is 
within the set limits (i.e. either 1% or 5%). This data analysis method, although being better, 
is by no means error-free, so as discussed above, hits should be regarded as only potential 
interactors. Hits may be sorted into confidence categories (e.g. low, medium, high) based on 
their probability of being true, when the data analysis is completed. (Readers are reminded 
that data will be subjected to further corrections to account for the Arg10->Pro6 conversion 
discussed in chapter 5.)  
As already mentioned, the majority of proteins (>80%) identified by QO-MS were 
also quantified by MaxQuant using sophisticated algorithms. The remaining <20% were not 
assigned an H/L ratio by MaxQuant, even though they had intensity of light and heavy 
peptides. This is due to the settings of the software (e.g. minimum ratio count is set to 2, so 
proteins with a single ratio count will not be quantified, etc.). One could relax the settings, 
so that all proteins are quantified, but that would compromise the accuracy of quantitation. 
So, non-quantified proteins were further analysed manually and a number of them were 
selected as potential hits (table 6.5). These include proteins that had only heavy peptides 
(i.e. intensity of L=0, intensity of H>0) and proteins with calculated H/L>2. The calculated 
H/L is derived by simply dividing intensity H (the sum of all heavy peptides intensities) by 
intensity of L (the sum of all light peptides intensity). This is different from the H/L ratio 
assigned to proteins by MaxQuant, which is the median intensity of all individual peptide 
ratios. In addition to the calculated H/L values, proteins were selected only if they were 
identified by at least 2 peptides (razor+unique). This selection process is likely to refined 
further by looking at other parameters, before the final list of hits is composed. The most 
interesting entries in this category are proteins with exclusively or predominantly heavy 
peptides. In the final list of hits, these proteins may be presented as very low confidence 
hits (e.g. if they are present in multiple experiments), or they may be completely omitted 
(e.g. if they only appear once). These proteins are shown as very low confidence hits in table 
6.2.   
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H/L calculated (>2) 
 
 
Protein IDs 
 
Gene 
 
Y1 
 
Y3 
 
Y1+Y3 
 
orf19.1219 
  
2.29 
 
orf19.1282 CKS1 
 
2.85 2.85 
orf19.1331 HSM3 
 
2.11 
 
orf19.1357 FCY21 
  
3.07 
orf19.1428 DUO1 
 
12.89 
 
orf19.1441 
  
2.05 
 
orf19.1446 CLB2 2.87 
  
orf19.1704 FOX3 2.11 
  
orf19.1738.1 
  
2.75 2.75 
orf19.1792 
 
4.13 
  
orf19.2084 CDH1 
 
36.32 
 
orf19.2301 
   
2.40 
orf19.2384 
 
3.66 
 
2.35 
orf19.2630 RAD51 
  
H 
orf19.2852 
 
3.16 
  
orf19.3289 
 
15.80 
  
orf19.3296 
 
H 
 
73.66 
orf19.3615 
   
4.62 
orf19.3695 
 
2.24 
 
2.24 
orf19.3809 BAS1 H 
 
H 
orf19.3871 DAD3 H H H 
orf19.3901 
  
8.70 
 
orf19.4101 
 
H 
 
H 
orf19.4109 PMT4 
 
3.67 
 
orf19.4161 
 
H 
  
orf19.4262 
  
2.17 
 
orf19.4275 RAD9 H H H 
orf19.4312 
  
2.92 
 
orf19.4432 KSP1 
 
4.26 
 
orf19.4937 CHS3 
 
2.89 
 
orf19.5008.1 DAD1 
  
6.64 
orf19.5166 DBF4 82.25 
  
orf19.5397 
 
5.31 
 
5.31 
orf19.5730 
  
4.14 4.14 
orf19.5759 SNQ2 
 
6.20 
 
orf19.5773 
 
4.23 
  
orf19.580 
 
12.89 
 
15.77 
orf19.6030 
 
H 
 
H 
orf19.6049 
 
136.68 H 158.86 
orf19.6124 ACE2 3.09 
 
3.09 
orf19.6155 
  
5.15 
 
orf19.6195 
  
8.26 
 
orf19.6346 
 
2.55 
  
orf19.6376 PTC5 
 
5.16 
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H/L calculated (>2) 
 
 
Protein IDs 
 
Gene 
 
Y1 
 
Y3 
 
Y1+Y3 
 
orf19.638 FDH1 
 
H H 
orf19.6536 IQG1 8.10 
 
8.10 
orf19.658 GIN1 H 
 
H 
orf19.6662 
 
H 
 
H 
orf19.6689 ARG4 
 
H 
 
orf19.6734 TCC1 
 
7.32 
 
orf19.6796 
  
H 
 
orf19.6838 
 
5.75 
  
orf19.6869 
 
H 
 
H 
orf19.6880 
   
5.39 
orf19.6884 GWT1 2.60 
 
2.60 
orf19.6941 
  
H 
 
orf19.6990 
 
2.10 
  
orf19.7060 
 
H 
 
H 
orf19.926 EXO1 H 
  
orf19.927 
  
2.68 
 
orf19.986 GLY1 4.51 
  
 
Table 6.5: Non-quantified proteins enriched in heavy peptides (experiments from yeast QO-MS). 
The H/L ratios presented here should not be compared to the H/L ratios in table 6.3, because both 
values were determined in a different manner. Blank spaces indicate that the protein was either 
quantified by MaxQuant or not identified in the dataset at all. Note that some proteins in this table 
are also present in table 6.3, but in different columns. For example, Clb2 was manually selected in Y1 
(here), but it was selected by MaxQuant in Y3 and Y1+Y3 (table 6.3). Dbf4 showed an impressive bias 
towards heavy peptides in Y1 (here), but it was quantified by MaxQuant only in the combined 
dataset (table 6.3). Dad3 and Rad9 were never quantified by the software, but are very likely to be 
hits because they were represented exclusively by heavy peptides (H) in all 3 datasets here.  
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6.3. Cdc14PD interactors in hyphae 
Cdc14PD was immunoprecipitated from hyphae induced for 60-135 min, as described in 
section 5.2. The experiment was repeated three times (H1, H2 and H3). Samples from H1 
and H2 were run through a QTOF-MS, while samples from H2 and H3 were analysed on a 
QO-MS.  
Data from experiments H1 and H2 obtained from the QTOF-MS was processed 
separately and together. Over 500 proteins were identified and over 400 of them were 
quantified in each data set. Results are summarised in table 6.1 and shown in detail in figure 
6.3 and table 6.6. Data was analysed as described in section 6.2.1, i.e. proteins with L/H < 
(median L/H)/2 are regarded as hits.  
As discussed above, the QO-MS is better suited for SILAC analysis than QTOF-MS, so 
the data obtained by it is higher quality. QO-MS identified about three times more proteins 
than QTOF-MS. Results are shown in figure 6.4 and table 6.7. Low confidence hits from non-
quantified proteins are listed in table 6.8. 
Overall, fewer hits were found in hyphae than in yeast (tables 6.1 and 6.2). In hyphae 
QTOF data analysis found 40 hits (table 6.6), and QO data produced 97 hits (table 6.7). 
These include some common as well as some form-specific hits. Since only two experiments 
were done by QO-MS in each form, very few of the hits are reproducible in both 
experiments. However, some of the non-reproducible hyphal hits were found in yeast (and 
vice versa) and this can also be regarded as a reproducibility of results. For example, Cdh1 
was a hit in Y1 an H2, but not in Y3 and H3 (it is actually among the low confidence hits in 
Y3, but these will be ignored in the current discussion). The fact that Cdh1 was selected 
twice as a hit, although in different morphological forms, suggests a high probability if 
interaction with Cdc14PD.  
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SILAC H1 QTOF-MS 
SILAC H2 QTOF-MS 
 
A 
 
B 
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Fig. 6.3: SILAC results from QTOF-MS experiments in hyphae. Red – hits, blue – contaminants.  
SILAC H1+H2 QTOF-MS  
C 
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L/H ratio 
 
 
Protein IDs 
 
Gene 
 
H1 (<0.32) 
 
H2 (<0.39) 
 
H1+H2 (<0.35) 
 
orf19.113 CIP1 0.08 
 
0.08 
orf19.1335 
  
0.02 
 orf19.1402 CCT2 
  
0.01 
orf19.1559 HOM2 
  
0.16 
orf19.1591 ERG10 0.26 
 
0.24 
orf19.1631 ERG6 
  
0.33 
orf19.1783 YOR1 
 
0.09 
 orf19.2016 
   
0.34 
orf19.2084 CDH1 
 
0.13 0.13 
orf19.267 
  
0.24 
 orf19.2684 
 
0.16 0.12 0.17 
orf19.269 SES1 
  
0.34 
orf19.327 HTA3 
  
0.10 
orf19.3290 
 
0.00 0.00 
 orf19.3655 
 
0.07 
  orf19.3788 SPC34 
 
0.04 
 orf19.3942.1 RPL43A 
  
0.19 
orf19.4076 MET10 0.26 
  orf19.4192 CDC14 0.04 0.05 0.04 
orf19.4506 LYS22 
  
0.27 
orf19.4536 CYS4 0.26 
  orf19.4675 ASK1 0.26 0.08 0.09 
orf19.4898 
  
0.39 
 orf19.5008.1 DAD1 
 
0.10 
 orf19.5025 MET3 0.25 0.33 0.32 
orf19.5073 DPM1 
  
0.34 
orf19.5180 PRX1 0.26 
 
0.28 
orf19.5285 PST3 0.31 
  orf19.5619 
 
0.00 
  orf19.5812 
 
0.11 
  orf19.6081 PHR2 0.25 0.32 0.32 
orf19.6234 
  
0.23 
 orf19.6402 CYS3 0.25 
  orf19.652 
 
0.05 0.05 0.05 
orf19.7264 
  
0.13 
 orf19.7364 
 
0.16 
  orf19.744 GDB1 
  
0.09 
orf19.7602 
   
0.35 
orf19.768 SYG1 0.00 
  orf19.88 ILV5 
 
0.10 
  
 
Table 6.6: Proteins identified as hits in each data set (hyphae QTOF-MS). Values show the L/H ratio 
of each protein. Empty cells indicate that the protein either did not reach the minimum threshold 
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(shown in brackets) or it was not identified in that experiment. Empty spaces in the Gene column 
mean that the gene has not been named in the Candida Genome Database.  
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SILAC H2 QO-MS 
SILAC H3 QO-MS 
 
A 
 
B 
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Fig. 6.4: SILAC results from QO-MS experiments in yeast. Red – hits with FDR<1%, black – hits with 
FDR<5%, blue – contaminants.  
SILAC H2+H3 QO-MS  
C 
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HS2 
 
 
HS3 
 
 
HS2+HS3 
 
 
Protein IDs 
 
Gene 
 
Ratio H/L 
normalized 
 
FDR 
 
Ratio H/L 
normalized 
 
FDR 
 
Ratio H/L 
normalized 
 
FDR 
 
CaalfMp01 COX2 
  
1.5579 <5% 
  orf19.1065 SSA2 2.1844 <1% 
  
1.6903 <1% 
orf19.1108 HAM1 
  
4.9168 <1% 4.9168 <1% 
orf19.113 CIP1 1.6306 <5% 
    orf19.1235 HOM3 
  
1.6181 <1% 
  orf19.1340 
   
1.9064 <1% 
  orf19.1375 LEU42 
  
2.146 <1% 2.1128 <1% 
orf19.1394 
   
1.6711 <1% 
  orf19.1415 FRE10 1.9462 <1% 
  
1.7978 <5% 
orf19.1428 DUO1 7.9148 <1% 
  
7.9148 <1% 
orf19.1467 COX13 
  
1.566 <5% 
  orf19.1515 CHT4 2.1621 <1% 
    orf19.1564 
   
1.5339 <5% 
  orf19.1591 ERG10 1.9886 <1% 
    orf19.1631 ERG6 2.347 <1% 
  
2.2693 <1% 
orf19.1801 CBR1 
    
1.6803 <5% 
orf19.1865 
 
3.0906 <1% 
  
3.0906 <1% 
orf19.1986 ARO2 
  
1.6225 <1% 
  orf19.2028 MXR1 
  
1.8038 <1% 
  orf19.2084 CDH1 5.2064 <1% 
  
5.2064 <1% 
orf19.2098 ARO8 1.617 <5% 1.7503 <1% 1.6827 <1% 
orf19.2389 
     
1.7737 <5% 
orf19.267 NET1 5.6399 <1% 4.8275 <1% 5.2122 <1% 
orf19.2672 NCP1 2.0435 <1% 
    orf19.2684 
 
6.4516 <1% 8.7403 <1% 6.4516 <1% 
orf19.2826 
 
4.7624 <1% 
  
4.7624 <1% 
orf19.2847 
 
2.9914 <1% 
    orf19.2909 ERG26 2.448 <1% 
  
2.5368 <1% 
orf19.2988 
   
2.0777 <1% 2.0777 <5% 
orf19.3240 ERG27 2.6505 <1% 
  
2.6505 <1% 
orf19.3312 
     
1.8227 <5% 
orf19.346 
   
1.5455 <5% 
  orf19.3561 CDC7 5.4195 <1% 
  
5.4195 <1% 
orf19.3616 ERG9 2.2525 <1% 
  
2.2241 <1% 
orf19.3788 SPC34 8.4606 <1% 
  
8.4606 <1% 
orf19.3846 LYS4 
  
1.9598 <1% 1.9598 <1% 
orf19.3911 SAH1 1.7654 <1% 
    orf19.3997 ADH1 1.9864 <1% 2.858 <1% 2.2645 <1% 
orf19.4076 MET10 1.7524 <1% 1.9576 <1% 1.7958 <1% 
orf19.4099 ECM17 
  
1.8032 <1% 
  orf19.4177 HIS5 
  
1.7235 <1% 
  orf19.4192 CDC14 49.394 <1% 9.5141 <1% 26.257 <1% 
orf19.4208 RAD52 12.346 <1% 
  
12.346 <1% 
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HS2 
 
 
HS3 
 
 
HS2+HS3 
 
 
Protein IDs 
 
Gene 
 
Ratio H/L 
normalized 
 
FDR 
 
Ratio H/L 
normalized 
 
FDR 
 
Ratio H/L 
normalized 
 
FDR 
 
orf19.4220 
   
1.6706 <1% 
  orf19.4261 TIF5 
  
1.7914 <1% 
  orf19.4275 RAD9 
    
3.8401 <1% 
orf19.4435 
 
2.2731 <1% 
  
2.2731 <1% 
orf19.449 
   
1.9313 <1% 1.9313 <1% 
orf19.4506 LYSS22 
  
2.3886 <1% 2.1107 <1% 
orf19.4675 ASK1 13.589 <1% 5.6727 <1% 13.094 <1% 
orf19.4837 DAM1 7.9903 <1% 
  
7.9903 <1% 
orf19.4988 
 
19.025 <1% 
  
19.025 <1% 
orf19.5025 MET3 2.1043 <1% 1.6937 <1% 2.0078 <1% 
orf19.506 YDJ1 1.5707 <5% 
    orf19.5117 OLE1 2.0981 <1% 
  
2.0981 <1% 
orf19.5131 
   
1.7149 <1% 
  orf19.5180 PRX1 1.8973 <1% 
    orf19.5293 
   
1.8131 <1% 1.6777 <5% 
orf19.5358 
 
8.0684 <1% 
  
8.0684 <1% 
orf19.5389 FKH2 
    
2.7786 <1% 
orf19.5484 SER1 
  
1.5575 <5% 
  orf19.5564 
   
1.5577 <5% 
  orf19.5614 
 
2.2491 <1% 
  
2.2491 <1% 
orf19.5620 
   
2.1288 <1% 
  orf19.5811 MET1 
  
1.5516 <5% 
  orf19.5845 RNR3 3.3892 <1% 
    orf19.5949 FAS2 1.6469 <5% 
    orf19.6010 CDC5 2.07 <5% 
  
2.07 <1% 
orf19.6081 PHR2 2.7364 <1% 
  
2.3358 <1% 
orf19.6086 LEU4 
  
1.6606 <1% 1.6606 <1% 
orf19.6155 
     
1.9545 <5% 
orf19.6245 
   
2.361 <1% 2.0026 <1% 
orf19.6257 GLT1 
  
2.2767 <1% 
  orf19.6402 CYS3 
  
1.5939 <1% 
  orf19.6515 HSP90 1.7447 <1% 
    orf19.652 
 
54.679 <1% 6.4406 <1% 22.934 <1% 
orf19.6524 TOM40 
  
1.816 <1% 
  orf19.6559 
   
1.5725 <5% 
  orf19.6583 
 
2.7916 <1% 
  
2.7916 <1% 
orf19.6632 ACO2 
  
2.1247 <1% 1.8576 <5% 
orf19.6701 
 
1.5939 <5% 
    orf19.6758 
 
2.2841 <1% 
  
2.2841 <1% 
orf19.6779 PRO2 
  
1.7307 <1% 
  orf19.6837 FMA1 2.2776 <1% 
  
2.267 <1% 
orf19.6942 ORC3 4.1333 <1% 
  
4.1333 <1% 
orf19.6994 BAT22 
  
1.5155 <5% 
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HS2 
 
 
HS3 
 
 
HS2+HS3 
 
 
Protein IDs 
 
Gene 
 
Ratio H/L 
normalized 
 
FDR 
 
Ratio H/L 
normalized 
 
FDR 
 
Ratio H/L 
normalized 
 
FDR 
 
orf19.700 SEO1 2.0787 <1% 
  
2.0787 <1% 
orf19.717 HSP60 1.818 <1% 
  
1.568 <5% 
orf19.7297 
   
1.5952 <1% 
  orf19.7325 SCO1 
    
1.9556 <1% 
orf19.7498 LEU1 
  
1.9464 <1% 
  orf19.76 SPB1 2.0606 <5% 
    orf19.7602 
 
1.6089 <5% 
  
1.5963 <5% 
orf19.7602 
       orf19.780 DUR1,2 
  
3.2289 <1% 
  orf19.922 ERG11 2.3954 <1% 
  
2.3269 <1% 
orf19.946 MET14 
  
1.5689 <1% 
   
Table 6.7: Proteins identified as hits in each dataset from hyphae QO-MS.   
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H/L calculated (>2) 
 
 
Protein IDs 
 
Gene 
 
H2 
 
H3 
 
H2+H3 
 
CaalfMp08.1 
 
3.85 
  orf19.1133 MSB1 
  
H 
orf19.124 CIC1 
 
2.63 
 orf19.125 EBP1 10.25 
 
40.95 
orf19.1252 YME1 H 
 
H 
orf19.1519 
   
H 
orf19.1609 
 
H 
 
H 
orf19.183 HIS3 
  
3.36 
orf19.2055 NPL6 6.10 
  orf19.2115 
 
H 
 
3.14 
orf19.2365 POL2 
  
2.37 
orf19.2381 
 
H 
 
H 
orf19.2549 SHP1 3.92 
  orf19.2770.1 SOD1 
 
11.77 14.25 
orf19.2782 
 
73.50 
  orf19.2827 
 
2.99 
 
2.36 
orf19.2847 
    orf19.2956 MGM101 H 
  orf19.2973 
 
H 
 
2.42 
orf19.2985 
   
2.31 
orf19.2989 GOR1 
  
2.52 
orf19.3000 ORC1 5.64 
 
34.89 
orf19.3040 EHT1 5.85 
 
7.54 
orf19.3103 
 
3.19 
  orf19.3296 
 
H 
 
H 
orf19.3309 
 
3.14 
 
2.26 
orf19.3474 IPL1 89.21 
 
H 
orf19.3540 MAK5 2.06 
  orf19.3551 DAD2 H 
 
4.89 
orf19.3647 SEC8 3.56 
  orf19.3802 PMT6 
  
3.59 
orf19.3871 DAD3 H 
 
29.87 
orf19.390 CDC42 2.26 
  orf19.4013 
   
6.66 
orf19.406 ERG1 
  
2.29 
orf19.4131 
 
H 
 
6.44 
orf19.4208 RAD52 
 
H 
 orf19.4221 ORC4 2.13 
 
10.72 
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H/L calculated (>2) 
 
 
Protein IDs 
 
Gene 
 
H2 
 
H3 
 
H2+H3 
 
orf19.4257 INT1 12.77 
  orf19.427 
 
4.94 
 
H 
orf19.4275 RAD9 4.15 
  orf19.4340 
 
2.71 
 
2.81 
orf19.439 
 
2.78 
  orf19.4444 PHO15 4.86 
 
6.15 
orf19.4449 
   
2.15 
orf19.4473 SPC19 H H 49.43 
orf19.4563 
 
H 
  orf19.4829 DOA1 3.17 
  orf19.489 DAP1 2.43 
  orf19.5166 DBF4 3.29 
 
73.50 
orf19.5246 
 
6.44 
 
6.10 
orf19.5389 FKH2 3.04 
  orf19.5395 
 
865.35 
  orf19.541 
  
H 
 orf19.5491 
 
25.75 
 
H 
orf19.5500 MAK16 2.25 
 
2.30 
orf19.5517 
 
2.30 
 
10.25 
orf19.5518 
 
10.72 
 
H 
orf19.5764 SKI8 
  
2.09 
orf19.58 RRP6 34.80 
 
5.92 
orf19.580 
 
64.87 
 
H 
orf19.5852 
   
5.42 
orf19.6049 
 
3.44 
 
89.21 
orf19.6124 ACE2 8.69 
 
H 
orf19.6291 
 
H 
 
9.38 
orf19.6408 
 
H 
 
5.85 
orf19.6418 
 
4.20 
 
3.67 
orf19.643 
 
H 
 
H 
orf19.6463 
 
2.42 
 
6.53 
orf19.6506 
 
H 
 
2.99 
orf19.658 GIN1 9.38 
 
H 
orf19.6689 ARG4 
 
12.14 12.14 
orf19.6692 MNN7 H 
 
9.77 
orf19.6809 
  
H H 
orf19.6886 
  
3.68 
 orf19.7080 LEU2 14.39 
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H/L calculated (>2) 
 
 
Protein IDs 
 
Gene 
 
H2 
 
H3 
 
H2+H3 
 
orf19.7107 
 
H 
 
2.43 
orf19.7119 RAD3 
  
3.45 
orf19.7198 
 
H 
 
8.69 
orf19.7215.3 
 
5.02 
  orf19.7322 
 
7.54 
  orf19.7394 GDA1 3.67 
  orf19.748 
 
2.68 
  orf19.7538 
 
6.15 
 
5.64 
orf19.926 EXO1 
  
H 
orf19.944 IFG3 
  
21.99 
 
Table 6.8: Non-quantified proteins enriched in heavy peptides (experiments from hyphae QO-MS).   
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6.4. Correction of H/L ratios of proline-containing peptides 
As discussed in chapter 5, significant proportion of the heavy arginine was metabolically 
converted to heavy proline in vivo. Consequently, the H/L ratios of all proline-containing 
peptides were falsely estimated by the quantitation software. The true ratios of these 
peptides were calculated using a post-quantitation R script written by Dr Joseph Longworth 
(University of Sheffield). The script compares the median H/L ratios of peptides with 
different number of proline residues and estimates the contribution of each proline to the 
ratios (figure 6.5). In the example shown in figure 6.5A, each proline amino acid reduces the 
H/L ratio of a peptide by 35.7%, hence the correction factor is 0.357 per proline residue. 
After calculating the correction factor, the R application normalises the isotopic ratios of all 
peptides and re-calculates the correct protein ratios in the dataset. As evident in figure 
6.5A, the peptide ratios appear very similar after the correction is applied. The change in 
protein ratios after the correction is not dramatic (figure 6.5B), but has a significant impact 
on the final list of hits. 
 All data sets obtained by QO-MS were corrected for arginine-to-proline conversion 
and outliers in each set were then determined as described in sections 6.2 and 6.3. The 
updated list of Cdc14 hits is shown in table 6.9. In total, 126 proteins were significantly 
enriched in labelled peptides, of which 117 were found in yeast and 43 were found in 
hyphae. Table 6.9 show the final list of Cdc14 hits that can be considered potential Cdc14 
interactors. The criteria for selecting these proteins as hits were as follows: 
 Proteins passed the FDR threshold of 0.05 in the Significance B test based on the 
Benjamini-Hochberg multiple hypothesis test.  
 Proteins remain outliers when both data sets from each condition (i.e. yeast and 
hyphae) are combined and analysed together. For example, in tables 6.4 proteins 
may appear as hits in Y1 or Y2, but are missing when Y1+Y2 are combined. Such 
proteins will not fulfil this criterion, so they are not present in table 6.9. 
 Proteins were identified by at least 2 peptides 
 Proteins were enriched in heavy peptides in the cell lysate. For further information 
about this point, see section 6.5.  
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B  A   
         
Fig. 6.5: Change in peptide and protein isotopic ratios after arginine-to-proline correction. (A) In 
the example shown here, the peptide ratios decrease as the number of prolines in the peptides go 
up. The R script has calculated that each proline lowers the peptide ratio by 0.357 and applies this 
correction factor in order to produce a more accurate set of ratios, where peptides have similar 
ratios regardless of the proline count. (B) A comparison of the protein isotopic ratios before and 
after the correction show that the change is very subtle, i.e. most dots in the graph lie near a straight 
diagonal line crossing the 0 intercept.  
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Protein IDs 
 
Gene 
 
Yeast 
 
Hyphae 
 
orf19.1108 HAM1 
 
+ 
orf19.1133 MSB1 
 
+ 
orf19.1223 DBF2 + 
 orf19.1357 FCY21 + 
 orf19.1428 DUO1 + + 
orf19.1446 CLB2 + 
 orf19.1451 SRB9 + 
 orf19.147 YAK1 + 
 orf19.1515 CHT4 + + 
orf19.1570 ERG27 + 
 orf19.1598 ERG24 + 
 orf19.1609 
  
+ 
orf19.1618 GFA1 + 
 orf19.1631 ERG6 + 
 orf19.1792 
 
+ 
 orf19.1801 CBR1 + 
 orf19.1941 NUF2 + 
 orf19.2084 CDH1 + + 
orf19.2369 
 
+ 
 orf19.2381 
 
+ + 
orf19.2389 
 
+ 
 orf19.2397 
 
+ 
 orf19.2400 
 
+ 
 orf19.2416.1 MLC1 + 
 orf19.267 NET1 + + 
orf19.2672 NCP1 + 
 orf19.2684 
 
+ + 
orf19.272 FAA21 + 
 orf19.2826 
 
+ + 
orf19.2827 
 
+ + 
orf19.2909 ERG26 + 
 orf19.3000 ORC1 + + 
orf19.3040 EHT1 + 
 orf19.3091 
 
+ 
 orf19.3221 CPA2 + 
 orf19.3231 CDC27 + 
 orf19.3240 ERG27 + 
 orf19.3252 DAL81 + 
 orf19.3289 
 
+ 
 orf19.3296 
 
+ 
 orf19.3311 IFD3 + 
 orf19.3356 ESP1 + 
 orf19.3362;orf19.2671 
 
+ 
 orf19.3474 IPL1 
 
+ 
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Protein IDs 
 
Gene 
 
Yeast 
 
Hyphae 
 
orf19.3477 
 
+ 
 orf19.3507 MCR1 + 
 orf19.3535 
 
+ 
 orf19.3551 DAD2 + + 
orf19.3561 CDC7 + + 
orf19.3684 
 
+ 
 orf19.3707 YHB1 + 
 orf19.3733 IDP2 + 
 orf19.3788 SPC34 + + 
orf19.3809 BAS1 + 
 orf19.3823 ZDS1 + 
 orf19.384 
 
+ 
 orf19.3856 CDC28 + 
 orf19.3871 DAD3 + 
 orf19.3954 
 
+ 
 orf19.4013 
 
+ 
 orf19.4043 
 
+ 
 orf19.406 ERG1 + 
 orf19.4101 
 
+ 
 orf19.4192 CDC14 + + 
orf19.4208 RAD52 + + 
orf19.4221 ORC4 + + 
orf19.427 
 
+ + 
orf19.4275 RAD9 + + 
orf19.4311 YNK1 + 
 orf19.4435 
 
+ + 
orf19.4473 SPC19 + + 
orf19.4675 ASK1 + + 
orf19.4716 GDH3 + 
 orf19.4777 DAK2 + 
 orf19.4837 DAM1 + + 
orf19.4988 
 
+ + 
orf19.5166 DBF4 + + 
orf19.520 
 
+ 
 orf19.5246 
 
+ 
 orf19.5276 
 
+ 
 orf19.5358 
 
+ + 
orf19.5389 FKH2 + + 
orf19.5437 RHR2 + 
 orf19.5491 
 
+ + 
orf19.5518 
 
+ + 
orf19.557 
 
+ 
 orf19.5614 
  
+ 
orf19.580 
 
+ 
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Protein IDs 
 
Gene 
 
Yeast 
 
Hyphae 
 
orf19.5825 NCB2 
 
+ 
orf19.6010 CDC5 + + 
orf19.6011 SIN3 + 
 orf19.6026 ERG2 + 
 orf19.6030 
 
+ 
 orf19.6049 
 
+ + 
orf19.6124 ACE2 + + 
orf19.6155 
 
+ 
 orf19.6234 
  
+ 
orf19.6254 ANT1 + 
 orf19.6257 GLT1 + 
 orf19.6291 
 
+ 
 orf19.638 FDH1 + 
 orf19.6385 ACO1 + 
 orf19.6408 
  
+ 
orf19.643 
  
+ 
orf19.6443 
 
+ 
 orf19.6496 TRS33 + 
 orf19.652 
 
+ + 
orf19.6536 IQG1 + 
 orf19.658 GIN1 + + 
orf19.6583 
 
+ + 
orf19.6596 
 
+ 
 orf19.6610 
 
+ 
 orf19.6837 FMA1 + 
 orf19.6868 
 
+ 
 orf19.6882 OSM1 + 
 orf19.6942 ORC3 + + 
orf19.7060 
 
+ 
 orf19.7185 
 
+ 
 orf19.7288 
 
+ 
 orf19.7306 
 
+ 
 orf19.7406 
 
+ 
 orf19.7469 ARG1 + 
 orf19.7663 
 
+ 
 orf19.771 LPG20 + 
 orf19.826 
 
+ 
 orf19.926 EXO1 + 
  
Table 6.9: Final list of Cdc14 hits composed after correcting for arginine-to-proline conversion. The 
+ indicates the protein was found as a hit in that experiment. If two ORFs are present in the Protein 
ID column, it means that the software could not determine, which one of them were present in the 
sample because they belong to the same protein family (i.e. they have the same tryptic peptides). 
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6.5. Measuring protein levels in the cell lysate 
SILAC experiments often rely on the assumption that proteins are expressed equally in both 
cell cultures that are grown in different media. Thus, proteins enriched in either light or 
heavy peptides are regarded as outliers in the downstream data analysis. However, it is 
possible that the difference in growth conditions has caused deferential expression of some 
proteins, which will appear as false positives.  
 In this study, SILAC experiments were carried out using a Cdc14PD mutant, and a wild 
type strain as a control. Assuming that all proteins were present in the same amount in both 
starting cultures, those enriched in heavy peptides would appear so by physical interaction 
with the bait. Although cells expressing Cdc14PD showed no phenotype suggesting metabolic 
disturbances, protein levels were formally assessed by mass spectrometry analysis of cell 
lysates. Cells of both strains were grown in the same condition used in a standard SILAC 
experiment, i.e. Cdc14PD cells were labelled with heavy amino acids, and wild type cells were 
grown in light medium. Equal amounts of cells were mixed together and lysed, and protein 
extracts were separated by SDS-PAGE. Protein samples were then prepared and run through 
the mass spectrometer as described in chapter 2. Data was analysed as described in this 
chapter, and all proteins present in the samples were identified and quantified. This 
experiment, performed in both yeast and hyphae, reveals the protein ratios in the starting 
material before immunoprecipitating Cdc14PD. In total, 2339 yeast protein and 2265 hyphal 
proteins were identified and quantified. The vast majority of those proteins had H/L ratios 
close to one. However, a few exceptions were also found, namely 131 proteins in yeast and 
131 proteins in hyphae were significantly enriched in either light or heavy isotopes 
determined by using the Significance B test FDR=0.05. Proteins that were found to be 
enriched in the lysate and also in the IP experiments are listed in table 6.10. These proteins 
cannot be considered as Cdc14 interactors, because they were more abundant in the 
Cdc14PD cells than the wild type cells. Thus, if they are non-specifically sticking to the matrix, 
heavy peptides will stick more often than light peptides. On the other side, these proteins 
cannot be completely excluded, because it is now known whether they associate with Cdc14 
or not. Note that a direct comparison of the H/L ratios of these proteins in the IP and in the 
cell extracts cannot be made because isotope ratios vary greatly between experiments.  
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Protein IDs 
 
Gene 
 
Yeast 
 
Hyphae 
 
orf19.1065 SSA2 
 
+ 
orf19.125 EBP1 
 
+ 
orf19.1442 PLB4.5 + 
 orf19.1608 
 
+ 
 orf19.1631 ERG6 
 
+ 
orf19.1779 MP65 + 
 orf19.1801 CBR1 
 
+ 
orf19.1865 
  
+ 
orf19.1996 CHA1 + 
 orf19.2124 
 
+ 
 orf19.2125 
 
+ 
 orf19.2417 SMC5 + 
 orf19.2770.1 SOD1 
 
+ 
orf19.3040 EHT1 
 
+ 
orf19.3240 ERG27 
 
+ 
orf19.355;orf19.6999 
 
+ 
 orf19.3616 ERG9 
 
+ 
orf19.3997;orf19.5113 ADH1 
 
+ 
orf19.4076 MET10 
 
+ 
orf19.4212;orf19.4213 FET99 + 
 orf19.4295 
 
+ 
 orf19.489 DAP1 + + 
orf19.5025 MET3 
 
+ 
orf19.5180 PRX1 
 
+ 
orf19.5517 
  
+ 
orf19.5730 
 
+ 
 orf19.5949 FAS2 
 
+ 
orf19.6081 PHR2 
 
+ 
orf19.6515 HSP90 
 
+ 
orf19.6689 ARG4 + + 
orf19.6758 
 
+ + 
orf19.6837 FMA1 
 
+ 
orf19.700;orf19.1855 SEO1 
 
+ 
orf19.7111.1 SOD3 + 
 orf19.717 HSP60 
 
+ 
orf19.7600 FDH3 + 
 orf19.7602 
  
+ 
orf19.922 ERG11 
 
+ 
orf19.979 FAS1 
 
+ 
 
Table 6.10: Ambiguous proteins that were enriched in heavy isotopes in both the IP and the cell 
lysates.  
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6.6. Gene ontology analysis of potential Cdc14 interactors  
The Cdc14 hits from table 6.9 were subjected to gene ontology (GO) analysis using the GO 
tools available on candidagenome.org. The aim is to group these proteins into categories 
based on their function or localisation in order to have a broader look at Cdc14 role in the 
cell. The query set for the analysis consisted of 125 putative Cdc14 interactors, while the 
background was all 2783 proteins identified by MS in all IP experiments. The results of the 
GO analysis are summarised in tables 6.11, 6.12 and 6.13. 
 The most common cellular processes identified here were related to cell cycle 
control, chromosome segregation, DNA metabolism, and organelle and cytoskeleton 
organisation. The most prevalent protein functions were DNA and cytoskeleton binding, and 
in agreement with this, the list was enriched in chromosomal and cytoskeletal proteins 
according to component analysis. These results suggest that in C. albicans, Cdc14 is actively 
involved in DNA maintenance not only during mitosis, but throughout the whole cell cycle. 
Based on this analysis, Cdc14 does not appear to have unique roles in C. albicans. However, 
there are many uncharacterised genes among the hits, which are not assigned any GO 
terms. Therefore, the significance of these interactions remain unknown. 
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GO term 
 
Cluster 
frequency 
 
Background frequency 
 
FDR 
 
single-organism cellular process 
76 out of 125 
genes, 60.8% 
1231 out of 2783 
background genes, 44.2% 0.12% 
cell cycle process 
42 out of 125 
genes, 33.6% 
255 out of 2783 
background genes, 9.2% 0.00% 
cell cycle 
42 out of 125 
genes, 33.6% 
264 out of 2783 
background genes, 9.5% 0.00% 
mitotic cell cycle process 
33 out of 125 
genes, 26.4% 
163 out of 2783 
background genes, 5.9% 0.00% 
mitotic cell cycle 
33 out of 125 
genes, 26.4% 
166 out of 2783 
background genes, 6.0% 0.00% 
chromosome organization 
31 out of 125 
genes, 24.8% 
246 out of 2783 
background genes, 8.8% 0.00% 
negative regulation of cellular process 
30 out of 125 
genes, 24.0% 
318 out of 2783 
background genes, 11.4% 0.02% 
regulation of cell cycle 
26 out of 125 
genes, 20.8% 
141 out of 2783 
background genes, 5.1% 0.00% 
regulation of cell cycle process 
25 out of 125 
genes, 20.0% 
115 out of 2783 
background genes, 4.1% 0.00% 
regulation of cellular component 
organization 
24 out of 125 
genes, 19.2% 
235 out of 2783 
background genes, 8.4% 0.09% 
DNA metabolic process 
23 out of 125 
genes, 18.4% 
172 out of 2783 
background genes, 6.2% 0.00% 
regulation of organelle organization 
21 out of 125 
genes, 16.8% 
159 out of 2783 
background genes, 5.7% 0.00% 
negative regulation of nucleobase-
containing compound metabolic process 
21 out of 125 
genes, 16.8% 
173 out of 2783 
background genes, 6.2% 0.00% 
nuclear chromosome segregation 
20 out of 125 
genes, 16.0% 
63 out of 2783 background 
genes, 2.3% 0.00% 
chromosome segregation 
20 out of 125 
genes, 16.0% 
75 out of 2783 background 
genes, 2.7% 0.00% 
regulation of mitotic cell cycle 
20 out of 125 
genes, 16.0% 
92 out of 2783 background 
genes, 3.3% 0.00% 
negative regulation of macromolecule 
biosynthetic process 
20 out of 125 
genes, 16.0% 
181 out of 2783 
background genes, 6.5% 0.12% 
negative regulation of cellular 
macromolecule biosynthetic process 
20 out of 125 
genes, 16.0% 
181 out of 2783 
background genes, 6.5% 0.12% 
negative regulation of RNA biosynthetic 
process 
19 out of 125 
genes, 15.2% 
151 out of 2783 
background genes, 5.4% 0.02% 
negative regulation of nucleic acid-
templated transcription 
19 out of 125 
genes, 15.2% 
151 out of 2783 
background genes, 5.4% 0.02% 
negative regulation of transcription, DNA-
templated 
19 out of 125 
genes, 15.2% 
151 out of 2783 
background genes, 5.4% 0.02% 
negative regulation of RNA metabolic 
process 
19 out of 125 
genes, 15.2% 
153 out of 2783 
background genes, 5.5% 0.02% 
cytoskeleton organization 
18 out of 125 
genes, 14.4% 
125 out of 2783 
background genes, 4.5% 0.00% 
microtubule cytoskeleton organization 
16 out of 125 
genes, 12.8% 
40 out of 2783 background 
genes, 1.4% 0.00% 
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GO term 
 
Cluster 
frequency 
 
Background frequency 
 
FDR 
 
positive regulation of cell cycle process 
16 out of 125 
genes, 12.8% 
42 out of 2783 background 
genes, 1.5% 0.00% 
microtubule-based process 
16 out of 125 
genes, 12.8% 
43 out of 2783 background 
genes, 1.5% 0.00% 
positive regulation of cell cycle 
16 out of 125 
genes, 12.8% 
45 out of 2783 background 
genes, 1.6% 0.00% 
nuclear division 
16 out of 125 
genes, 12.8% 
73 out of 2783 background 
genes, 2.6% 0.00% 
organelle fission 
16 out of 125 
genes, 12.8% 
79 out of 2783 background 
genes, 2.8% 0.00% 
regulation of cell cycle phase transition 
15 out of 125 
genes, 12.0% 
61 out of 2783 background 
genes, 2.2% 0.00% 
regulation of mitotic cell cycle phase 
transition 
15 out of 125 
genes, 12.0% 
61 out of 2783 background 
genes, 2.2% 0.00% 
regulation of chromosome segregation 
14 out of 125 
genes, 11.2% 
37 out of 2783 background 
genes, 1.3% 0.00% 
DNA-dependent DNA replication 
14 out of 125 
genes, 11.2% 
63 out of 2783 background 
genes, 2.3% 0.00% 
positive regulation of organelle 
organization 
14 out of 125 
genes, 11.2% 
65 out of 2783 background 
genes, 2.3% 0.00% 
DNA replication 
14 out of 125 
genes, 11.2% 
67 out of 2783 background 
genes, 2.4% 0.00% 
regulation of chromosome organization 
14 out of 125 
genes, 11.2% 
75 out of 2783 background 
genes, 2.7% 0.00% 
negative regulation of cell cycle 
14 out of 125 
genes, 11.2% 
88 out of 2783 background 
genes, 3.2% 0.02% 
positive regulation of cellular component 
organization 
14 out of 125 
genes, 11.2% 
91 out of 2783 background 
genes, 3.3% 0.02% 
attachment of spindle microtubules to 
kinetochore 
13 out of 125 
genes, 10.4% 
19 out of 2783 background 
genes, 0.7% 0.00% 
mitotic spindle organization 
13 out of 125 
genes, 10.4% 
20 out of 2783 background 
genes, 0.7% 0.00% 
spindle organization 
13 out of 125 
genes, 10.4% 
23 out of 2783 background 
genes, 0.8% 0.00% 
microtubule cytoskeleton organization 
involved in mitosis 
13 out of 125 
genes, 10.4% 
24 out of 2783 background 
genes, 0.9% 0.00% 
mitotic nuclear division 
13 out of 125 
genes, 10.4% 
50 out of 2783 background 
genes, 1.8% 0.00% 
sister chromatid segregation 
13 out of 125 
genes, 10.4% 
53 out of 2783 background 
genes, 1.9% 0.00% 
regulation of nuclear division 
13 out of 125 
genes, 10.4% 
60 out of 2783 background 
genes, 2.2% 0.00% 
negative regulation of gene expression, 
epigenetic 
13 out of 125 
genes, 10.4% 
82 out of 2783 background 
genes, 2.9% 0.02% 
chromatin silencing 
13 out of 125 
genes, 10.4% 
82 out of 2783 background 
genes, 2.9% 0.02% 
gene silencing 
13 out of 125 
genes, 10.4% 
86 out of 2783 background 
genes, 3.1% 0.10% 
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GO term 
 
Cluster 
frequency 
 
Background frequency 
 
FDR 
 
regulation of microtubule-based process 
12 out of 125 
genes, 9.6% 
19 out of 2783 background 
genes, 0.7% 0.00% 
regulation of microtubule cytoskeleton 
organization 
12 out of 125 
genes, 9.6% 
19 out of 2783 background 
genes, 0.7% 0.00% 
nuclear DNA replication 
12 out of 125 
genes, 9.6% 
33 out of 2783 background 
genes, 1.2% 0.00% 
cell cycle DNA replication 
12 out of 125 
genes, 9.6% 
34 out of 2783 background 
genes, 1.2% 0.00% 
mitotic sister chromatid segregation 
12 out of 125 
genes, 9.6% 
43 out of 2783 background 
genes, 1.5% 0.00% 
regulation of mitotic nuclear division 
12 out of 125 
genes, 9.6% 
43 out of 2783 background 
genes, 1.5% 0.00% 
regulation of cytoskeleton organization 
12 out of 125 
genes, 9.6% 
53 out of 2783 background 
genes, 1.9% 0.00% 
negative regulation of mitotic cell cycle 
12 out of 125 
genes, 9.6% 
56 out of 2783 background 
genes, 2.0% 0.00% 
negative regulation of cell cycle process 
12 out of 125 
genes, 9.6% 
68 out of 2783 background 
genes, 2.4% 0.02% 
organic hydroxy compound metabolic 
process 
12 out of 125 
genes, 9.6% 
69 out of 2783 background 
genes, 2.5% 0.02% 
organic hydroxy compound biosynthetic 
process 
11 out of 125 
genes, 8.8% 
45 out of 2783 background 
genes, 1.6% 0.00% 
alcohol metabolic process 
11 out of 125 
genes, 8.8% 
51 out of 2783 background 
genes, 1.8% 0.00% 
DNA replication initiation 
10 out of 125 
genes, 8.0% 
24 out of 2783 background 
genes, 0.9% 0.00% 
regulation of sister chromatid 
segregation 
10 out of 125 
genes, 8.0% 
30 out of 2783 background 
genes, 1.1% 0.00% 
regulation of mitotic sister chromatid 
segregation 
10 out of 125 
genes, 8.0% 
30 out of 2783 background 
genes, 1.1% 0.00% 
positive regulation of mitotic cell cycle 
10 out of 125 
genes, 8.0% 
33 out of 2783 background 
genes, 1.2% 0.00% 
alcohol biosynthetic process 
10 out of 125 
genes, 8.0% 
37 out of 2783 background 
genes, 1.3% 0.00% 
double-strand break repair 
10 out of 125 
genes, 8.0% 
51 out of 2783 background 
genes, 1.8% 0.07% 
protein-DNA complex assembly 
10 out of 125 
genes, 8.0% 
55 out of 2783 background 
genes, 2.0% 0.11% 
positive regulation of chromosome 
segregation 
9 out of 125 
genes, 7.2% 
14 out of 2783 background 
genes, 0.5% 0.00% 
phytosteroid biosynthetic process 
9 out of 125 
genes, 7.2% 
23 out of 2783 background 
genes, 0.8% 0.00% 
secondary alcohol biosynthetic process 
9 out of 125 
genes, 7.2% 
23 out of 2783 background 
genes, 0.8% 0.00% 
cellular alcohol biosynthetic process 
9 out of 125 
genes, 7.2% 
23 out of 2783 background 
genes, 0.8% 0.00% 
ergosterol biosynthetic process 
9 out of 125 
genes, 7.2% 
23 out of 2783 background 
genes, 0.8% 0.00% 
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GO term 
 
Cluster 
frequency 
 
Background frequency 
 
FDR 
 
cellular lipid biosynthetic process 
9 out of 125 
genes, 7.2% 
23 out of 2783 background 
genes, 0.8% 0.00% 
phytosteroid metabolic process 
9 out of 125 
genes, 7.2% 
24 out of 2783 background 
genes, 0.9% 0.00% 
secondary alcohol metabolic process 
9 out of 125 
genes, 7.2% 
24 out of 2783 background 
genes, 0.9% 0.00% 
ergosterol metabolic process 
9 out of 125 
genes, 7.2% 
24 out of 2783 background 
genes, 0.9% 0.00% 
sterol biosynthetic process 
9 out of 125 
genes, 7.2% 
26 out of 2783 background 
genes, 0.9% 0.00% 
steroid biosynthetic process 
9 out of 125 
genes, 7.2% 
26 out of 2783 background 
genes, 0.9% 0.00% 
cellular alcohol metabolic process 
9 out of 125 
genes, 7.2% 
27 out of 2783 background 
genes, 1.0% 0.00% 
sterol metabolic process 
9 out of 125 
genes, 7.2% 
29 out of 2783 background 
genes, 1.0% 0.00% 
chromatin silencing at silent mating-type 
cassette 
9 out of 125 
genes, 7.2% 
30 out of 2783 background 
genes, 1.1% 0.00% 
steroid metabolic process 
9 out of 125 
genes, 7.2% 
31 out of 2783 background 
genes, 1.1% 0.00% 
mitotic cell cycle checkpoint 
9 out of 125 
genes, 7.2% 
35 out of 2783 background 
genes, 1.3% 0.00% 
negative regulation of cell cycle phase 
transition 
9 out of 125 
genes, 7.2% 
36 out of 2783 background 
genes, 1.3% 0.02% 
negative regulation of mitotic cell cycle 
phase transition 
9 out of 125 
genes, 7.2% 
36 out of 2783 background 
genes, 1.3% 0.02% 
cell cycle checkpoint 
9 out of 125 
genes, 7.2% 
41 out of 2783 background 
genes, 1.5% 0.04% 
mitotic spindle organization in nucleus 
8 out of 125 
genes, 6.4% 
8 out of 2783 background 
genes, 0.3% 0.00% 
positive regulation of nuclear division 
8 out of 125 
genes, 6.4% 
15 out of 2783 background 
genes, 0.5% 0.00% 
regulation of G2/M transition of mitotic 
cell cycle 
8 out of 125 
genes, 6.4% 
23 out of 2783 background 
genes, 0.8% 0.00% 
regulation of cell cycle G2/M phase 
transition 
8 out of 125 
genes, 6.4% 
23 out of 2783 background 
genes, 0.8% 0.00% 
positive regulation of cytoskeleton 
organization 
8 out of 125 
genes, 6.4% 
30 out of 2783 background 
genes, 1.1% 0.02% 
regulation of DNA-dependent DNA 
replication 
8 out of 125 
genes, 6.4% 
30 out of 2783 background 
genes, 1.1% 0.02% 
regulation of DNA replication 
8 out of 125 
genes, 6.4% 
31 out of 2783 background 
genes, 1.1% 0.02% 
pre-replicative complex assembly 
involved in cell cycle DNA replication 
7 out of 125 
genes, 5.6% 
18 out of 2783 background 
genes, 0.6% 0.00% 
pre-replicative complex assembly 
7 out of 125 
genes, 5.6% 
18 out of 2783 background 
genes, 0.6% 0.00% 
pre-replicative complex assembly 
involved in nuclear cell cycle DNA 
7 out of 125 
genes, 5.6% 
18 out of 2783 background 
genes, 0.6% 0.00% 
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GO term 
 
Cluster 
frequency 
 
Background frequency 
 
FDR 
 
replication 
mitotic DNA integrity checkpoint 
7 out of 125 
genes, 5.6% 
22 out of 2783 background 
genes, 0.8% 0.02% 
regulation of exit from mitosis 
7 out of 125 
genes, 5.6% 
23 out of 2783 background 
genes, 0.8% 0.02% 
positive regulation of attachment of 
spindle microtubules to kinetochore 
6 out of 125 
genes, 4.8% 
7 out of 2783 background 
genes, 0.3% 0.00% 
regulation of attachment of spindle 
microtubules to kinetochore 
6 out of 125 
genes, 4.8% 
7 out of 2783 background 
genes, 0.3% 0.00% 
metaphase plate congression 
6 out of 125 
genes, 4.8% 
9 out of 2783 background 
genes, 0.3% 0.00% 
mitotic metaphase plate congression 
6 out of 125 
genes, 4.8% 
9 out of 2783 background 
genes, 0.3% 0.00% 
establishment of chromosome 
localization 
6 out of 125 
genes, 4.8% 
10 out of 2783 background 
genes, 0.4% 0.00% 
positive regulation of mitotic nuclear 
division 
6 out of 125 
genes, 4.8% 
11 out of 2783 background 
genes, 0.4% 0.00% 
mitotic DNA replication 
6 out of 125 
genes, 4.8% 
18 out of 2783 background 
genes, 0.6% 0.10% 
negative regulation of mitotic nuclear 
division 
6 out of 125 
genes, 4.8% 
19 out of 2783 background 
genes, 0.7% 0.11% 
chromosome localization 
6 out of 125 
genes, 4.8% 
19 out of 2783 background 
genes, 0.7% 0.11% 
DNA double-strand break processing 
5 out of 125 
genes, 4.0% 
5 out of 2783 background 
genes, 0.2% 0.00% 
regulation of microtubule polymerization 
or depolymerization 
5 out of 125 
genes, 4.0% 
7 out of 2783 background 
genes, 0.3% 0.00% 
regulation of mitotic spindle organization 
5 out of 125 
genes, 4.0% 
7 out of 2783 background 
genes, 0.3% 0.00% 
regulation of spindle organization 
5 out of 125 
genes, 4.0% 
8 out of 2783 background 
genes, 0.3% 0.00% 
DNA replication checkpoint 
5 out of 125 
genes, 4.0% 
10 out of 2783 background 
genes, 0.4% 0.02% 
regulation of nuclear cell cycle DNA 
replication 
5 out of 125 
genes, 4.0% 
11 out of 2783 background 
genes, 0.4% 0.07% 
regulation of spindle pole body 
separation 
4 out of 125 
genes, 3.2% 
4 out of 2783 background 
genes, 0.1% 0.00% 
microtubule nucleation 
4 out of 125 
genes, 3.2% 
4 out of 2783 background 
genes, 0.1% 0.00% 
positive regulation of microtubule 
polymerization or depolymerization 
4 out of 125 
genes, 3.2% 
5 out of 2783 background 
genes, 0.2% 0.02% 
regulation of microtubule polymerization 
4 out of 125 
genes, 3.2% 
5 out of 2783 background 
genes, 0.2% 0.02% 
positive regulation of microtubule 
polymerization 
4 out of 125 
genes, 3.2% 
5 out of 2783 background 
genes, 0.2% 0.02% 
attachment of mitotic spindle 
microtubules to kinetochore 
4 out of 125 
genes, 3.2% 
5 out of 2783 background 
genes, 0.2% 0.02% 
regulation of cell cycle checkpoint 4 out of 125 6 out of 2783 background 0.02% 
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GO term 
 
Cluster 
frequency 
 
Background frequency 
 
FDR 
 
genes, 3.2% genes, 0.2% 
regulation of mitotic spindle elongation 
4 out of 125 
genes, 3.2% 
6 out of 2783 background 
genes, 0.2% 0.02% 
microtubule polymerization 
4 out of 125 
genes, 3.2% 
6 out of 2783 background 
genes, 0.2% 0.02% 
microtubule polymerization or 
depolymerization 
4 out of 125 
genes, 3.2% 
7 out of 2783 background 
genes, 0.3% 0.14% 
regulation of spindle elongation 
4 out of 125 
genes, 3.2% 
7 out of 2783 background 
genes, 0.3% 0.14% 
mitotic DNA replication checkpoint 
4 out of 125 
genes, 3.2% 
7 out of 2783 background 
genes, 0.3% 0.14% 
positive regulation of spindle pole body 
separation 
3 out of 125 
genes, 2.4% 
3 out of 2783 background 
genes, 0.1% 0.10% 
meiotic DNA double-strand break 
processing 
3 out of 125 
genes, 2.4% 
3 out of 2783 background 
genes, 0.1% 0.10% 
 
Table 6.11: GO analysis of Cdc14 hits based on cellular process. 
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GO term 
 
Cluster frequency 
 
Background frequency 
 
FDR 
 
double-stranded DNA binding 
17 out of 125 genes, 
13.6% 
77 out of 2783 background 
genes, 2.8% 0.00% 
microtubule binding 8 out of 125 genes, 6.4% 
14 out of 2783 background 
genes, 0.5% 0.00% 
microtubule plus-end binding 5 out of 125 genes, 4.0% 
5 out of 2783 background 
genes, 0.2% 0.00% 
DNA replication origin binding 9 out of 125 genes, 7.2% 
25 out of 2783 background 
genes, 0.9% 0.00% 
tubulin binding 8 out of 125 genes, 6.4% 
20 out of 2783 background 
genes, 0.7% 0.00% 
DNA binding 
25 out of 125 genes, 
20.0% 
206 out of 2783 background 
genes, 7.4% 0.00% 
sequence-specific double-
stranded DNA binding 
12 out of 125 genes, 
9.6% 
54 out of 2783 background 
genes, 1.9% 0.00% 
sequence-specific DNA binding 
14 out of 125 genes, 
11.2% 
87 out of 2783 background 
genes, 3.1% 0.25% 
cytoskeletal protein binding 
10 out of 125 genes, 
8.0% 
46 out of 2783 background 
genes, 1.7% 0.22% 
structural constituent of 
cytoskeleton 4 out of 125 genes, 3.2% 
8 out of 2783 background 
genes, 0.3% 0.80% 
 
Table 6.12: GO analysis of Cdc14 hits based on protein function. 
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GO term 
 
Cluster frequency 
 
Background frequency 
 
FDR 
 
microtubule cytoskeleton 
27 out of 125 
genes, 21.6% 
108 out of 2783 
background genes, 3.9% 0.00% 
chromosome, centromeric region 
18 out of 125 
genes, 14.4% 
47 out of 2783 background 
genes, 1.7% 0.00% 
condensed chromosome outer 
kinetochore 
9 out of 125 genes, 
7.2% 
9 out of 2783 background 
genes, 0.3% 0.00% 
condensed nuclear chromosome 
outer kinetochore 
9 out of 125 genes, 
7.2% 
9 out of 2783 background 
genes, 0.3% 0.00% 
condensed chromosome kinetochore 
13 out of 125 
genes, 10.4% 
22 out of 2783 background 
genes, 0.8% 0.00% 
condensed nuclear chromosome 
kinetochore 
12 out of 125 
genes, 9.6% 
20 out of 2783 background 
genes, 0.7% 0.00% 
condensed chromosome, centromeric 
region 
13 out of 125 
genes, 10.4% 
25 out of 2783 background 
genes, 0.9% 0.00% 
chromosomal region 
19 out of 125 
genes, 15.2% 
63 out of 2783 background 
genes, 2.3% 0.00% 
kinetochore 
13 out of 125 
genes, 10.4% 
28 out of 2783 background 
genes, 1.0% 0.00% 
condensed nuclear chromosome, 
centromeric region 
12 out of 125 
genes, 9.6% 
23 out of 2783 background 
genes, 0.8% 0.00% 
chromosomal part 
32 out of 125 
genes, 25.6% 
200 out of 2783 
background genes, 7.2% 0.00% 
chromosome 
32 out of 125 
genes, 25.6% 
208 out of 2783 
background genes, 7.5% 0.00% 
spindle 
16 out of 125 
genes, 12.8% 
50 out of 2783 background 
genes, 1.8% 0.00% 
DASH complex 
7 out of 125 genes, 
5.6% 
7 out of 2783 background 
genes, 0.3% 0.00% 
cytoskeletal part 
28 out of 125 
genes, 22.4% 
170 out of 2783 
background genes, 6.1% 0.00% 
cytoskeleton 
28 out of 125 
genes, 22.4% 
171 out of 2783 
background genes, 6.1% 0.00% 
nuclear chromosome 
27 out of 125 
genes, 21.6% 
163 out of 2783 
background genes, 5.9% 0.00% 
condensed nuclear chromosome 
13 out of 125 
genes, 10.4% 
36 out of 2783 background 
genes, 1.3% 0.00% 
nuclear chromosome part 
26 out of 125 
genes, 20.8% 
156 out of 2783 
background genes, 5.6% 0.00% 
condensed chromosome 
14 out of 125 
genes, 11.2% 
44 out of 2783 background 
genes, 1.6% 0.00% 
nuclear origin of replication 
recognition complex 
6 out of 125 genes, 
4.8% 
6 out of 2783 background 
genes, 0.2% 0.00% 
origin recognition complex 
6 out of 125 genes, 
4.8% 
6 out of 2783 background 
genes, 0.2% 0.00% 
spindle pole body 
16 out of 125 
genes, 12.8% 
68 out of 2783 background 
genes, 2.4% 0.00% 
microtubule organizing centre 
16 out of 125 
genes, 12.8% 
69 out of 2783 background 
genes, 2.5% 0.00% 
mitotic spindle pole body 13 out of 125 56 out of 2783 background 0.00% 
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GO term 
 
Cluster frequency 
 
Background frequency 
 
FDR 
 
genes, 10.4% genes, 2.0% 
microtubule 
8 out of 125 genes, 
6.4% 
19 out of 2783 background 
genes, 0.7% 0.00% 
spindle microtubule 
7 out of 125 genes, 
5.6% 
14 out of 2783 background 
genes, 0.5% 0.00% 
DNA replication preinitiation complex 
7 out of 125 genes, 
5.6% 
15 out of 2783 background 
genes, 0.5% 0.00% 
spindle midzone 
7 out of 125 genes, 
5.6% 
15 out of 2783 background 
genes, 0.5% 0.00% 
pre-replicative complex 
7 out of 125 genes, 
5.6% 
16 out of 2783 background 
genes, 0.6% 0.00% 
nuclear pre-replicative complex 
7 out of 125 genes, 
5.6% 
16 out of 2783 background 
genes, 0.6% 0.00% 
mitotic spindle 
10 out of 125 
genes, 8.0% 
37 out of 2783 background 
genes, 1.3% 0.00% 
supramolecular complex 
8 out of 125 genes, 
6.4% 
28 out of 2783 background 
genes, 1.0% 0.06% 
supramolecular polymer 
8 out of 125 genes, 
6.4% 
28 out of 2783 background 
genes, 1.0% 0.06% 
supramolecular fibre 
8 out of 125 genes, 
6.4% 
28 out of 2783 background 
genes, 1.0% 0.06% 
polymeric cytoskeletal fibre 
8 out of 125 genes, 
6.4% 
28 out of 2783 background 
genes, 1.0% 0.06% 
protein-DNA complex 
9 out of 125 genes, 
7.2% 
37 out of 2783 background 
genes, 1.3% 0.05% 
chromosome passenger complex 
3 out of 125 genes, 
2.4% 
3 out of 2783 background 
genes, 0.1% 0.32% 
anaphase-promoting complex 
3 out of 125 genes, 
2.4% 
4 out of 2783 background 
genes, 0.1% 0.51% 
microtubule associated complex 
3 out of 125 genes, 
2.4% 
4 out of 2783 background 
genes, 0.1% 0.50% 
 
Table 6.13: GO analysis of Cdc14 hits based on cellular components. 
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6.7. Discussion 
The development and application of a SILAC-based screen for Cdc14PD interactors resulted 
in the identification of over 100 potential candidates. The SILAC protocol described in 
chapter 5 was successfully applied here and proved to be a powerful method for studying 
protein interactions in C. albicans. One of the biggest strength of this study is that it used an 
unbiased approach for identification of unknown Cdc14 interactions. Hits selection was 
based on clearly defined rules guided by the experimental conditions, and not influenced by 
previous knowledge of Cdc14 interactions. However, given the conserved roles of Cdc14 
homologs, at least some of the interactions found here also occur in other organisms, 
especially fungi. In the list of hits identified by MS, there are several well-known Cdc14 
interactors. In S. cerevisiae, Cdc14 is held in the nucleolus by Net1 throughout interphase. 
The Net1 homologue in C. albicans has not been characterised but was found as a hit in all 
four QO-MS experiments in both yeast and hyphae, suggesting a similar function. The 
mitotic exit network kinases Dbf2 and Cdc5 were also recovered. Other kinases in the list 
include Yak1 and both subunits of Cdc7-Dbf4. The mitotic cyclin Clb2 and the APC/C 
activator Cdh1 are both involved in counteracting CDK activity initiated by Cdc14. Almost 
the entire Dam1/DASH complex that orchestrates chromosome segregation was present, 
including Ask1, Dad1, Dad2, Dad3, Dam1, Duo1, Spc19, Spc34 (only Dad4 and Hsk3 were not 
recovered). It is intriguing whether Cdc14 interacts with all of these proteins or the whole 
complex was purified via one specific interaction. Another complex amongst the hits is the 
origin recognition complex (Orc1, Orc3 and Orc4) involved in DNA replication. Other hits 
with a role in DNA replication are orf19.2369, orf19.3289, orf5358, orf19.2389 and Cdc7-
Dbf4, suggesting a prominent role for Cdc14 in controlling this process. Other proteins 
involved in various DNA processes were recovered too: Rad52, Rad9, orf19.652, orf19.6155 
and 19.6291 are all DNA repair proteins; orf19.1865 directs DNA recombination; orf19.7663 
takes part in chromosome segregation; Fkh2 and orf19.4295 are transcriptional 
corepressors; orf19.427 plays a role in chromatin silencing. Full gene onthology analysis of 
the final list of Cdc14 interactors will be performed and will reveal more information about 
the role of this phosphatase in C. albicans. When Cdc14 was first characterised, it became 
known as a mitotic exit protein and it was thought to be inactive during interphase while in 
the nucleus. This notion was later disproved, as in higher eukaryotes, Cdc14 actively controls 
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DNA dynamics. The results presented here suggest that in C. albicans Cdc14 has a 
prominent role in the nucleus related to DNA maintenance and organisation.  
Cdc14 deletion mutants have severe defect in cell separation due to failure to 
degrade the septum after cytokinesis. Cdc14 may be activating this process by targeting the 
hydrolytic enzyme Cht4 that was recovered from two experiments. Amongst the low 
confidence hits are the known target Iqg1 that directs actomyosin ring disassembly, the 
transcriptional regulator Ace2 and additional DNA-binding proteins. 
Many potential Cdc14 interactors were identified from both yeast and hyphae 
experiments. Cdc14 localises to the nucleus in both of these forms, so it is likely that its role 
in DNA maintenance is universal. None of the proteins that were form-specific suggest an 
obvious role of Cdc14 in morphogenesis. However, almost half of the hits are 
uncharacterised proteins, i.e. those shown with their ORF number and without a name. The 
role of these hits in the cell and the significance of their potential interaction with Cdc14 
remain to be found. 
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Chapter 7 
 
Discussion 
 
 
 
7.1. Quantitative MS methods for studying kinase and phosphatase 
interactions in C. albicans 
The main aim of this project was to identify kinase and phosphatase interactions in C. 
albicans using quantitative MS approaches. Experimenting with two different methods of 
quantitation, label-free and SILAC, allows for a parallel comparison of both. While both 
techniques have been hugely refined in the past decade and numerous reviews in the 
literature discus their merits, this study found SILAC to be a superior approach for the aims 
of the project even when all other experimental differences are taken into account. These 
differences include using different MS instruments for both methods, as well as 
overexpressing the bait and stabilising bait-substrate interactions in SILAC experiments. 
Label-free techniques strongly rely on precise and accurate replication of each affinity 
purification procedure. Differences in the end results of bait and control experiments are 
then attributed to bait interactions. Label-free experiments described in chapter 3 were 
replicated with meticulous care, yet the number of identified proteins in each of them 
varied by several hundreds. This is largely due to the gentle beads-washing conditions, 
which allow large (but varied) amount of contaminants to remain in the sample. As a result, 
clear discrimination between prays and contaminants cannot be made. For example the 
experiment using Dbf2 as a bait found over 300 more proteins than one of the control 
experiments, where no bait was used (“Control 2” in table 3.1) but these are clearly not all 
prays. This problem would not be solved if a better MS instrument was used, the bait was 
overexpressed and bait-pray interactions were enhanced. Therefore, the advantages of the 
SILAC method are not due to the later improvements in the AP-MS protocol.  
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 It is important to note that label-free MS can be a powerful approach for studying 
protein interactions, when implemented in the right context. Indeed, a label-free proteomic 
analysis of Clp1 (homologue of Cdc14 in S. pombe) interactions found 128 hits from MS 
experiments performed under 5 different conditions using either a substrate-trapping or a 
wild type phosphatase as a bait (Chen et al., 2013). The Chen et al. study had several 
differences to the project described here. The authors used tandem affinity purification 
(TAP) which strongly reduces the amount of background proteins in the final sample. They 
performed 10 MS experiments with the bait which allows them to carry out a better 
statistical analysis on their data. In addition, the study was carried by a group of highly 
experienced MS scientists, who have a previously composed database of common 
contaminants. That allows them to compare results from a large number of label-free 
experiments and achieve low FDR of the final list of hits. It is also clear that the choice of MS 
instrument and processing software have met the requirements of label-free experiments 
(the MS instrument used in the study is a linear trap quadrupole from Thermo Electron). So, 
while the SILAC protocol produced better results in the current project, it is believed that 
similar results can be achieved with label-free MS methods. However, label-free MS 
requires rigorous statistical analysis and use of a protein frequency library where known 
contaminant proteins for a specific set of experimental parameters (cell line, bead matrix, 
buffer conditions) may be excluded. It is also better suited for stringent purifications such as 
TAP, where contamination is reduced to minimum. 
This study found over 100 potential Cdc14 interactors, but it certainly missed to 
identify others. It is recognised that some interactions will not be detected by the methods 
employed here, so further experiments are likely to find more unknown targets. The main 
advantage of SILAC over label-free quantitation is that bait and control samples are mixed 
early in the experimental procedure, so differences between samples cannot arise by 
handling errors. However, this is also a disadvantage for SILAC, because protein interactions 
in the mixed cell lysate may still occur. Substrates bound by Cdc14 after cell lysis will not be 
enriched in heavy isotopes. Thus, they will be false negatives. Such dynamic interactions can 
be detected by MAP-SILAC (mixing after purification) (Wang and Huang, 2014). As the name 
suggests, in MAP-SILAC samples are mixed after the affinity purification procedure to order 
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to avoid exchange between differentially labelled protein complexes. The disadvantage of 
this method is that it may introduce handling error differences between the samples. 
Other reasons for not capturing an interaction may be that it occurred below the 
threshold of AP-MS detection or it did not withstand the course of the experiment. Although 
some improvements were made to stabilise transient interactions and enhance low 
abundant interactions, many of them would still be lost. Nevertheless, these improvements 
certainly played a role in the success of the study. This becomes evident when the results 
from SILAC and label-free Cdc14 experiments are directly compared to one another. Many 
of the most confident hits in SILAC experiments that were identified repeatedly by both 
QTOF and QO instruments were not identified in the label free IP of Cdc14, for example 
orf19.652, orf19.2684 and Rad52. While label-free experiments were certainly analysed by a 
less sensitive MS instrument, these three hits had relatively high intensities, so failure of 
detection cannot be explained with MS sensitivity. It is more likely that these hits (which can 
be regarded as interacting partners of Cdc14 based on very strong evidence) were either not 
present in the MS sample (i.e. they were lost, because bait-pray interactions were weak), or 
they were present in the MS sample at very low abundance because Cdc14 was not 
overexpressed. From that, it can be concluded that using an overexpressed substrate-
trapping mutant of Cdc14 in conjunction with quantitative SILAC-MS was a right decision. 
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7.2. Strengths and limitations of using an overexpressed mutant 
version of Cdc14 in interaction studies 
Quantitative MS analysis of protein interactions involves detecting subtle changes in protein 
levels between two samples. Despite the huge advantages of MS technology available 
today, detecting protein interactions at physiological levels remains a challenging task. This 
is especially true for proteins with relatively low abundance, such as Cdc14.  
 In the Chen et al. study described in the previous section, the authors used both wild 
type Clp1 and Clp1PD as a bait. Out of 128 hits that they found in total, 73 (57%) were 
enriched three or more times in the Clp1PD compared to Clp1 experiments. As this and many 
other studies have shown, substrate-trapping mutants are a great tool in protein interaction 
experiments.  
Early AP-MS experiments described in chapter 3 illustrate the difficulty of capturing 
interacting proteins in vivo and later identifying them among the crowd of contaminants. As 
already discussed above, experiments with wild type Cdc14 failed to identify even the most 
prominent interactors found with MET3-Cdc14PD. The early experiments were performed on 
a less sensitive instrument, but this is unlikely to be the sole reason for the lack of hits. A 
high-sensitivity mass spectrometer would most likely detect more interacting partners, but 
they would not stand out from the contaminants (even if SILAC is used). The ratio of prays-
to-contaminants was increased by using an overexpressed substrate-trapping Cdc14PD while 
quantitation was improved by using SILAC and high-sensitivity MS.  
The non-physiological conditions of the experiment have almost certainly created 
some aberrant interactions. A study in budding yeast found that a gradual change in the 
Cdc14-to-CDKs ratio during mitosis is responsible sequential substrate dephosphorylation by 
Cdc14 (Bouchoux and Uhlmann, 2011). Constitutively high levels of Cdc14 are likely to 
disrupt the natural sequence of dephosphorylation events. However, since the 
overexpressed phosphatase was inactive, and an active Cdc14 was present in the cells, 
abnormalities would not be due to excessive Cdc14 dephosphorylation. Rather than that, 
high levels of Cdc14PD may deplete the pool of substrates that active Cdc14 
dephosphorylates. That may have an effect on downstream events governed by these 
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substrates, even if no phenotype was seen by microscopic observations. This has two 
important consequences: 1) some of the hits in this study may be non-physiological 
substrates of Cdc14 and 2) some of the hits may be false positives due to being more 
abundant in the Cdc14PD strain that the wild type strain. To clarify the second point: if a 
contaminating protein is more abundant in the labelled than the non-labelled strain, it will 
appear with higher H/L ratio relative to the whole population. It will therefore be regarded 
as a hit, although it did not interact directly with the bait. Thus, hits in this study should be 
regarded as potential interactors of Cdc14, but further experiments would be required to 
confirm these interactions. 
In conclusion, while the non-physiological conditions of the experiments limit the 
significance of the findings presented here, it is believed that many physiological 
interactions would not have been revealed in different experimental conditions. Therefore, 
this study has an important contribution to understanding the C. albicans interactome. 
The list of hits presented in this study shows proteins that are likely interacting with 
Cdc14. These include substrates of the phosphatase, activating subunits, inhibitors, 
upstream regulators, anchoring proteins and other interactors. Since substrate interactions 
were artificially enhanced, the list is likely to be enriched in substrates. These cannot be 
distinguished from the rest without further investigation, but comparisons can be drawn 
between Cdc14 homologues in other species. For example Dbf2, as part of the mitotic exit 
network, is known to phosphorylate  
Another important consideration when interpreting the results is that physical 
interactions detected by AP-MS are not necessarily direct. Proteins bound together in a 
stable complex may be purified via a single member. Two complexes were significantly 
enriched in the list of potential interactors: the Dam1/Dash complex and the origin 
recognition complex. Members of these complexes should not be regarded as direct Cdc14 
interactors. It is likely that other proteins have also been purified via indirect interaction. 
Thus, this study presents a global view of the Cdc14 interactome, which include both 
immediate and distal physical interactions. 
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7.3. Future work 
The data obtained in this project will be subjected to further bioinformatics analysis. A close 
comparison to known Cdc14 interactors in other species will also be performed. One can 
further compare the results of this study to the results of similar AP-MS experiments with 
Cdc14 homologues (e.g. the Chen et al. study described above). This will provide additional 
validation that the list of final hits is enriched in Cdc14 interactors and that the experimental 
approach is working. 
Finally, the project aims to confirm some of the interactions by further experiments, 
such as co-IP, and investigate the role of Cdc14 dephosphorylation of a few chosen targets. 
Unknown proteins will be tagged with GFP in order to examine their localisation. Selected 
genes will be deleted in order to look for deletion phenotype and investigate the function of 
these genes. 
 Investigating every single interaction found by IP-MS is beyond the scope of this 
project. This study provided a global analysis of Cdc14 interactions in C. albicans, but the 
importance of individual interaction may be researched further by other groups.  
 The methods of quantitative SILAC-MS used in this study proved to be a valuable tool 
for large scale analysis of protein interactions in C. albicans. The protocols may therefore be 
applied in further studies of C. albicans interactome. SILAC could also be applied in studies 
of protein dynamics, protein turnover rate, whole proteome analysis and others. 
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